tamsulosin profile

ID Source	ID
PubMed CID	129211
CHEMBL ID	836
CHEBI ID	9398
SCHEMBL ID	34378
MeSH ID	M0234193

Synonym
BIDD:GT0261
AB01275521-01
(-)-ym617
gtpl488
5-{(2r)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
tamsulosinum [inn-latin]
benzenesulfonamide, 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxy-, (r)-
tamsulosina [inn-spanish]
tamsulosine [inn-french]
c20h28n2o5s
tamsulosin [inn:ban]
C07124
106133-20-4
tamsulosin ,
(-)-tamsulosin
DB00706
(r)-(-)-tamsulosin
(r)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
flomax (tn)
amsulosin
NCGC00167442-01
5-[(2r)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide
tamsulosine
tamsulosinum
CHEBI:9398 ,
tamsulosina
HMS2090P15
tamsulon
CHEMBL836 ,
hgp-0412
hip-1402
hip1402
D08560
tamsulosin (inn)
tamsulon (tn)
bdbm50060964
5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
STK626950
5-[(2r)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-[(2r)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
A801388
A835382
AKOS005266643
NCGC00167442-02
5-((2r)-2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxy-benzenesulfonamide
unii-g3p28oml5i
g3p28oml5i ,
flowmax
hsdb 7744
contiflo od
S1435
tamsulosin [hsdb]
(-)-(r)-5-(2-((2-(o-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
tamsulosin [vandf]
tamsulosin [inn]
tamsulosin [mi]
tamsulosin [who-dd]
HY-B0661
SCHEMBL34378
DRHKJLXJIQTDTD-OAHLLOKOSA-N
5-[(2r)-2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzene-sulfonamide
smr004703489
MLS006011810
Q-101875
DTXSID3023631 ,
5-[(2r)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzene-1-sulfonamide
sr-05000001519
SR-05000001519-1
(r)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-benzenesulfonamide
(r)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)-propyl)-2-methoxybenzenesulfonamide
Q418480
F15143
(r)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxybenzenesulfonamide
HMS3884M15
CCG-268745
AS-82157
EN300-7417041
jgx ,
tamsulosine (inn-french)
tamsulosina (inn-spanish)
g04ca02
ym-12617-2
(r)-5-
dtxcid803631
tamsulosinum (inn-latin)
5-((2r)-2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide

Excerpt	Reference	Relevance
"Tamsulosin is a medication that is commonly used in men with urinary symptoms related to an enlarged prostate."	( Randomised, quadruple blinded, placebo controlled, multicentre trial investigating prophylactic tamsulosin in prevention of postoperative urinary retention in men after endoscopic total extraperitoneal inguinal hernia repair (STOP-POUR trial): a study pro Bieri, M; Bieri, U; Graf, N; Hefermehl, LJ; Nocito, A; Slieker, J; Soppe, S; Tedaldi, R; Teufelberger, G, 2021)	1.56
"The tamsulosin is a drug well known by urologist that have a safety profile probed with the years. "	( Physiopathology of the Priapism Secondary to Tamsulosin: Clinical Cases of Our Hospital and Literature Review. Campos Hernández, JP; Gómez Gómez, E; Mellado Castillero, A; Prieto Castro, R, 2022)	1.54
"Tamsulosin is a therapeutic drug of alpha-adrenergic antagonists. "	( The effect of tamsulosin in postoperative urinary retention: a meta-analysis of randomized controlled trials. Gao, B; Wang, Y; Wang, Z; Zhang, D, 2023)	2.71
"Tamsulosin is an alpha-1 adrenergic receptor blocker used to treat benign prostatic hyperplasia."	( A first case of fixed drug eruption due to Tamsulosin. Ahmadi, A; Jahani Amiri, K; Mofarrah, R; Montazer, F; Nouripour, B, 2020)	1.54
"Tamsulosin is a uroselective alpha-1a blocker used for the treatment of lower urinary tract symptoms."	( Preoperative Tamsulosin to Prevent Postoperative Urinary Retention: A Randomized Controlled Trial. Carchman, EH; Howington, B; Kennedy, GD; Leverson, G; Papageorge, CM, 2021)	1.71
"Tamsulosin is an antagonist of a subtype-specific alpha-1A- and alpha-1D-adrenoceptor (AR) that is expressed in the prostate gland, urethra, and bladder. "	( Intraoperative Floppy Iris Syndrome Induced by Tamsulosin: The Risk and Preventive Strategies. Aalam, W; Al Haleem, ENA; Banji, D; Tobaiqy, M, )	1.83
"Tamsulosin is a selective α1-AR antagonist."	( Tamsulosin attenuates high glucose- induced injury in glomerular endothelial cells. Hu, W; Sun, C; Sun, L; Zhang, L; Zhou, S, 2021)	2.79
"Tamsulosin is an alpha blocker that works by relaxing bladder neck muscles."	( Perioperative use of tamsulosin significantly decreases rates of urinary retention in men undergoing pelvic surgery. Cataldo, T; Curran, T; Nagle, D; Poylin, V, 2015)	1.46
"Tamsulosin is an alpha(1)-adrenergic antagonist known to be linked with intraoperative floppy-iris syndrome (IFIS), which is characterized by iris atonicity and a propensity toward progressive intraoperative pupil constriction and iris prolapse. "	( Management of intraoperative floppy-iris syndrome-associated iris prolapse using a single iris retractor. Alexander, P; Tint, NL; Yeung, AM, 2009)	1.8
"Tamsulosin is a safe and effective drug that enhances spontaneous passage of distal ureteral stones sized 10 mm or smaller."	( Efficacy of tamsulosin in the management of lower ureteral stones: a randomized double-blind placebo-controlled study of 100 patients. Al-Ansari, A; Al-Naimi, A; Alobaidy, A; Assadiq, K; Azmi, MD; Shokeir, AA, 2010)	2.18
"Tamsulosin is an alpha(1)-adrenoceptor antagonist used for the treatment of lower urinary tract symptoms that are suggestive of benign prostatic hyperplasia. "	( Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. de la Rosette, JJ; Franco-Salinas, G; Michel, MC, 2010)	2.07
"Tamsulosin is a safe and effective therapy for renal and ureteral stones after SWL. "	( Tamsulosin as adjunctive treatment after shockwave lithotripsy in patients with upper urinary tract stones: a systematic review and meta-analysis. Liu, LR; Wei, Q; Yuan, HC; Zheng, S, 2010)	3.25
"Tamsulosin is an α-adrenoceptor blocker that is relatively selective for the α(1A)-adrenoceptor subtype within the prostatic smooth muscles."	( Dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic enlargement. Hashim, H; Ismail, M, 2012)	1.48
"Tamsulosin is a safe and effective medical expulsive therapy choice for ureteral stones. "	( Tamsulosin for ureteral stones: a systematic review and meta-analysis of a randomized controlled trial. Ding, H; Dong, Z; Lu, Z; Ma, B; Wang, H; Wang, Z, 2012)	3.26
"Tamsulosin is a uroselective alpha1A/alpha1D adrenergic receptor antagonist."	( Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Bijelic, R; Milicevic, S, 2012)	1.41
"Tamsulosin is an alpha-1 adrenoceptor antagonist applied in treating lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). "	( Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia. Lee, LM; Lin, KH; Lin, YW; Wen, YC, 2012)	2.08
"Tamsulosin appears to be a suitable compound for studying the characteristics of drug binding to human AGP F1/S variants under clinical conditions."	( Selective binding of tamsulosin to genetic variants of human alpha1-acid glycoprotein. Hanada, K; Ogata, H; Tochikura, N, 2007)	1.38
"Tamsulosin is a potent, third-generation selective alpha(1A) adrenoceptor-blocking agent."	( Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses. Grey, AD; Nargund, VH, 2008)	2.51
"Tamsulosin-HCl is an alpha1A-adrenoceptor antagonist that is mainly eliminated by metabolism in animals and humans and is highly bound to alpha1-acid glycoprotein in blood plasma. "	( Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. Higuchi, S; Matsushima, H; Soeishi, Y; van Hoogdalem, EJ, 1997)	1.98
"Tamsulosin is an improvement over other alpha-adrenergic antagonists for the management of symptoms of benign prostatic hyperplasia. "	( Tamsulosin for the treatment of benign prostatic hypertrophy. Lee, M, 2000)	3.19
"Tamsulosin is an alpha1-adrenoceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia with a tolerability similar to that of placebo in short-term, placebo-controlled studies with limited patient numbers. "	( A 6-month large-scale study into the safety of tamsulosin. Bressel, HU; Goepel, M; Michel, MC; Rübben, H, 2001)	2.01
"Tamsulosin is a selective alpha1A- and alpha1D-adrenoceptor antagonist. "	( Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Jarvis, B; Lyseng-Williamson, KA; Wagstaff, AJ, 2002)	3.2
"Tamsulosin is a subtype-selective alpha(1A)- and alpha(1D )-adrenoceptor antagonist. "	( Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Dunn, CJ; Faulds, DM; Matheson, A, 2002)	3.2

Excerpt	Reference	Relevance
"Tamsulosin has a risk of complications of up to 80 %, whereas doxazosin and alfuzosin only have a 15-20 % chance of complications. "	( [Intraoperative floppy iris syndrom (IFIS) associated with tamsulosin]. Bigdon, E; Casagrande, M; Hassenstein, A; Spitzer, MS, 2022)	2.41
"Tamsulosin OCAS 0.4 mg has a favourable efficacy/safety profile and should be considered the treatment of choice for patients requiring optimal symptom control without increasing the risk of cardiovascular adverse events."	( Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Schulman, CC, 2008)	3.23
"Tamsulosin has a markedly lower re-treatment percentage than alfuzosin and terazosin."	( Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. de la Rosette, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS, 2002)	1.04
"Tamsulosin has a rapid onset of action and is effective in patients with moderate or severe symptoms."	( Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Dunn, CJ; Faulds, DM; Matheson, A, 2002)	2.48
"Tamsulosin has more reversible adverse effect, compared to placebo (p = 0.03)."	( A randomized trial of adjuvant tamsulosin as a medical expulsive therapy for renal stones after shock wave lithotripsy. El-Assmy, AM; Elgamal, M; Elzalouey, AE; Hashem, A; Laymon, M; Sharaf, DE, 2022)	1.73
"Tamsulosin has been associated with dementia, but the results have been inconsistent. "	( Use of α1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease. Hartikainen, S; Latvala, L; Murtola, TJ; Tiihonen, M; Tolppanen, AM, 2022)	2.44
"Tamsulosin has a risk of complications of up to 80 %, whereas doxazosin and alfuzosin only have a 15-20 % chance of complications. "	( [Intraoperative floppy iris syndrom (IFIS) associated with tamsulosin]. Bigdon, E; Casagrande, M; Hassenstein, A; Spitzer, MS, 2022)	2.41
"Tamsulosin has been used for the off-label treatment of lower urinary tract symptoms (LUTS) in women. "	( Tamsulosin for treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. Cheng, X; Huang, ZG; Liu, TT; Qiu, Y; Zhang, HL; Zou, XQ, 2017)	3.34
"Tamsulosin 0.4 mg has favorable efficacy and tolerability in Asian men with symptomatic BPH."	( Efficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial. Bae, JH; Chang, IH; Chung, JH; Chung, JI; Ha, US; Han, DH; Han, JH; Jung, J; Kim, JH; Kim, SW; Kim, TH; Kim, YI; Lee, SH; Lee, SW; Oh, CY; Yoo, TK, 2018)	1.51
"Tamsulosin has been the most commonly prescribed α1-blocker since the mid-2000s, in line with its demonstrated highest persistence and return rates."	( Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia. Bae, WJ; Cho, HJ; Choi, JB; Ha, US; Han, K; Hong, SH; Kim, SW; Lee, JY; Moon, HW; Park, SH; Yang, JH, 2018)	1.2
"Tamsulosin MR has been on the market for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) for many years. "	( Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Schulman, CC, 2008)	3.23
"Tamsulosin OCAS 0.4 mg has a favourable efficacy/safety profile and should be considered the treatment of choice for patients requiring optimal symptom control without increasing the risk of cardiovascular adverse events."	( Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Schulman, CC, 2008)	3.23
"Tamsulosin has beneficial effects in a significant proportion of women with voiding difficulty."	( The effectiveness of tamsulosin in treating women with voiding difficulty. Chang, SJ; Chiang, IN; Yu, HJ, 2008)	2.11
"Tamsulosin has also shown promise in ameliorating (early) storage symptoms and urinary retention associated with transurethral microwave thermotherapy, external-beam radiotherapy, and brachytherapy."	( The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia. Nickel, JC, 2003)	1.04
"Tamsulosin has selectivity for the a alpha(1) and alpha(1d) receptor subtypes. "	( Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Lowe, FC, 2004)	1.77
"Tamsulosin has selective alpha1A-adrenoreceptor antagonistic properties and obviously binds for a long period to the postsynaptic nerve endings of the iris dilator muscle, thus affecting iris dilatation and leading to complications in cataract surgery. "	( Influence of tamsulosin on the iris and its implications for cataract surgery. Dugué, B; Keski-Rahkonen, P; Lehtonen, M; Leppänen, E; Mauriala, T; Pärssinen, O, 2006)	2.15
"Tamsulosin has a markedly lower re-treatment percentage than alfuzosin and terazosin."	( Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. de la Rosette, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS, 2002)	1.04
"Tamsulosin has not been associated with clinically significant changes in blood pressure in clinical trials."	( Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Dunn, CJ; Faulds, DM; Matheson, A, 2002)	2.48
"Tamsulosin has a rapid onset of action and is effective in patients with moderate or severe symptoms."	( Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Dunn, CJ; Faulds, DM; Matheson, A, 2002)	2.48

Excerpt	Reference	Relevance
"The tamsulosin group had lower failed URS (38% vs 61%, p = 0.20)."	( The effect of preoperative tamsulosin on ureteroscopic access in school-aged children. Kraft, KH; McGee, LM; Sack, BS; Wan, J, 2021)	1.4
"The tamsulosin effect was lower with greater baseline PV and tended to decrease over time."	( Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression. Averbeck, MA; Concas, F; Cortés, V; Gravas, S; Kamola, PJ; Kattan, MW; Lulic, Z; Manyak, M; Oelke, M; Palacios-Moreno, JM; Roehrborn, CG; Thompson, D, 2023)	1.39
"tamsulosin for lower urinary tract symptoms (LUTS) secondary to benign prostate hyperplasia (BPH) is limited."	( Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials. Chen, X; Guo, B; Hou, H; Liu, M; Wang, M; Zhang, Z, 2020)	1.54
"Tamsulosin may increase the risk of dementia in older men with BPH."	( Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Albertsen, PC; Duan, Y; Grady, JJ; Helen Wu, Z, 2018)	3.37
"Tamsulosin may also increase patient satisfaction by reducing the invasive treatment and decreasing the time to stone passage."	( Tamsulosin for urolithiasis: a review of the recent literature and current controversies. Mazer-Amirshahi, M; Nadendla, R; O'Connell, F; Pourmand, A, 2016)	2.6
"Tamsulosin may cause a higher incidence of ejaculatory disorders than naftopidil, although the efficacy of 0.2 mg tamsulosin may be better than that of 50 mg naftopidil."	( Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Furuya, R; Iwasawa, A; Masumori, N; Mori, M; Sonoda, T; Tsukamoto, T, 2009)	1.99
"Tamsulosin can cause intraoperative floppy iris syndrome and increase the risk of phacoemulsification complications. "	( Effect of timing and duration of tamsulosin exposure on complications in resident-performed phacoemulsification. Han, Y; Ku, TK; Naseri, A; Porco, TC; Rutar, T, )	1.86
"Tamsulosin alone did not cause any significant changes in comparison to placebo."	( The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. Kähönen, M; Kööbi, T; Nieminen, T; Tammela, TL, 2006)	1.41
"Tamsulosin may cause adverse ocular effects including recurrent choroidal detachments. "	( Choroidal detachment following the use of tamsulosin (Flomax). Flach, A; Lee, SE; McCaffery, S; O'Brien, JM; Petrovic, V; Shapiro, BL, 2007)	2.05
"Tamsulosin improves lower urinary tract symptoms and flow. "	( Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. MacDonald, R; Nelson, D; Wilt, TJ, 2002)	3.2

Excerpt	Reference	Relevance
"Tamsulosin treatment reduced the risk of POUR by two-thirds (odds ratio [OR], 0.337; 95% confidence interval [CI], 0.117-0.971; p=0.044)."	( Preventive effects of tamsulosin for postoperative urinary retention after lower limb arthroplasty: A randomized controlled study. Chang, JD; Choi, CI; Choo, MS; Han, JH; Kim, JK; Lee, SH, 2021)	1.66
"The tamsulosin treatment period and pupil diameter during five stages of the surgery were also noted."	( Modified Corneal Incisions for Cataract Surgery in Patients Treated with Tamsulosin: A Prospective Study. Blau-Most, M; Geffen, N; Mimouni, M; Segal, O; Segev, F, 2019)	1.23
"In tamsulosin treated patients, using modified corneal incisions may be feasible in order to reduce the incidence and severity of IFIS during cataract surgery. "	( Modified Corneal Incisions for Cataract Surgery in Patients Treated with Tamsulosin: A Prospective Study. Blau-Most, M; Geffen, N; Mimouni, M; Segal, O; Segev, F, 2019)	1.37
"Tamsulosin treatment (0.4 mg, h.s.) for 3 months not only improved voiding and storage symptoms, but also reduced nocturia episodes. "	( Male patients with a higher frequency of nocturnal urinary episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturia. Kuo, HC; Lee, CL, 2019)	1.96
"Tamsulosin-treated patients had a 0.30-fold lower risk of developing acute urinary retention compared with control patients (95% confidence interval 0.12-0.76; P = 0.011)."	( Impact of tamsulosin on urinary retention following early catheter removal after robot-assisted laparoscopic radical prostatectomy: a prospective randomized controlled trial. Ahn, H; Choo, MS; Hong, JH; Hong, S; Jeong, IG; Kim, CS; Lim, JH; Yoon, JH; You, D, 2014)	1.53
"Tamsulosin treatment should therefore be considered for patients with LUS."	( A comparison of nifedipine and tamsulosin as medical expulsive therapy for the management of lower ureteral stones without ESWL. Cao, D; Han, P; Liu, L; Lv, X; Qian, S; Wei, Q; Yang, L; Yuan, H, 2014)	1.41
"The tamsulosin-treated patients dilated less with phenylephrine than controls (0.61±0.4 vs."	( The differential pupillary response to 2.5% phenylephrine in patients taking tamsulosin. Hillelsohn, JH; Hymowitz, MB; Liu, GT; Schultz, JS; Shrivastava, A, 2015)	1.13
"Tamsulosin treatment seems to bring on the expulsion of distal ureteral stones, although at the expense of an appreciable risk of side effects."	( [Tamsulosin efficacy and safety for conservative management of renal colic: systematic review and meta-analysis of randomized controlled trials]. Benítez Camps, M; Cerain Herrero, MJ; de Miguel Llorente, N; Flores Mateo, G; Martorell Sole, E; Murillo-Huapaya, C; Pedro Pijoan, AM, 2015)	2.77
"Tamsulosin treatment does not improve the stone expulsion rate in patients with distal ureteral stones < or = 7 mm. "	( Is there a role for tamsulosin in the treatment of distal ureteral stones of 7 mm or less? Results of a randomised, double-blind, placebo-controlled trial. Frauenfelder, T; Hermanns, T; Rufibach, K; Sauermann, P; Strebel, RT; Sulser, T, 2009)	2.12
"Tamsulosin treatment is recommended for patients with the stone diameter smaller than 8 mm because of its feasibility, effectiveness and safety. "	( Comparison of tamsulosin with extracorporeal shock wave lithotripsy in treating distal ureteral stones. Ding, ST; Lü, JJ; Lue, YH; Xia, QH; Zhang, H; Zhang, MY, 2009)	2.16
"• Tamsulosin treatment resulted in a significant reduction in mean systolic blood pressure (-4.2 mmHg, within-group P= 0.004) relative to the negligible change of silodosin (-0.1 mmHg, within-group P= 0.96)"	( Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Cheng, CL; Cheng, HL; Chiang, PH; Lin, AT; Tsui, KH; Wu, HC; Wu, TT; Yang, SS; Yu, HJ, 2011)	1.21
"Tamsulosin OCAS® treatment led to significant improvements in LUTS, HUS and QoL in Thai patients with bladder outlet obstruction from BPH with few side effects."	( The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study. Lojanapiwat, B; Permpongkosol, S, )	1.86
"Tamsulosin treatment was also associated with a significantly lower interval to the elimination of stone fragments (P < .001), a significantly lower rehospitalization rate (P < .001), and a significantly lower proportion of patients with acute renal colic (P < .05) than standard care alone."	( Efficacy of tamsulosin oral controlled absorption system after extracorporeal shock wave lithotripsy to treat urolithiasis. Dimitrov, PD; Georgiev, MI; Mladenov, VD; Ormanov, DI; Panchev, PK; Popov, EP; Simeonov, PP; Vassilev, VD, 2011)	1.47
"Tamsulosin treatment resulted in significant improvements versus placebo across all efficacy parameters, except for peak urinary flow rates."	( Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Imaoka, T; Kim, SC; Morisaki, Y; Viktrup, L; Wang, CJ; Yokoyama, O; Yoshida, M, 2013)	1.32
"Tamsulosin treatment was effective in 33 (68.7 %) patients at the first administration and 35 (72.9 %) at the third month."	( The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term. Akin, Y; Gulmez, H; Ucar, M; Yucel, S, 2013)	1.41
"Tamsulosin treatment of BPH patients for more than 12 months showed a sustained, stable efficacy. "	( Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Arai, Y; Ichioka, K; Matsui, Y; Ohara, H; Terada, N; Terai, A; Yoshimura, K, 2004)	2.05
"With tamsulosin treatment, both mesopic and scotopic PD decreased, respectively, from 3.9 +/- 0.7 and 5.7 +/- 0.6 mm at day 0 to 3.6 +/- 0.9 and 5.5 +/- 0.8 mm at day 28, and 3.6 +/- 0.7 and 5.4 +/- 0.7 mm at month 6 (ANOVA; P = 0.021 and = 0.040, respectively)."	( The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study. Adibelli, FM; Akova, YA; Altan-Yaycioglu, R; Gul, U; Pelit, A; Yaycioglu, O, 2007)	0.79
"tamsulosin daily for the treatment of patients with symptoms of moderate to severe benign prostatic hyperplasia."	( A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. Narayan, P; Tewari, A, 1998)	1.24
"Men treated with tamsulosin having standard cataract extraction surgery were placed in a treatment group that received phenylephrine 1.0%-ketorolac 0.3% injection in the irrigation solution and a control group) that received basic saline solution. "	( Effect of phenylephrine 1.0%-ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. Juzych, MS; Nariman, N; Pankratz, J; Rana, S; Rana, VK; Segars, L; Silverstein, SM; Stephens, R, 2018)	1.07
"Treatment with tamsulosin did not differ from a control group in the overall incidence of side effects (RR 1.14, 95% CI 0.86-1.51, p = 0.36)."	( Tamsulosin as a Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chand, H; Chen, H; Chen, J; Chen, M; Chen, Z; Cheng, X; Cui, Y; Hu, J; Li, C; Li, H; Li, Y; Liu, P; Yang, Z; Zeng, F; Zu, X, 2019)	2.3
"Treatment with tamsulosin and tolterodine appears to be beneficial in intramural ureteral stone clearance, particularly in intramural ureter stone with symptoms of vesical irritability."	( Tamsulosin and tolterodine in the medical expulsive therapy for intramural ureteral stones with vesical irritability: a prospective randomized study. Lv, JL; Tang, Ql, 2013)	2.17
"Treatment with tamsulosin is associated with improved LUTS and decreased depressive symptoms, which could enhance QoL."	( Tamsulosin Treatment Affecting Patient-reported Outcomes in Benign Prostatic Hyperplasia-associated Depressive Symptoms. Jang, EY; Kim, KS; Kim, YT; Moon, HS, 2016)	2.23
"Pretreatment with tamsulosin at a dose of 0.4 microg/kg i.v."	( The involvement of urothelial alpha1A adrenergic receptor in controlling the micturition reflex. Kawatani, M; Momota, Y; Nimura, T; Wang, X; Yanase, H, 2008)	0.67
"Treatment with tamsulosin improves the stone free rate and reduces the occurrence of colic episodes, after ureteroscopic laser lithotripsy of large renal and ureteric calculi. "	( Adjunctive tamsulosin improves stone free rate after ureteroscopic lithotripsy of large renal and ureteric calculi: a prospective randomized study. John, TT; Razdan, S, 2010)	1.1
"Treatment with tamsulosin after ESWL appears to be effective in assisting stone clearance in patients with renal and ureteric calculi. "	( alpha-Blockers to assist stone clearance after extracorporeal shock wave lithotripsy: a meta-analysis. Duijvesz, D; Lock, TM; Rovers, MM; Zhu, Y, 2010)	0.71
"Treatment with tamsulosin seemed to reduce the PSA levels and identified patients at high risk of prostate cancer."	( Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy. De Nunzio, C; Mariani, S; Miano, L; Miano, R; Trucchi, A; Tubaro, A; Vicentini, C, 2010)	0.97
"Treatment with tamsulosin was effective in raising the success rate of voiding without catheter after an episode of acute urinary retention. "	( [Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention]. Chen, SG; Hua, LX; Qian, LX; Sui, YG; Wu, HF; Xu, ZQ; Zhang, W, 2003)	1.58
"Treatment with tamsulosin for symptomatic BPH patients is associated with significant improvement in the generic HRQOL, in addition to disease-specific QOL and symptoms, at 3 months after drug administration. "	( Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey. Awa, Y; Egoshi, K; Furuya, Y; Hamano, S; Ichikawa, T; Mikami, K; Nakatsu, H; Ohki, T; Okano, T; Ota, S; Suzuki, H; Yano, M, 2006)	1.02
"Treatment with tamsulosin hydrochloride showed significant improvement of each IPSS and the bother score."	( Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score. Inadome, A; Maeda, Y; Masunaga, K; Nagata, T; Satoji, Y; Sugiyama, Y; Yoshida, M, 2007)	1.08
"Treatment with tamsulosin for 12 weeks also produced significant improvements in average urinary flow rate (P = 0.040), irritative (P = 0.013) and obstructive (P = 0.014) symptom scores and symptoms of nocturia (P = 0.022) and hesitancy (P = 0.004)."	( Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Abrams, P; Schulman, CC; Vaage, S, 1995)	2.07

Excerpt	Reference	Relevance
" During the 60-week study period, 51 patients (21%) experienced an adverse event considered to be possibly or probably related to study medication, the most common of which were dizziness and abnormal ejaculation, both occurring in 5% of patients."	( Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tam Cortvriend, J; Jonas, U; Lock, TM; Schulman, CC; Speakman, MJ; Vaage, S, 1996)	1.74
" Safety was evaluated by monitoring adverse events and vital signs (including 8 h after the first dose), and by laboratory determinations."	( A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Abrams, P; Arkell, D; Pocock, R; Speakman, M; Stott, M, 1997)	0.55
" During the 3-year study period, 95 patients (27%) experienced an adverse event considered to be possibly or probably related to study medication, the most common of which (occurring in	( Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Cortvriend, J; Jonas, U; Lock, TM; Schulman, CC; Speakman, MJ; Vaage, S, 1999)	1.75
" No unknown adverse reactions were observed in either groups, and the drugs were shown to be highly safe."	( [The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy]. Fujioka, T; Goto, Y; Isurugi, K; Katoh, T; Numasato, S; Obara, W; Omori, S; Suzuki, Y, 2001)	0.57
"We systematically reviewed the effectiveness and adverse effects of tamsulosin for lower urinary tract symptoms compatible with benign prostatic obstruction."	( Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. MacDonald, R; Nelson, D; Wilt, TJ, 2002)	1.99
" Treatment withdrawals and adverse effects increased markedly as the tamsulosin dose increased."	( Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. MacDonald, R; Nelson, D; Wilt, TJ, 2002)	1.99
" Adverse effects were generally mild but the incidence, including treatment withdrawals, increased substantially at higher doses."	( Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. MacDonald, R; Nelson, D; Wilt, TJ, 2002)	1.76
" Six subjects experienced adverse events while receiving placebo and seven while on tamsulosin."	( Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation. Forrest, A; Ito, Y; Kamimura, H; Miyazawa, Y; Paul Starkey, L; Schentag, JJ; Swarz, H, 2002)	0.8
"To systematically review and evaluate the effectiveness and adverse effects of the alpha-antagonist, terazosin, for treating urinary symptoms associated with benign prostatic obstruction (BPO)."	( Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. Howe, W; MacDonald, R; Wilt, TJ, 2002)	0.31
" Adverse effects were greater than with placebo and included dizziness, asthenia, headache and postural hypotension."	( Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. Howe, W; MacDonald, R; Wilt, TJ, 2002)	0.31
" Adverse effects were generally mild but more frequent than with other alpha-antagonists and associated with a two- to four-fold increase in treatment discontinuation."	( Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. Howe, W; MacDonald, R; Wilt, TJ, 2002)	0.31
" Some significant changes in vital signs and a number of mild adverse reactions were reported, but the overall safety profile of tamsulosin and theophylline was acceptable."	( Effects of the concomitant administration of tamsulosin (0.8 mg/day) on the pharmacokinetic and safety profile of theophylline (5 mg/kg): a placebo-controlled evaluation. Forrest, A; Ito, Y; Kamimura, H; Miyazawa, Y; Schentag, JJ; Starkey, LP; Swarz, H, )	0.6
" Both doses of alfuzosin were well tolerated, with dizziness the most frequent adverse event (placebo, 4%; alfuzosin 10 mg, 6%; 15 mg, 7%; tamsulosin, 2%); the respective incidence rates of sexual function adverse events were 0%, 3%, 1% and 8%."	( Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. Nordling, J, 2005)	0.77
" The incidence of sexual function adverse events was higher with tamsulosin than with placebo."	( Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. Nordling, J, 2005)	0.8
" Data on all randomized patients were included in the safety analyses for adverse effects and changes in blood pressure."	( Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. Gotoh, M; Kamihira, O; Kinukawa, T; Ohshima, S; Ono, Y; Origasa, H, 2005)	0.69
" The adverse effects were comparable, with no significant differences in systolic and diastolic blood pressure after treatment in both groups."	( Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. Gotoh, M; Kamihira, O; Kinukawa, T; Ohshima, S; Ono, Y; Origasa, H, 2005)	0.69
"This study suggests that naftopidil is as effective and safe as tamsulosin."	( Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. Gotoh, M; Kamihira, O; Kinukawa, T; Ohshima, S; Ono, Y; Origasa, H, 2005)	0.93
" The incidence of adverse events was similar for tamsulosin (25%) and alfuzosin (19."	( A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. Acepcion, V; Lapitan, MC; Mangubat, J, )	0.64
"alpha(1)-Blockers were effective and safe for treating young and middle-aged men with symptomatic bladder neck obstruction."	( Obstructive primary bladder neck disease: evaluation of the efficacy and safety of alpha1-blockers. Artibani, W; Calpista, A; Cisternino, A; De Marco, V; Iafrate, M; Prayer Galetti, T; Zeccolini, G, 2006)	0.33
" The efficacy of two treatments was assessed every 2 weeks during treatment, and at the end of the study using responses to IIEF, VAS evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes and adverse drug effects."	( Safety and efficacy of tamsulosin in the treatment of painful ejaculation: a randomized, double-blind, placebo-controlled study. Safarinejad, MR, )	0.44
" Both drugs were well tolerated, with one adverse event in 1514 treatment days for PRO 160/120 and one event in 1164 days for tamsulosin."	( Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Bondarenko, B; Engelmann, U; Funk, P; Schläfke, S; Walther, C, 2006)	0.74
" The primary parameters used for safety evaluation were vital signs (blood pressure and heart rate) and adverse events."	( Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Birowo, P; Djati, W; Rahardjo, D; Soebadi, DM; Sugandi, S; Wahyudi, I, 2006)	0.64
" Tamsulosin was well tolerated; only three patients (6%) in the tamsulosin group reported an adverse event (dizziness) while 11 patients (22%) in the doxazosin group reported an adverse event (dizziness), one of whom withdrew from the study."	( Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Birowo, P; Djati, W; Rahardjo, D; Soebadi, DM; Sugandi, S; Wahyudi, I, 2006)	1.55
" Tamsulosin OCAS was well tolerated and the proportion of women discontinuing because of adverse events was low (4."	( A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. Bolodeoku, J; Cardozo, L; Robinson, D; Terpstra, G, 2007)	1.47
" Prazosin prevented hepatotoxicity when administered 1 h before a toxic paracetamol insult and importantly, when administered up to 1 h post paracetamol injection."	( alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice. Kitteringham, NR; Macdonald, I; Park, BK; Randle, LE; Sathish, JG; Williams, DP, 2008)	0.35
" The adverse event profile was similar to that observed in the overall CombAT population, and drug-related adverse events were more common with combination therapy (26%) than with tamsulosin (15%) or dutasteride (9%)."	( Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Chung, BH; Major-Walker, K; Montorsi, F; Morrill, BB; Roehrborn, CG; Siami, P; Wilson, TH, 2009)	0.82
" No studies have documented whether use of tamsulosin or other alpha-blocker drug therapies affect the risk of serious postoperative adverse events."	( Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. Anderson, GM; Bell, CM; Bronskill, SE; Cernat, G; Fischer, HD; Gill, SS; Gruneir, A; Hatch, WV; Paterson, JM; Rochon, PA, 2009)	0.94
"To assess the risk of adverse events following cataract surgery in older men prescribed tamsulosin or other alpha-blocking drugs used to treat BPH."	( Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. Anderson, GM; Bell, CM; Bronskill, SE; Cernat, G; Fischer, HD; Gill, SS; Gruneir, A; Hatch, WV; Paterson, JM; Rochon, PA, 2009)	0.9
" The risk of these adverse events was compared between men treated with tamsulosin or other alpha-blockers and men with no exposure to these medications in the year prior to cataract surgery."	( Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. Anderson, GM; Bell, CM; Bronskill, SE; Cernat, G; Fischer, HD; Gill, SS; Gruneir, A; Hatch, WV; Paterson, JM; Rochon, PA, 2009)	0.91
"3%) had an adverse event."	( Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. Anderson, GM; Bell, CM; Bronskill, SE; Cernat, G; Fischer, HD; Gill, SS; Gruneir, A; Hatch, WV; Paterson, JM; Rochon, PA, 2009)	0.68
"Exposure to tamsulosin within 14 days of cataract surgery was significantly associated with serious postoperative ophthalmic adverse events."	( Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. Anderson, GM; Bell, CM; Bronskill, SE; Cernat, G; Fischer, HD; Gill, SS; Gruneir, A; Hatch, WV; Paterson, JM; Rochon, PA, 2009)	1.06
" Thus, tulosine is a safe and effective drug for treatment of prostatic adenoma."	( [Efficacy and safety of tulosine in patients with prostatic adenoma]. Gorilkovskiĭ, LM; Zingerenko, MB, )	0.13
" Adverse events were monitored throughout the study."	( Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Fakhoury, A; Fincher, R; He, W; Kaplan, SA; McCammon, K, 2009)	0.35
"The most frequent adverse events in the solifenacin plus tamsulosin and placebo plus tamsulosin groups were dry mouth (7% and 3%, respectively) and dizziness (3% and 2%, respectively)."	( Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Fakhoury, A; Fincher, R; He, W; Kaplan, SA; McCammon, K, 2009)	0.6
" After 8 weeks of treatment, treatment outcomes and adverse effects were evaluated."	( Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study. Choo, MS; Han, DH; Jeong, H; Kim, H; Lee, KS; Lee, SJ; Lee, YS; Park, HJ; Park, WH; Yoo, TK; Yoon, H, 2010)	0.67
" Adverse events of tamsulosin also showed no significant difference from the placebo group (Z=1."	( Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis. Kou, M; Lan, XX; Ren, RM, 2010)	1
" Adverse events of tamsuloisn show no significant difference compared with placebo."	( Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis. Kou, M; Lan, XX; Ren, RM, 2010)	0.67
" No serious adverse events (SAE) were recorded during the study."	( Long-term efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: data from China. Ji, JT; Liu, ZY; Shao, Y; Sun, YH; Wu, YY; Xu, CL; Zhang, LM; Zhang, ZS, 2011)	0.65
" No patient reported any serious (grade ≥ 2) adverse event (AE)."	( A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Carini, M; Gacci, M; Lapini, A; Maggi, M; Rossetti, MA; Serni, S; Siena, G; Tosi, N; Vignozzi, L; Vittori, G, 2012)	0.6
" No adverse events were reported."	( Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia. Lee, LM; Lin, KH; Lin, YW; Wen, YC, 2012)	0.64
" α(1) Blockers generally lead to more adverse effects compared with placebo, and those caused by terazosin were more frequent than others."	( The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J, 2013)	0.39
" The adverse effects caused by α(1) blockers are generally mild and well-tolerated."	( The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J, 2013)	0.39
" Combination therapy was well tolerated, and adverse events were consistent with the safety profiles of both compounds."	( Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Angulo, JC; Garcia-Hernandez, A; Haab, F; Katona, F; Klaver, M; Oelke, M; Traudtner, K; Van Kerrebroeck, P; Vik, V, 2013)	0.66
"Combined tamsulosin and imidafenacin treatment is effective and safe in patients with BPH with persistent OAB symptoms after tamsulosin monotherapy."	( Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study. Gotoh, M; Masumori, N; Nishizawa, O; Takahashi, S; Takeda, M; Yoshida, M, 2013)	0.81
" Safety assessment included laboratory tests and patient's reporting of adverse event."	( A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Mandal, AK; Mete, UK; Singh, DV; Singh, SK, 2014)	0.62
"Dutasteride can be used to improve urinary symptoms (IPSS and Q max) and reduce TPV but with awareness of its potential adverse events."	( Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. Choi, JY; Park, T, 2014)	0.4
" But most adverse events were mild in degree."	( [Clinical effectiveness and safety of combined therapy with alpha-blocker and an anticholinergic drug for bladder outlet obstruction with overactive bladder: a Meta-analysis of outcomes]. Li, J; Liu, B; Wang, Y; Wu, Y, 2014)	0.4
"Alpha-blocker combined with an anticholinergic drug in the treatment of BOO+OAB was better than that of alpha-blocker alone, and was safe and well tolerated."	( [Clinical effectiveness and safety of combined therapy with alpha-blocker and an anticholinergic drug for bladder outlet obstruction with overactive bladder: a Meta-analysis of outcomes]. Li, J; Liu, B; Wang, Y; Wu, Y, 2014)	0.4
" Treatment-emergent adverse events were reported in 499 (46."	( Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Chapple, C; Drake, MJ; Drogendijk, T; Klaver, M; Oelke, M; Sokol, R; Traudtner, K; Van Kerrebroeck, P, 2015)	0.64
" We also assessed postvoid residual, maximum urinary ﬂow rate, incidence of urinary retention (UR), adverse events."	( Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis. Guo, XL; Li, MC; Liu, JH; Wang, SG; Wang, T; Wang, ZY; Yang, J; Ye, ZQ, )	0.4
" In addition, tamsulosin is well tolerated, and its adverse events rarely led to dropouts of patients."	( The Efficacy and Safety of Tamsulosin Combined with Extracorporeal Shockwave Lithotripsy for Urolithiasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chen, K; Liu, L; Lv, T; Meng, Q; Mi, H; Sun, X; Wang, S; Xu, G, 2015)	1.07
"Overall, evidence suggests that tamsulosin combined with SWL is safe and effective in enhancing stone expulsion for patients with urolithiasis."	( The Efficacy and Safety of Tamsulosin Combined with Extracorporeal Shockwave Lithotripsy for Urolithiasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chen, K; Liu, L; Lv, T; Meng, Q; Mi, H; Sun, X; Wang, S; Xu, G, 2015)	1
"Systematic searches were conducted on PubMed, SCOPUS and The Cochrane Library so as to identify randomized and controlled clinical trials in patients treated with tamsulosin with ureteral stone expulsion and adverse events published until 2014 December, without language restriction."	( [Tamsulosin efficacy and safety for conservative management of renal colic: systematic review and meta-analysis of randomized controlled trials]. Benítez Camps, M; Cerain Herrero, MJ; de Miguel Llorente, N; Flores Mateo, G; Martorell Sole, E; Murillo-Huapaya, C; Pedro Pijoan, AM, 2015)	1.52
"Alfuzosin has been widely used to treat benign prostatic hyperplasia and prostatitis, and is claimed to be a selective agent for the lower urinary tract with low incidence of adverse side-effects and hypotensive changes."	( Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis. Chen, K; Kang, R; Li, J; Liu, C; Wan, SP; Wu, W; Zeng, G, 2015)	0.42
"Alfuzosin is a safe and effective agent for the expulsive therapy of ureteral stones smaller than 10 mm in size."	( Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis. Chen, K; Kang, R; Li, J; Liu, C; Wan, SP; Wu, W; Zeng, G, 2015)	0.42
"The aim of the study is to present the effects of BPH pharmacological treatment on the occurrence of sexually adverse effects in men: changes in sexual desire, erectile, ejaculatory and the orgasmic function."	( Adverse Effects of Pharmacological Therapy of Benign Prostatic Hyperplasia on Sexual Function in Men. Bogdanović, D; Djenić, N; Ignjatović, I; Stojanović, N, )	0.13
" The main adverse effect on sexual function in men is the deterioration in ejaculation or the absence thereof."	( Adverse Effects of Pharmacological Therapy of Benign Prostatic Hyperplasia on Sexual Function in Men. Bogdanović, D; Djenić, N; Ignjatović, I; Stojanović, N, )	0.13
" Adverse events occurred more frequently with silodosin than with tamsulosin; however, none of the adverse events required treatment discontinuation."	( Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Arai, Y; Chiba, K; Horiuchi, S; Moriyama, S; Noro, A; Saito, K; Takeshita, H; Washino, S, 2016)	0.89
" Safety was analyzed using adverse events."	( Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study. Chang, IH; Hwang, SD; Kim, JH; Kim, KH; Shim, SR; Shin, IS; Song, YS; Yoon, SJ, 2016)	1.06
"2 mg has similar efficacy and fewer adverse events compared with other alpha-blockers as an initial treatment strategy for men with lower urinary tract symptoms."	( Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study. Chang, IH; Hwang, SD; Kim, JH; Kim, KH; Shim, SR; Shin, IS; Song, YS; Yoon, SJ, 2016)	1.06
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" After 4 weeks of medication, we compared the clinical global impression of change (CGIC) , PE profile (PEP) scores, intravaginal ejaculation latency time (IELT) , and adverse reactions between the two groups of patients."	( [Efficacy and safety of dapoxetine in the treatment of premature ejaculation]. Chen, XY; Qu, YW; Wang, SG, 2016)	0.43
" The incidence of adverse reactions was significantly lower in the dapoxetine than in the control group (3."	( [Efficacy and safety of dapoxetine in the treatment of premature ejaculation]. Chen, XY; Qu, YW; Wang, SG, 2016)	0.43
"Dapoxetine is effective for the treatment of PE, with its advantages of prolonging the intravaginal ejaculation latency time, improving the quality of sexual life, and low incidence of adverse reactions."	( [Efficacy and safety of dapoxetine in the treatment of premature ejaculation]. Chen, XY; Qu, YW; Wang, SG, 2016)	0.43
" Adverse events (AEs) were not increased with treatment progression."	( Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial. Cai, JL; Jing, S; Na, YQ; Yan, YF; Yang, Y; Zhou, Z, 2016)	0.65
"Tamsulosin, dutasteride and imidafenacin combination therapy improves overactive bladder symptoms and quality of life without causing serious adverse drug reactions in patients with enlarged prostate not responding to tamsulosin."	( Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study) Asakura, H; Seki, N; Tokunaga, S; Yamanishi, T, 2017)	2.15
"Patient-reported outcomes associated with adverse events (AEs) reported with generics have not been evaluated."	( Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study. Iyer, G; Marimuthu, SP; Segal, JB; Singh, S, 2017)	0.71
"We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System after reviewing 1237 case reports in the US FDA's Adverse Event Reporting System (FAERS; 2011-2013)."	( Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study. Iyer, G; Marimuthu, SP; Segal, JB; Singh, S, 2017)	0.96
" The safety assessments were adverse reactions, laboratory test results, and vital signs at week 24."	( Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial. Ahn, TY; Hyun, JS; Jung, J; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Park, NC; Ryu, JK; Son, H; Yang, DY; Yang, SK, 2017)	0.7
" No clinically significant adverse events regarding the investigational products were observed during the 24-week period."	( Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial. Ahn, TY; Hyun, JS; Jung, J; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Park, NC; Ryu, JK; Son, H; Yang, DY; Yang, SK, 2017)	0.7
" The International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), post-void residual (PVR) urine volume, blood pressure, heart rate and adverse events were compared among the three groups at 4, 8 and 12 weeks."	( Efficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial. Bae, JH; Chang, IH; Chung, JH; Chung, JI; Ha, US; Han, DH; Han, JH; Jung, J; Kim, JH; Kim, SW; Kim, TH; Kim, YI; Lee, SH; Lee, SW; Oh, CY; Yoo, TK, 2018)	0.79
" No patients experienced any serious adverse effects in any of the three groups."	( Efficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial. Bae, JH; Chang, IH; Chung, JH; Chung, JI; Ha, US; Han, DH; Han, JH; Jung, J; Kim, JH; Kim, SW; Kim, TH; Kim, YI; Lee, SH; Lee, SW; Oh, CY; Yoo, TK, 2018)	0.79
" We did not observe any adverse events or significant endothelial cell loss (p = 0."	( Efficacy and safety of low-concentration, bisulphite-containing, intracameral epinephrine and topical atropine treatments for the prevention of intraoperative floppy iris syndrome. Bulut, AE; Esen, F; Toker, E, 2018)	0.48
"Concomitant TURBT and TURP appear to be oncologically safe procedures in terms of total and prostatic urethra recurrence, and improve QL in men with BC who require surgery for symptomatic BPH."	( Oncological safety and quality of life in men undergoing simultaneous transurethral resection of bladder tumor and prostate: results from a randomized controlled trial. Branchi, A; Castellani, D; Claudini, R; Dellabella, M; Gasparri, L, 2018)	0.48
" Patients discontinued tamsulosin primarily because of adverse events (AEs) or insufficient response."	( Safety of Tamsulosin: A Systematic Review of Randomized Trials with a Focus on Women and Children. Chughtai, BI; Kaplan, SA, 2018)	1.19
" Even though tamsulosin has a higher incidence of retrograde ejaculation than placebo, no significant difference was observed in the incidence of other adverse events."	( Efficacy and Safety of Tamsulosin in the Medical Expulsion Therapy for Distal Ureteral Calculi: A Systematic Review and Meta-Analysis of Placebo-Controlled Trials. Liu, FD; Lv, JL; Qin, ZQ; Tao, RZ, 2019)	1.19
" It should be a safe and effective medical expulsive therapy choice for distal ureteral stones when stone sizes are less than 10 mm."	( Efficacy and Safety of Tamsulosin in the Medical Expulsion Therapy for Distal Ureteral Calculi: A Systematic Review and Meta-Analysis of Placebo-Controlled Trials. Liu, FD; Lv, JL; Qin, ZQ; Tao, RZ, 2019)	0.82
" For safety, combination-therapy had a higher incidence rate of any adverse events (AEs) and discontinuation due to AEs than monotherapy with the exception of pain."	( Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction. Cui, Y; Gao, Z; Wu, J; Xu, Z; Zheng, X; Zhou, Z, )	0.38
"Short-term utilisation of Tamsulosin as MET in second and third trimester of pregnancy is not associated with adverse maternal or infant outcomes."	( Safety and efficacy of Tamsulosin as medical expulsive therapy in pregnancy. Cloutier, J; Morin, F; Theriault, B, 2020)	1.17
" Safety assessments included treatment emergent adverse events, and post-void residual volume, and maximum urinary flow measurements."	( Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). Cambronero Santos, J; Chapple, C; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT; Schermer, CR; Staskin, D, 2020)	0.77
" Higher overall treatment emergent adverse event rates were observed with tamsulosin plus placebo, although higher rates of drug related treatment emergent adverse events were noted with tamsulosin plus mirabegron."	( Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). Cambronero Santos, J; Chapple, C; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT; Schermer, CR; Staskin, D, 2020)	1
"To assess the impact of baseline characteristics on Men's Sexual Health Questionnaire (MSHQ) total scores and to evaluate the clinical relevance of MSHQ changes and their association with spontaneously reported sexual adverse events (SexAEs) in patients with benign prostatic hyperplasia."	( Men's Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of Giuliano, F; Lulic, Z; Manyak, MJ; Palacios-Moreno, JM; Roehrborn, CG; Rosen, RC; Wilson, TH, 2020)	0.76
" Safety assessments that included treatment-emergent adverse events (odds ratio = 0."	( The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. Chen, Z; Gao, Y; Liang, L; Lin, J; Liu, L; Su, S, 2020)	0.77
"This analysis demonstrates that mirabegron is an effective and safe treatment for OAB symptoms induced by BPH in men receiving tamsulosin therapy with a low occurrence of side effects."	( The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. Chen, Z; Gao, Y; Liang, L; Lin, J; Liu, L; Su, S, 2020)	0.97
"The adverse effects were minor and were managed symptomatically without any drug discontinuity."	( Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. Gupta, S; Singh, I; Tk, A, 2020)	0.83
" The analysis focused on treatment-emergent adverse events relating to the cardiovascular system or blood pressure, and changes in vital signs during 12 weeks of follow-up."	( Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O, 2021)	0.87
"Cardiovascular-related treatment-emergent adverse events were reported by 6/566 patients, although only one serious treatment-emergent adverse event was related to treatment (unstable angina in the tamsulosin + placebo group)."	( Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O, 2021)	1.06
"Cardiovascular-related adverse events were uncommon in both treatment groups."	( Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O, 2021)	0.87
" An analysis of safety outcomes revealed extremely high adverse events (AEs) and pain in the combination group."	( Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis. Sun, F; Sun, K; Wang, J; Wang, T; Wu, G; Wu, J; Yao, H; Zhang, D, )	0.39
"To describe the otorhinolaryngological adverse effects of the main drugs used in urological practice."	( Otorhinolaryngological adverse effects of urological drugs. Ganança, FF; Lopes, KC; Maia, NPD, )	0.13
"A review of the scientific literature was performed using a combination of specific descriptors (side effect, adverse effect, scopolamine, sildenafil, tadalafil, vardenafil, oxybutynin, tolterodine, spironolactone, furosemide, hydrochlorothiazide, doxazosin, alfuzosin, terazosin, prazosin, tamsulosin, desmopressin) contained in publications until April 2020."	( Otorhinolaryngological adverse effects of urological drugs. Ganança, FF; Lopes, KC; Maia, NPD, )	0.31
"The main drugs used in Urology may cause several otorhinolaryngological adverse effects."	( Otorhinolaryngological adverse effects of urological drugs. Ganança, FF; Lopes, KC; Maia, NPD, )	0.13
"Most of the drugs used in urological practice have otorhinolaryngological adverse effects."	( Otorhinolaryngological adverse effects of urological drugs. Ganança, FF; Lopes, KC; Maia, NPD, )	0.13
" Efficacy was evaluated using the OABS Score (OABSS), mean change in nocturnal frequency (NF), PVR and IPSS, while safety was assessed by recording treatment emergent adverse events (TEAE)."	( Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical stud Behera, DP; Gupta, S; Singh, I; T K, A, 2021)	0.93
"Mirabegron can be significantly efficacious and safe in ameliorating non-neurogenic OABS induced by BPE vs placebo by initiating combination therapy from the start as opposed to the usual 'add on therapy' protocol."	( Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical stud Behera, DP; Gupta, S; Singh, I; T K, A, 2021)	0.93
" We sought to define the safe threshold of force for the passage of a ureteral access sheath using a novel ureteral access sheath force sensor."	( Determining the Safety Threshold for the Passage of a Ureteral Access Sheath in Clinical Practice Using a Purpose-Built Force Sensor. Clayman, RV; Cottone, C; Jiang, P; Kaler, KS; Klopfer, MJ; Landman, J; Lu, S; Okhunov, Z; Patel, RM; Tapiero, S, 2021)	0.62
" The frequency, duration of treatment and risk of any adverse event (AE) or serious AE (SAE) was compared for combination therapy versus each monotherapy using non-inferiority testing."	( Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database. Bhak, RH; Cortes, V; Cunnington, M; Duh, MS; Kapse, P; Lulic, Z; Miller, D; Park, S; Son, H; Yoo, SB, 2021)	0.89
" The outcomes included the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score, Chinese Medicine Symptoms Score (CMSS), expressed prostatic secretions (EPS) and adverse events (AEs)."	( Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial. Deng, YJ; Gao, QH; Guo, J; Liu, SJ; Zeng, Y; Zhao, M, 2022)	0.72
"Preoperative tamsulosin can not only increase the one-time success rate of ureteral navigation and the stone-free rate of URS but also reduce the incidence of postoperative adverse symptoms such as postoperative fever and postoperative pain."	( The Effect of Preoperative Tamsulosin on Ureteral Navigation, Operation, and Safety: A Systematic Review and Meta-Analysis. Cheng, C; Jin, X; Ma, Y; Wen, J; Xiang, L, 2023)	1.58
"Patients on alpha-blockers (ABs) treatment may have an increased risk of adverse events (AEs)."	( Adverse events related to alpha-blockers: analysis of real-life data from Eudra-Vigilance. Baldassarri, V; Cicione, A; D'Annunzio, S; DE Nunzio, C; Franco, A; Guarnotta, G; Lombardo, R; Mancini, E; Nacchia, A; Rovesti, LM; Tema, G; Tubaro, A; Voglino, OA, 2023)	0.91
"Eudra-Vigilance (EV) database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA)."	( Adverse events related to alpha-blockers: analysis of real-life data from Eudra-Vigilance. Baldassarri, V; Cicione, A; D'Annunzio, S; DE Nunzio, C; Franco, A; Guarnotta, G; Lombardo, R; Mancini, E; Nacchia, A; Rovesti, LM; Tema, G; Tubaro, A; Voglino, OA, 2023)	0.91

Excerpt	Reference	Relevance
" Mean Cmax and AUC of unbound drug (Cmax,u and AUCu), however, were almost the same in the two groups."	( Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. Akaza, H; Aoyagi, K; Higuchi, S; Ito, M; Kamimura, H; Kikuchi, K; Koiso, K; Matsushima, H; Miyazaki, M; Ohba, S; Sueyoshi, T; Watanabe, T, 1996)	0.62
" To test this hypothesis, we conducted three randomized, double-masked, placebo-controlled studies to evaluate how coadministration of tamsulosin would affect the pharmacodynamic profiles of nifedipine, enalapril, and atenolol."	( Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Lowe, FC, )	0.66
"A radioreceptor assay has been developed for alpha1-adrenoceptor subtypes and applied to a pharmacokinetic analysis of tamsulosin and terazosin."	( Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. Michel, MC; Schäfers, RF; Taguchi, K, 1998)	0.79
"8 mg) affects the pharmacokinetic and safety profile of intravenous digoxin (0."	( Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation. Forrest, A; Ito, Y; Kamimura, H; Miyazawa, Y; Paul Starkey, L; Schentag, JJ; Swarz, H, 2002)	0.57
" Theophylline and tamsulosin pharmacokinetic data were determined following administration of the drugs on days 1 and 9 and day 9, respectively."	( Effects of the concomitant administration of tamsulosin (0.8 mg/day) on the pharmacokinetic and safety profile of theophylline (5 mg/kg): a placebo-controlled evaluation. Forrest, A; Ito, Y; Kamimura, H; Miyazawa, Y; Schentag, JJ; Starkey, LP; Swarz, H, )	0.72
"To evaluate pharmacokinetic and pharmacodynamic interactions between tamsulosin and acenocoumarol."	( A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol. Clarke, C; Mullins, F; Rolan, P; Terpstra, IJ; Visser, JN, 2003)	0.78
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" The pharmacokinetics of tamsulosin are not affected to a major extent by age, and pharmacokinetic alterations in renally impaired patients relate largely to an increased concentration of alpha(1)-acid glycoprotein."	( Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. de la Rosette, JJ; Franco-Salinas, G; Michel, MC, 2010)	0.93
" The pharmacokinetics of tamsulosin hydrochloride (HCl) have been extensively studied in adults, but no pharmacokinetic data for paediatrics have been published to date."	( Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Higuchi, S; Ieiri, I; Liesenfeld, KH; Sarashina, A; Schäfer, HG; Staab, A; Tadayasu, Y; Tatami, S; Tsuda, Y; Yamamura, N, 2010)	0.95
"A population pharmacokinetic model of tamsulosin HCl was developed in paediatric patients."	( Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Higuchi, S; Ieiri, I; Liesenfeld, KH; Sarashina, A; Schäfer, HG; Staab, A; Tadayasu, Y; Tatami, S; Tsuda, Y; Yamamura, N, 2010)	0.92
"A population pharmacokinetic model of tamsulosin HCl in paediatric patients was established and it described the data well."	( Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Higuchi, S; Ieiri, I; Liesenfeld, KH; Sarashina, A; Schäfer, HG; Staab, A; Tadayasu, Y; Tatami, S; Tsuda, Y; Yamamura, N, 2010)	0.92
"The Mean ± SD of pharmacokinetic parameters tmax, Cmax, AUC24, AUClast and AUCinf for Tamsulosin were 11."	( A pharmacokinetic and bioequivalence study of Contiflo ICON 400 µg tablets in healthy Indian subjects. Arora, R; Arora, V; Balaji, A; Jha, D; Madan, S; Monif, T; Thudi, NR, 2010)	0.58
" However, data on potential drug-drug interactions between tamsulosin and inhibitors of CYP2D6 and 3A4 are limited and information on potential pharmacodynamic consequences of such pharmacokinetic interactions is missing."	( Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Mattheus, M; Mehlburger, L; Michel, MC; Tatami, S; Troost, J; Tsuda, Y; Wein, M, 2011)	0.82
"85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11."	( Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Mattheus, M; Mehlburger, L; Michel, MC; Tatami, S; Troost, J; Tsuda, Y; Wein, M, 2011)	0.81
" Saliva and plasma samples were collected for 3-5 half-life values of sitagliptin, cinacalcet, metformin, montelukast, tolterodine, hydrochlorothiazide (HCT), lornoxicam, azithromycin, diacerhein, rosuvastatin, cloxacillin, losartan and tamsulosin after oral dosing."	( Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. Arafat, T; Idkaidek, N, 2012)	0.56
" The validated method was successfully applied to a pharmacokinetic study in humans."	( Determination of tamsulosin in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Bae, JW; Byeon, JY; Choi, CI; Jang, CG; Lee, HI; Lee, SY; Lee, YJ, 2012)	0.72
" The levofloxacin concentrations were detected by high performance liquid chromatography (HPLC), and the pharmacokinetic parameters were calculated using the 3p97 software program."	( Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis. He, HX; He, Y; Qin, GD; Xiao, MZ; Yang, J; Zeng, Y; Zhou, YD, 2013)	1.83
"The primary aim of this study was to evaluate whether there was clinically significant pharmacokinetic (PK) interaction between finasteride and tamsulosin in healthy Chinese male subjects."	( Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers. Chen, W; Chu, N; Li, X; Wang, G; Wang, J; Xu, H; Yang, M; Yuan, F, 2015)	0.87
" Pharmacokinetic parameters were estimated via noncompartmental methods."	( Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers. Chen, W; Chu, N; Li, X; Wang, G; Wang, J; Xu, H; Yang, M; Yuan, F, 2015)	0.67
" In the presence or absence of tamsulosin, there were no apparent changes in dutasteride AUC and Cmax ."	( Effect of tamsulosin on the pharmacokinetics of dutasteride in Chinese male healthy volunteers. Fossler, MJ; Li, H; Wang, C; Yang, J; Zhao, H, 2015)	1.11
" This study aims to develop and validate the physiologically based pharmacokinetic (PBPK) model of tamsulosin in CYP2D6wt/wt, CYP2D6wt/10, and CYP2D610/10 genotypes, using Simcyp® simulator."	( Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Bae, JW; Cho, CK; Jang, CG; Kang, P; Lee, SY; Lee, YJ; Park, HJ, 2021)	1.08

Excerpt	Reference	Relevance
" The efficacy and prostate reduction of an anti-androgenic agent, chlormadinone acetate, combined with alpha adrenergic blocker, tamsulosin hydrochloride, were evaluated using 40-BPH patients insufficiently treated with tamsulosin hydrochloride alone."	( [Clinical efficacy and reduction effect on prostatic volume of chlormadinone acetate combined with tamsulosin hydrochloride in benign prostatic hyperplasia patients insufficiently treated with tamsulosin hydrochloride only]. Asari, T; Egawa, M; Haginaka, T; Kameda, K; Katsumi, T; Kawaguchi, K; Miyazaki, K; Murayama, K; Nishino, A; Sakai, A; Ueki, O, 1998)	0.72
"To evaluate the efficacy and tolerability of extended-release oxybutynin in combination with the alpha1-blocker tamsulosin in reducing lower urinary tract symptoms in men."	( Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Aquilina, JW; Armstrong, RB; Chen, A; MacDiarmid, SA; Nitti, VW; Orman, C; Peters, KM, 2008)	0.79
"Tamsulosin combined with extended-release oxybutynin resulted in significantly greater improvement in total IPSS compared with tamsulosin and placebo after 8 (P=."	( Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Aquilina, JW; Armstrong, RB; Chen, A; MacDiarmid, SA; Nitti, VW; Orman, C; Peters, KM, 2008)	2.02
"To investigate the clinical efficacy of Shuganyiyang Capsule combined with conventional Western medicine (tamsulosin hydrochloride sustained release tablets + prostat tablets) for the treatment of type III prostatitis complicated by erectile dysfunction (ED)."	( [Clinical efficacy of Shuganyiyang capsule combined with Western medicine for the treatment of type III prostatitis complicated by erectile dysfunction]. Chen, L; Feng, YG; Zhou, ZH, 2013)	0.6
"Eighty patients with type III prostatitis complicated by ED were equally randomized to an experimental and a control group, the former treated with Shuganyiyang Capsule combined with tamsulosin hydrochloride sustained release tablets and prostat tablets, while the latter with tamsulosin hydrochloride and prostat only, both for 8 weeks."	( [Clinical efficacy of Shuganyiyang capsule combined with Western medicine for the treatment of type III prostatitis complicated by erectile dysfunction]. Chen, L; Feng, YG; Zhou, ZH, 2013)	0.58
"Shuganyiyang Capsule combined with conventional Western medicine, such as alpha blockers and galenica, produces definite effect on chronic prostatitis complicated by ED, improves the psychological conditions of the patient, and enhances the therapeutic efficiency of chronic prostatits."	( [Clinical efficacy of Shuganyiyang capsule combined with Western medicine for the treatment of type III prostatitis complicated by erectile dysfunction]. Chen, L; Feng, YG; Zhou, ZH, 2013)	0.39
" Therefore, we performed a meta-analysis to provide an update on the clinical efficacy and safety of tamsulosin combined with SWL for urolithiasis."	( The Efficacy and Safety of Tamsulosin Combined with Extracorporeal Shockwave Lithotripsy for Urolithiasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chen, K; Liu, L; Lv, T; Meng, Q; Mi, H; Sun, X; Wang, S; Xu, G, 2015)	0.93
"Overall, evidence suggests that tamsulosin combined with SWL is safe and effective in enhancing stone expulsion for patients with urolithiasis."	( The Efficacy and Safety of Tamsulosin Combined with Extracorporeal Shockwave Lithotripsy for Urolithiasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chen, K; Liu, L; Lv, T; Meng, Q; Mi, H; Sun, X; Wang, S; Xu, G, 2015)	1
" Alpha blockers in combination with muscarinic receptor antagonists may have the potential to improve symptoms."	( A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia. Cao, Y; Chen, T; Guo, L; Niu, H; Wang, Y; Yang, X, 2016)	0.65
"Randomized controlled trials evaluating solifenacin or its combination with tamsulosin for the treatment of SRSs were identified via a comprehensive search of Pubmed, Embase, Ovid, The Cochrane Library and relevant sources up to February 2017."	( The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis. Bai, B; Lei, Y; Mu, J; Wang, J; Zhang, T; Zhang, X, 2017)	0.93
" The aim of this study was to evaluate a new technology, extracorporeal physical vibrational lithecbole (EPVL) combined with tamsulosin, as a treatment for distal ureteral calculi (DUC)."	( Treatment of Distal Ureteral Calculi Using Extracorporeal Physical Vibrational Lithecbole Combined with Tamsulosin: A New Option to Speed Up Obstruction Relief. Chen, X; Cheng, Y; Hu, J; Jia, X; Liu, G; Wu, W; Xie, G, 2018)	0.9
"To compare the clinical efficacy differences among acupuncture combined with western medicine, acupuncture alone and western medicine alone for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."	( [Acupuncture combined with western medicine for CP/CPPS:a randomized controlled trial]. Chen, G; Chen, H; Chen, J; Li, T; Ouyang, L; Wang, X; Xiang, J; Zhang, S, 2016)	0.43
" The patients in the needle-medicine group were treated with acupuncture combined with western medicine; the scalp points included Shenting (GV 24), Xinhui (GV 22), Qianding (GV 21), Baihui (GV 20), Chengguang (BL 6), Tongtian (BL 7), etc."	( [Acupuncture combined with western medicine for CP/CPPS:a randomized controlled trial]. Chen, G; Chen, H; Chen, J; Li, T; Ouyang, L; Wang, X; Xiang, J; Zhang, S, 2016)	0.43
"The efficacy of acupuncture combined with western medicine for CP/CPPS is superior to that of acupuncture alone and western medicine alone, which could improve the symptom of prostatitis as well as status of anxiety and depression."	( [Acupuncture combined with western medicine for CP/CPPS:a randomized controlled trial]. Chen, G; Chen, H; Chen, J; Li, T; Ouyang, L; Wang, X; Xiang, J; Zhang, S, 2016)	0.43
"To evaluate the efficacy and safety of tamsulosin combined with dapoxetine in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) that is complicated by premature ejaculation (PE), a total of 251 CP/CPPS patients with PE were recruited from nine hospitals across China and were randomly divided into two groups: one received tamsulosin as a control, and the other received a combination therapy of tamsulosin and dapoxetine."	( Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Ji, Z; Li, Z; Liang, C; Song, W; Tian, R; Wang, Z; Xia, S; Zhang, L; Zhao, J; Zhao, L, 2019)	1.1
"Aim of our systematic review is to evaluate and summarize the efficacy and safety of tadalafil alone or in combination with tamsulosin for the management of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)."	( Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED. Chapple, C; Gacci, M; Gravas, S; Kaplan, S; McVary, KT; Morselli, S; Sebastianelli, A; Serni, S; Spatafora, P; Vignozzi, L, 2020)	1.03
"To investigate the clinical effect of pelvic floor muscle rehabilitation training combined with psychological nursing intervention in the treatment of intractable type ⅢB prostatitis."	( [Pelvic floor muscle rehabilitation training combined with psychological nursing intervention in the treatment of type ⅢB prostatitis]. Cao, TH; Chen, YF; Ge, YP; Li, GP; Zhang, MX, 2023)	0.91
"On the basis of Tamsulosin medication, the application of pelvic floor rehabilitation training combined with psychological care can significantly enhance the therapeutic effect on type IIIB prostatitis, effectively relieve prostatitis pain, improve erectile function, lessen anxiety and depression symptoms, increase the level of lecithosomes and promote the recovery of prostatic function."	( [Pelvic floor muscle rehabilitation training combined with psychological nursing intervention in the treatment of type ⅢB prostatitis]. Cao, TH; Chen, YF; Ge, YP; Li, GP; Zhang, MX, 2023)	1.26

Excerpt	Reference	Relevance
" The mean absolute oral bioavailability (+/-SD) was approximated at 100 +/- 19%."	( Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. Higuchi, S; Matsushima, H; Soeishi, Y; van Hoogdalem, EJ, 1997)	0.54
" The absolute bioavailability (BA) increased from 19."	( Effect of alpha(1)-acid glycoprotein on the pharmacokinetics of tamsulosin in rats treated with turpentine oil. Higuchi, S; Matsushima, H; Watanabe, T, 2000)	0.55
" While many of the compounds tested displayed poor pharmacokinetics, compound 48 was found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs."	( In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia. Barrish, A; Barrow, JC; Broten, TP; Chang, RS; Ellis, JD; Forray, C; Freidinger, RM; Gilbert, KF; Glass, KL; Homnick, CF; Kassahun, K; Kling, P; Leppert, P; Nagarathnam, D; Nantermet, PG; O'Malley, SS; Olah, TV; Ransom, RW; Reiss, D; Rittle, KE; Schorn, TW; Selnick, HG; Steele, TG, 2000)	0.31
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."	( Rapid, simple and highly sensitive LC-ESI-MS/MS method for the quantification of tamsulosin in human plasma. Koteshwara, M; Manoj, S; Ramakrishna, NV; Varma, DP; Vishwottam, KN; Wishu, S, 2005)	0.55
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."	( Quantification of pramipexole in human plasma by liquid chromatography tandem mass spectrometry using tamsulosin as internal standard. Ajjala, D; Kandikere, V; Maurya, S; Mudigonda, K; Nirogi, RV; Shrivastava, W, 2007)	0.55
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" The oral bioavailability of the MR formulation in the fasted state is close to 100%."	( Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. de la Rosette, JJ; Franco-Salinas, G; Michel, MC, 2010)	0.63
"918) due to the decreased dissolution and absorption rate of the formulation."	( Formulation variation and in vitro-in vivo correlation for a rapidly swellable three-layered tablet of tamsulosin HCl. Choi, YW; Jeong, SH; Kang, JM; Kwon, MC; Lee, MJ; Lee, SH; Park, JS; Shim, JY, 2011)	0.58
" Our results suggest that MTCR microparticles may be potential oral dosage forms to control the release and to improve the bioavailability of tamsulosin hydrochloride."	( Preparation and in vivo evaluation of spray dried matrix type controlled-release microparticles of tamsulosin hydrochloride for orally disintegrating tablet. Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS, 2012)	0.8

Excerpt	Relevance	Reference
" Patient's impression and subjective symptoms were improved in a certain dose-response relationship Side effects were observed in 3 patients but none were serious."	( [Clinical efficacy and safety of long-term administration of YM617 for urinary obstruction of the lower urinary tract]. Akino, H; Arai, Y; Fukuyama, T; Hida, S; Okabe, T; Okada, K; Takeuchi, H; Tomoyoshi, T; Yoshida, O, 1991)	0.28
" In the isolated tissue, pretreatment with CEC (10(-5) M, 10 and 30 min) time-dependently shifted to the right the dose-response curve for phenylephrine and decreased the maximal contraction of aortas induced by phenylephrine, but did not shift or decrease those of prostates."	( Alpha 1-adrenoceptor subtype in the rat prostate is preferentially the alpha 1A type. Honda, K; Yazawa, H, 1993)	0.29
" Unchanged drug and metabolites in urine and bile were quantified in rat and dog dosed with 14C-TMS(1 mg/kg)."	( Metabolism of tamsulosin in rat and dog. Higuchi, S; Kaniwa, H; Matsushima, H; Soeishi, Y; Teraya, Y; Watanabe, T, 1996)	0.65
" Plasma and blood radioactivity concentrations attained peak levels (Cmax) within 1 h after dosing and then declined biphasically."	( Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Cornelissen, K; Higuchi, S; Matsushima, H; Soeishi, Y; Ward, J; Watanabe, T, 1996)	0.56
"4-mg oral dosing was measurable."	( Highly sensitive method for the determination of tamsulosin hydrochloride in human plasma dialysate, plasma and urine by high-performance liquid chromatography-electrospray tandem mass spectrometry. Higuchi, S; Kamimura, H; Matsushima, H; Takanuki, KI; Watanabe, T, 1997)	0.55
"To evaluate the efficacy and safety in a dose-ranging study of tamsulosin (once-daily) as a modified-release formulation compared with placebo in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and to establish the optimum dosage for phase III clinical studies."	( A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Abrams, P; Arkell, D; Pocock, R; Speakman, M; Stott, M, 1997)	0.79
" Another advantage compared with alfuzosin (and prazosin) is the once-daily dosing regimen of tamsulosin."	( Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Buzelin, JM; Fonteyne, E; Khan, A; Kontturi, M; Witjes, WP, 1997)	0.88
"The pharmacokinetics of tamsulosin hydrochloride, a selective alpha1-adrenoceptor antagonist, was investigated after single iv and oral dosing to rats and dogs, and oral dosing to healthy male volunteers."	( Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Higuchi, S; Kamimura, H; Matsushima, H; Soeishi, Y; Tsunoo, M; Watanabe, T, 1998)	0.86
"Once-daily dosing of TAM after breakfast at a fixed dose level (0."	( A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. de Mey, C; McEwen, J; Michel, MC; Moreland, T, 1998)	0.56
" It is a more convenient alternative that does not require initial dosage titration, has a fast onset of action, and has a low potential to cause hypotension when used alone or in combination with commonly used antihypertensive agents."	( Tamsulosin for the treatment of benign prostatic hypertrophy. Lee, M, 2000)	1.75
"3 mg/kg of TAM was dosed intravenously, total and nonrenal clearances (CL(tot) and CL(nr)) in turpentine-treated rats were 47% and 44% lower than those in nontreated controls, respectively."	( Effect of alpha(1)-acid glycoprotein on the pharmacokinetics of tamsulosin in rats treated with turpentine oil. Higuchi, S; Matsushima, H; Watanabe, T, 2000)	0.55
"To determine whether the time of dosing (morning or evening) affects the tolerability or efficacy of tamsulosin in the treatment of lower urinary tract symptoms."	( Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin? Goepel, M; Mehlburger, L; Michel, MC; Neumann, HG; Schumacher, H, 2001)	0.75
" The results were analysed statistically for differences between dosing times, using analysis of covariance for the quantitative variables and logistic regression for the qualitative variables."	( Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin? Goepel, M; Mehlburger, L; Michel, MC; Neumann, HG; Schumacher, H, 2001)	0.53
"While no specific recommendation about the dosing time was given in the trial, the retrospective analysis showed that 4420 and 2087 patients received tamsulosin in the morning and evening, respectively."	( Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin? Goepel, M; Mehlburger, L; Michel, MC; Neumann, HG; Schumacher, H, 2001)	0.73
"In contrast to other alpha-blockers, night-time dosing is not necessary to improve the tolerability or efficacy of tamsulosin."	( Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin? Goepel, M; Mehlburger, L; Michel, MC; Neumann, HG; Schumacher, H, 2001)	0.74
" The inhibition peaked about 90 min after dosing and lasted up to 240 min."	( Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention possibly contributes to uroselectivity of tamsulosin. Matsushima, H; Miyata, K; Ohtake, A; Saitoh, C; Sato, S; Usuda, S, 2001)	0.61
"8 mg daily had a rapid onset of action and was effective and well tolerated, with minimal differences observed between dosage groups."	( A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Bruskewitz, R; Narayan, P, )	0.36
" Plasma tamsulosin concentrations were measured at regular intervals after dosing on day 15."	( Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation. Forrest, A; Ito, Y; Kamimura, H; Miyazawa, Y; Paul Starkey, L; Schentag, JJ; Swarz, H, 2002)	1.01
"2 mg dosage was given daily, and uroflowmetry was followed."	( [Tamsulosin for the treatment of chronic abacterial prostatitis]. Chen, XS; Ye, ZQ; Zeng, XY, 2002)	1.22
" Mean sodium diclofenac dosage per patient in groups 1 to 3 was 19."	( Nifedipine versus tamsulosin for the management of lower ureteral stones. Fiori, C; Fontana, D; Ghignone, G; Porpiglia, F; Scarpa, RM, 2004)	0.66
" He had been administered distigmine bromide orally for over two years at a daily dosage of 10 mg as a treatment for underactive neurogenic bladder."	( [A case of acute distigmine bromide intoxication in the therapeutic dosage for treatment of underactive neurogenic bladder]. Fujita, N; Koike, H; Nagai, H; Tada, M; Umeda, M, 2004)	0.32
" Higher rates of twice-daily (or 2 units per day) dosing are associated with higher incremental cost-effectiveness ratios."	( Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. Chrischilles, EA; Klein, RW; Kreder, KJ; Ohsfeldt, RL, )	0.45
" Blood pressure (BP) and heart rate were recorded before dosing and for 24 hours after dosing."	( Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. Bedding, A; Emmick, JT; Jackson, G; Kloner, RA; Mitchell, MI; Pereira, A; Warner, MR, 2004)	0.54
" Meanwhile the number of pain episodes, analgesic dosage and the number of days for spontaneous passage of the calculi through the ureter were also recorded."	( The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. Basar, H; Basar, MM; Batislam, E; Ferhat, M; Tuglu, D; Yilmaz, E, 2005)	0.33
" In study 1, CV alpha1-adrenoceptor antagonism was assessed by measuring the inhibition of phenylephrine (PE)-induced increases in diastolic blood pressure (DBP) and total peripheral resistance (TPR) before and after dosing with placebo, tamsulosin OCAS, and alfuzosin XL in 18 young subjects."	( Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). Chapple, CR; Michel, MC, 2006)	0.78
"In study 1, tamsulosin OCAS induced statistically significantly less inhibition of PE-induced increases in DBP at 2 h after dosing and in TPR at 2 and 4 h after dosing than alfuzosin XL."	( Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). Chapple, CR; Michel, MC, 2006)	0.97
" In conclusion, the prediction of alpha(1)-adrenoceptor occupancy in the human prostate by alpha(1)-adrenoceptor antagonists may provide the rationale for the optimum dosage regimen of these drugs in the therapy of BPH."	( Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Kagawa, Y; Kato, Y; Kawabe, K; Okura, T; Yamada, S, 2007)	0.55
"To evaluate the efficacy of tamsulosin oral-controlled absorption system (OCAS) vs placebo in overactive bladder (OAB), to evaluate the safety and tolerability of once-daily dosing with tamsulosin OCAS, and to compare the efficacy and safety with tolterodine extended-release (ER)."	( A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. Bolodeoku, J; Cardozo, L; Robinson, D; Terpstra, G, 2007)	0.85
" The incidence of hypotension was low in healthy men given increasing doses of doxazosin with chronically dosed tadalafil or placebo."	( Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. Darstein, C; Guillaume, M; Jimenez, MC; Lonsdale, F; Mitchell, MI, 2007)	0.54
"After the dosage form of tamsulosin hydrochloride was changed from a capsule to on orally disintegrating tablet (ODT, Harnal D), we often received patient complaints and noted an increase in noncompliance with medication regimens."	( [Some problems for dosage form based on questionnaire surveying compliance in patients taking tamsulosin hydrochloride]. Hirayama, H; Ishimatsu, T; Ogata, I; Seo, H; Tsuruda, A; Tsuzaki, S; Yamasaki, K, 2008)	0.87
" Mean analgesic dosage per patient in groups 1, 2, and 3 were 231, 256, and 347 mg, respectively."	( Efficacy of an alpha1 blocker in expulsive therapy of lower ureteral stones. Chang, CH; Huang, SW; Wang, CJ, 2008)	0.35
" Reports of pain and supplemental analgesic dosing were consistently lower with tamsulosin, but data on the incidence of subsequent retreatment with ESWL or ureteroscopy was rarely reported."	( Efficacy of tamsulosin with extracorporeal shock wave lithotripsy for passage of renal and ureteral calculi. Losek, RL; Mauro, LS, 2008)	0.95
" This result suggests that blending these two-part pellets (SR and ER) can provide an alternative to preparing a controlled-release dosage form, instead of blending of the coating polymer."	( Development of a tamsulosin hydrochloride controlled-release capsule consisting of two different coated pellets. Tang, X; Yang, R; Zhang, X, 2009)	0.69
" The inhibition was also observed in human liver S9 fractions, suggesting that a reassessment of the oral dosage of tamsulosin is necessary when udenafil and tamsulosin are co-administered to patients with benign prostatic hyperplasia."	( Interaction between udenafil and tamsulosin in rats: non-competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1/2. Bae, SK; Kang, HE; Kim, YG; Lee, DC; Lee, MG; Yoo, M, 2009)	0.84
" The number of colic episodes, lower urinary tract symptoms, analgesic dosage and days for spontaneous passage of the stones through the ureter were recorded by diary."	( Adjunctive medical therapy with an alpha-1A-specific blocker after shock wave lithotripsy of lower ureteral stones. Chang, CH; Huang, SW; Wang, CJ, 2009)	0.35
"Administration of an alpha-1A-specific blocker reduced analgesic dosage and colic episodes after SWL of lower ureteral stones."	( Adjunctive medical therapy with an alpha-1A-specific blocker after shock wave lithotripsy of lower ureteral stones. Chang, CH; Huang, SW; Wang, CJ, 2009)	0.35
" Moreover, the frequency of pain episodes, the need for diclofenac, and its total dosage were significantly lower in the tamsulosin group."	( Efficacy of tamsulosin in the management of lower ureteral stones: a randomized double-blind placebo-controlled study of 100 patients. Al-Ansari, A; Al-Naimi, A; Alobaidy, A; Assadiq, K; Azmi, MD; Shokeir, AA, 2010)	0.95
"Patients' records were reviewed, and age, medical, surgical, and ocular history; gender; medications; and duration and dosage of tamsulosin were recorded."	( The effect of alpha1-adrenergic receptor antagonist tamsulosin (Flomax) on iris dilator smooth muscle anatomy. Chang, DF; Destafeno, JJ; Kim, T; Proia, AD; Santaella, RM; Stinnett, SS, 2010)	0.82
" Pain episodes, day of spontaneous stone expulsion, total analgesic dosage and drug side-effects were recorded."	( Tamsulosin as an expulsive therapy for steinstrasse after extracorporeal shock wave lithotripsy: a randomized controlled study. Abuzeid, A; Gamal, WM; Moursy, E, 2010)	1.8
"Reversed-phase high-performance liquid chromatography (RP-HPLC) and thin-layer chromatography (TLC) methods have been developed and validated for simultaneous estimation of tamsulosin hydrochloride and finasteride in bulk drug and in combined dosage forms."	( Validated RP-HPLC and TLC methods for simultaneous estimation of tamsulosin hydrochloride and finasteride in combined dosage forms. Patel, DB; Patel, NJ, 2010)	0.79
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
"The study actually assessed unbound tamsulosin concentrations in both blood plasma and prostate tissue and reported that the unbound tamsulosin concentrations after multiple dosing in men with BPH, were much higher in prostate than in blood plasma."	( Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity? Korstanje, C; Krauwinkel, W; van Doesum-Wolters, FL, 2011)	2.09
" Both number of colic episodes and analgesic dosage were significantly lower with tamsulosin as compared to control and doxazosin."	( Tamsulosin and doxazosin as adjunctive therapy following shock-wave lithotripsy of renal calculi: randomized controlled trial. Fareed, K; Fouda, K; Gaafar, S; Marzouk, E; Yakoubi, R; Zahran, AR; Zaytoun, OM, 2012)	2.05
" Our results suggest that MTCR microparticles may be potential oral dosage forms to control the release and to improve the bioavailability of tamsulosin hydrochloride."	( Preparation and in vivo evaluation of spray dried matrix type controlled-release microparticles of tamsulosin hydrochloride for orally disintegrating tablet. Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS, 2012)	0.8
" Comparison of DR(10) values (the dose required to shift the dose-response curve 10-fold to the right) in both tissues showed that the inhibitory effect of silodosin was significantly more potent in the salivary gland than in the urethra (18-fold), but tamsulosin (2."	( Effects of α1-adrenoceptor antagonists on phenylephrine-induced salivary secretion and intraurethral pressure elevation in anesthetized rats. Hatanaka, T; Noguchi, Y; Ohtake, A; Sasamata, M; Sato, S; Suzuki, M; Ueshima, K; Yanai-Inamura, H, 2012)	0.56
"05 for the dose-response slope, all variables)."	( Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Angulo, JC; Garcia-Hernandez, A; Haab, F; Katona, F; Klaver, M; Oelke, M; Traudtner, K; Van Kerrebroeck, P; Vik, V, 2013)	0.66
"To evaluate long-term (up to 52 wk) safety and efficacy of flexible dosing of two fixed-dose combinations (FDC) of Soli plus TOCAS in men with moderate to severe storage symptoms and voiding symptoms."	( Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Chapple, C; Drake, MJ; Drogendijk, T; Klaver, M; Oelke, M; Sokol, R; Traudtner, K; Van Kerrebroeck, P, 2015)	0.64
" Blood samples were collected up to 48 hours after dosing on study day 1 and up to 24 hours after dosing on study day 9 for determination of plasma concentrations with a validated LC-MS/MS method."	( Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers. Chen, W; Chu, N; Li, X; Wang, G; Wang, J; Xu, H; Yang, M; Yuan, F, 2015)	0.67
"Daily tamsulosin therapy does not enhance the clearance of stone fragments but decreases the pain episodes, analgesia dosage and need for adjuvant intervention after SWL for renal stones."	( Role of Tamsulosin Therapy after Extracorporeal Shockwave Lithotripsy for Renal Stones: Randomized Controlled Trial. Ahmed, AF; El-Feky, M; El-Kholy, M; Elsotohi, E; Kotb, A; Ragab, A; Salem, E; Shalaby, E, 2016)	1.35
"This research aims to evaluate the role of tamsulosin in the medical expulsion therapy for distal ureteral stones, including her effects in stone expulsion time, expulsion rates, stone size, pain episodes and analgesic dosage usage."	( The Role of the Tamsulosin in the Medical Expulsion Therapy for Distal Ureteral Stones. Hyseni, N; Nuraj, P, 2017)	1.06
"A validated and selective high-performance thin-layer chromatography (HPTLC) method was developed for the analysis of mixures of tamsulosin hydrochloride (TAM) with either tolterodine tartrate (TOL) or solifenacin succinate (SOL) in bulk drug and in combined dosage forms."	( Novel Validated HPTLC Method for the Analysis of Two Binary Mixtures Containing Tamsulosin Hydrochloride with Antimuscarinic Agents. Abdel Moneim, MM; Belal, SF; El-Kimary, EI; Khamis, EF, 2018)	0.91
"The combination of solifenacin in a double dosage along with tamsulosin can be recommended for elderly benign prostatic hyperplasia patients with overactive bladder symptoms."	( Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Gainullina, Y; Kosilov, K; Kosilova, L; Kuzina, I; Kuznetsov, V; Loparev, S; Prokofyeva, A, 2018)	0.92
" The developed method was successfully applied to determine the studied drugs in dosage forms and human plasma samples and the results were satisfactory as revealed by statistical analysis of the data."	( Simultaneous HPLC determination of alfuzosin, tamsulosin and vardenafil in human plasma and pharmaceutical formulations using time programmed fluorescence detection. Belal, F; Borg, H; Fathy, M; Walash, MI; Zayed, S, 2019)	0.77
" Furthermore, the methods were successfully applied for the quantification of the two drugs in their combined dosage form."	( Smart spectrophotometric assessment of tamsulosin hydrochloride and tadalafil in their new pharmaceutical formulation for treatment of benign prostatic hyperplasia and erectile dysfunction. Rezk, MR; Tantawy, MA; Wadie, M; Weshahy, SA, 2020)	0.83
" Additional dose-response analyses were carried out."	( Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ, 2021)	0.62
" This study is the first to develop and optimize a synchronous spectrofluorimetric method coupled with derivative and derivative ratio mathematical tools for the determination of tamsulosin andtadalafil in their newly released dosage form."	( Assay of new combination of tamsulosin and tadalafil using synchronous spectrofluorimetric method coupled with mathematical tools. Abdelhafez, AM; Gawad, DA; Hassan, EM; M Youssef, R, 2022)	1.21
" Dose-response analysis using defined daily doses of drug (DDDs) was conducted."	( Use of α1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease. Hartikainen, S; Latvala, L; Murtola, TJ; Tiihonen, M; Tolppanen, AM, 2022)	1
" However, very few studies were reported for their simultaneous quantification in their combined dosage form and were mainly based on chromatographic analysis."	( A New Chemometrically Assisted UV Spectrophotometric Method for Simultaneous Determination of Tamsulosin and Dutasteride in Their Pharmaceutical Mixture. Abbas, AEF; Attia, KAM; Eid, SM; Serag, A, 2022)	0.94
"The proposed models were effectively used to determine TAM/DUT in their combined dosage form, and statistical comparison with the reported method revealed satisfactory results."	( A New Chemometrically Assisted UV Spectrophotometric Method for Simultaneous Determination of Tamsulosin and Dutasteride in Their Pharmaceutical Mixture. Abbas, AEF; Attia, KAM; Eid, SM; Serag, A, 2022)	0.94
"Overall, this work presents powerful simple, selective, sensitive, and precise methods for simultaneous quantification of TAM/DUT in their dosage form with satisfactory results."	( A New Chemometrically Assisted UV Spectrophotometric Method for Simultaneous Determination of Tamsulosin and Dutasteride in Their Pharmaceutical Mixture. Abbas, AEF; Attia, KAM; Eid, SM; Serag, A, 2022)	0.94

Role	Description
alpha-adrenergic antagonist	An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide	A secondary amino compound that is ammonia in which nitrogen is substituted by a 1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl group and a 2-(2-ethoxyphenoxy)ethyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	36.1254	0.0056	12.3677	36.1254	AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Alpha-1A adrenergic receptor	Oryctolagus cuniculus (rabbit)	Ki	0.0021	0.0000	0.0204	0.2512	AID36753
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Ki	0.0008	0.0001	0.5326	10.0000	AID3814
Alpha-2A adrenergic receptor	Homo sapiens (human)	Ki	0.0382	0.0001	0.8074	10.0000	AID35936; AID35938
Tryptophan 5-hydroxylase 1	Rattus norvegicus (Norway rat)	Ki	0.0130	0.0005	0.0914	0.4900	AID64468
D(2) dopamine receptor	Homo sapiens (human)	Ki	0.0455	0.0000	0.6518	10.0000	AID64468; AID64664
Alpha-1A adrenergic receptor	Bos taurus (cattle)	Ki	0.0001	0.0000	0.5072	3.7020	AID36466
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	0.0079	0.0003	0.4834	10.0000	AID36397
Alpha-1B adrenergic receptor	Mesocricetus auratus (golden hamster)	Ki	0.0002	0.0000	2.0167	9.6000	AID32974
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0434	0.0000	0.9296	10.0000	AID36252; AID36371
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0001	0.0000	0.5751	10.0000	AID32975
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	Ki	0.0780	0.0003	0.3708	8.1600	AID64664
Alpha-1D adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.0008	0.0002	0.7568	8.8970	AID1320516; AID1743296
Alpha-1D adrenergic receptor	Homo sapiens (human)	Ki	0.0021	0.0000	0.3609	10.0000	AID1296472; AID290868; AID296252; AID321752; AID35303; AID35309; AID35468; AID36252; AID545213
5-hydroxytryptamine receptor 7	Homo sapiens (human)	Ki	0.0840	0.0003	0.3806	10.0000	AID6590
Alpha-1A adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.0013	0.0002	0.5614	5.4000	AID1320512; AID1743294
Alpha-1A adrenergic receptor	Homo sapiens (human)	Ki	0.0017	0.0000	0.2726	10.0000	AID290866; AID296250; AID321750; AID36252; AID36466; AID36478; AID36483; AID36753; AID545211
Alpha-1B adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.0045	0.0002	0.6526	8.3300	AID1320515; AID1743295
Alpha-1B adrenergic receptor	Homo sapiens (human)	Ki	0.0124	0.0000	0.4713	10.0000	AID290867; AID296251; AID321751; AID36252; AID37200; AID37205; AID37478; AID545212
D(3) dopamine receptor	Homo sapiens (human)	Ki	0.0003	0.0000	0.6020	10.0000	AID65117
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0001	0.0000	0.9650	10.0000	AID32968; AID545211; AID692053
Alpha-1D adrenergic receptor	Mus musculus (house mouse)	IC50 (µMol)	0.0018	0.0018	0.0018	0.0018	AID1491368
Alpha-1B adrenergic receptor	Mus musculus (house mouse)	IC50 (µMol)	0.0018	0.0018	0.0018	0.0018	AID1491368
Alpha-1A adrenergic receptor	Mus musculus (house mouse)	IC50 (µMol)	0.0018	0.0018	0.0018	0.0018	AID1491368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Alpha-1A adrenergic receptor	Oryctolagus cuniculus (rabbit)	Kd	0.0002	0.0002	0.0143	0.0501	AID37056
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.6277	9.3325	AID37056
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.6277	9.3325	AID37056
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.6277	9.3325	AID37056
Alpha-1D adrenergic receptor	Homo sapiens (human)	Kd	0.0000	0.0000	0.1945	1.2882	AID36126
Alpha-1A adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.0001	0.0001	0.5098	7.1000	AID1323687
Alpha-1A adrenergic receptor	Homo sapiens (human)	Kd	0.0000	0.0000	0.2048	1.2882	AID36126
Alpha-1B adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.0001	0.0001	1.3010	5.6000	AID1323689
Alpha-1B adrenergic receptor	Homo sapiens (human)	Kd	0.0001	0.0000	0.1199	1.2882	AID36126; AID37056
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cytokine production	Alpha-2A adrenergic receptor	Homo sapiens (human)
DNA replication	Alpha-2A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
Ras protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
Rho protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2A adrenergic receptor	Homo sapiens (human)
actin cytoskeleton organization	Alpha-2A adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell migration	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
cellular response to hormone stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2A adrenergic receptor	Homo sapiens (human)
vasodilation	Alpha-2A adrenergic receptor	Homo sapiens (human)
glucose homeostasis	Alpha-2A adrenergic receptor	Homo sapiens (human)
fear response	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of potassium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
intestinal absorption	Alpha-2A adrenergic receptor	Homo sapiens (human)
thermoception	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of lipid catabolic process	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of uterine smooth muscle contraction	Alpha-2A adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of wound healing	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transmembrane transporter activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
temperature homeostasis	D(2) dopamine receptor	Homo sapiens (human)
response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein phosphorylation	D(2) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(2) dopamine receptor	Homo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressure	D(2) dopamine receptor	Homo sapiens (human)
regulation of heart rate	D(2) dopamine receptor	Homo sapiens (human)
regulation of sodium ion transport	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
autophagy	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
neuron-neuron synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
axonogenesis	D(2) dopamine receptor	Homo sapiens (human)
synapse assembly	D(2) dopamine receptor	Homo sapiens (human)
sensory perception of smell	D(2) dopamine receptor	Homo sapiens (human)
long-term memory	D(2) dopamine receptor	Homo sapiens (human)
grooming behavior	D(2) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(2) dopamine receptor	Homo sapiens (human)
protein localization	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell population proliferation	D(2) dopamine receptor	Homo sapiens (human)
associative learning	D(2) dopamine receptor	Homo sapiens (human)
visual learning	D(2) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to light stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to toxic substance	D(2) dopamine receptor	Homo sapiens (human)
response to iron ion	D(2) dopamine receptor	Homo sapiens (human)
response to inactivity	D(2) dopamine receptor	Homo sapiens (human)
Wnt signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
striatum development	D(2) dopamine receptor	Homo sapiens (human)
orbitofrontal cortex development	D(2) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(2) dopamine receptor	Homo sapiens (human)
adenohypophysis development	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell migration	D(2) dopamine receptor	Homo sapiens (human)
peristalsis	D(2) dopamine receptor	Homo sapiens (human)
auditory behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(2) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
response to histamine	D(2) dopamine receptor	Homo sapiens (human)
response to nicotine	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of urine volume	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of renal sodium excretion	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of multicellular organism growth	D(2) dopamine receptor	Homo sapiens (human)
response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleep	D(2) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(2) dopamine receptor	Homo sapiens (human)
drinking behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(2) dopamine receptor	Homo sapiens (human)
response to morphine	D(2) dopamine receptor	Homo sapiens (human)
pigmentation	D(2) dopamine receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of innate immune response	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of insulin secretion	D(2) dopamine receptor	Homo sapiens (human)
acid secretion	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to ethanol	D(2) dopamine receptor	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	D(2) dopamine receptor	Homo sapiens (human)
response to axon injury	D(2) dopamine receptor	Homo sapiens (human)
branching morphogenesis of a nerve	D(2) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(2) dopamine receptor	Homo sapiens (human)
epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(2) dopamine receptor	Homo sapiens (human)
release of sequestered calcium ion into cytosol	D(2) dopamine receptor	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of synapse structural plasticity	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(2) dopamine receptor	Homo sapiens (human)
excitatory postsynaptic potential	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of growth hormone secretion	D(2) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	D(2) dopamine receptor	Homo sapiens (human)
regulation of locomotion involved in locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cellular response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor production	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	D(2) dopamine receptor	Homo sapiens (human)
hyaloid vascular plexus regression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of neuron migration	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(2) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-1A adrenergic receptor	Bos taurus (cattle)
positive regulation of MAPK cascade	Alpha-1A adrenergic receptor	Bos taurus (cattle)
regulation of cardiac muscle contraction	Alpha-1A adrenergic receptor	Bos taurus (cattle)
regulation of smooth muscle contraction	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2C adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2C adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2C adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-1D adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1D adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1D adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1D adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	5-hydroxytryptamine receptor 7	Homo sapiens (human)
circadian rhythm	5-hydroxytryptamine receptor 7	Homo sapiens (human)
blood circulation	5-hydroxytryptamine receptor 7	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 7	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 7	Homo sapiens (human)
MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
apoptotic process	Alpha-1A adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
activation of phospholipase C activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1A adrenergic receptor	Homo sapiens (human)
adult heart development	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to hormone	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of autophagy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of action potential	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
calcium ion transport into cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell growth involved in cardiac muscle cell development	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase C signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
pilomotor reflex	Alpha-1A adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-1B adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1B adrenergic receptor	Homo sapiens (human)
regulation of cardiac muscle contraction	Alpha-1B adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1B adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1B adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1B adrenergic receptor	Homo sapiens (human)
response to ethanol	D(3) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(3) dopamine receptor	Homo sapiens (human)
intracellular calcium ion homeostasis	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
learning or memory	D(3) dopamine receptor	Homo sapiens (human)
learning	D(3) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(3) dopamine receptor	Homo sapiens (human)
visual learning	D(3) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(3) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(3) dopamine receptor	Homo sapiens (human)
response to histamine	D(3) dopamine receptor	Homo sapiens (human)
social behavior	D(3) dopamine receptor	Homo sapiens (human)
response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(3) dopamine receptor	Homo sapiens (human)
response to morphine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of mitotic nuclear division	D(3) dopamine receptor	Homo sapiens (human)
acid secretion	D(3) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of oligodendrocyte differentiation	D(3) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(3) dopamine receptor	Homo sapiens (human)
musculoskeletal movement, spinal reflex action	D(3) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(3) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(3) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(3) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(3) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(3) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(3) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(3) dopamine receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein kinase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-1B adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-2C adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
thioesterase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
heterotrimeric G-protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(2) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(2) dopamine receptor	Homo sapiens (human)
protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(2) dopamine receptor	Homo sapiens (human)
dopamine binding	D(2) dopamine receptor	Homo sapiens (human)
ionotropic glutamate receptor binding	D(2) dopamine receptor	Homo sapiens (human)
identical protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterocyclic compound binding	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(2) dopamine receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Bos taurus (cattle)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
identical protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1D adrenergic receptor	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1B adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(3) dopamine receptor	Homo sapiens (human)
protein binding	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(3) dopamine receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
cytoplasm	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
basolateral plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
neuronal cell body	Alpha-2A adrenergic receptor	Homo sapiens (human)
axon terminus	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic active zone membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
dopaminergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
postsynaptic density membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
glutamatergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
GABA-ergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor complex	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
Golgi membrane	D(2) dopamine receptor	Homo sapiens (human)
acrosomal vesicle	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cilium	D(2) dopamine receptor	Homo sapiens (human)
lateral plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
endocytic vesicle	D(2) dopamine receptor	Homo sapiens (human)
axon	D(2) dopamine receptor	Homo sapiens (human)
dendrite	D(2) dopamine receptor	Homo sapiens (human)
synaptic vesicle membrane	D(2) dopamine receptor	Homo sapiens (human)
sperm flagellum	D(2) dopamine receptor	Homo sapiens (human)
dendritic spine	D(2) dopamine receptor	Homo sapiens (human)
perikaryon	D(2) dopamine receptor	Homo sapiens (human)
axon terminus	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(2) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(2) dopamine receptor	Homo sapiens (human)
dopaminergic synapse	D(2) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(2) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(2) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Bos taurus (cattle)
cytoplasm	Alpha-1A adrenergic receptor	Bos taurus (cattle)
plasma membrane	Alpha-1A adrenergic receptor	Bos taurus (cattle)
caveola	Alpha-1A adrenergic receptor	Bos taurus (cattle)
nuclear membrane	Alpha-1A adrenergic receptor	Bos taurus (cattle)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
trans-Golgi network membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 7	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 7	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1A adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleus	Alpha-1B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1B adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
synapse	D(3) dopamine receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID545218	Antagonist activity at Alpha-1B adrenoceptor in Wistar rat spleen assessed as phenylephrine induced contractions after 30 mins	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID1320515	Antagonist activity at human full-length N-terminal SNAP-tagged alpha1B adrenoceptor expressed in HEK293 cells assessed as inhibition of agonist-induced calcium mobilization preincubated for 10 mins followed by agonist addition by fluo-4 AM dye-based assa	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α
AID1323689	Intrinsic activity at human alpha1B adrenergic receptor expressed in CHOK1 cells co-expressing aequorin assessed as inhibition of agonist induced calcium mobilization preincubated for 15 mins followed by agonist addition measured for 20 secs in presence o	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID1636357	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1491368	Displacement of [3H]prazosin from alpha1 adrenoceptor in C57BL/6 mouse hippocampal homogenates after 40 mins by liquid scintillation counting method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Evaluation of the antidepressant therapeutic potential of isocyanine and pseudoisocyanine analogues of the organic cation decynium-22.
AID545217	Antagonist activity at alpha1A adrenoceptor in Wistar rat vas deferens assessed as noradrenaline induced contractions after 30 mins	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID545224	Selectivity ratio of EC50 for alpha1A adrenoceptor in Wistar rat vas deferens to EC50 for Alpha-1D adrenoceptor in Wistar rat thoracic aorta	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID545214	Selectivity ratio of Ki for human alpha1A adrenoceptor to Ki for human Alpha-1B adrenoceptor	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID1320513	Antagonist activity at human full-length N-terminal SNAP-tagged alpha1A adrenoceptor expressed in HEK293 cells assessed as inhibition of agonist-induced calcium mobilization at 10 uM preincubated for 10 mins followed by agonist addition by fluo-4 AM dye-b	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α
AID232245	Selectivity ratio (antolog[pA2 of IUP-pED50 of SHR]) of the compound	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID35468	Binding affinity was tested on human Alpha-1D adrenergic receptor	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID229425	Selectivity ratio against D2L (dopaminergic) receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID230343	Ratio of rat prostate KB to rat aorta KB	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID229427	Selectivity ratio against D3 (dopaminergic) receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID35155	In vitro antagonistic activity against alpha-1B receptor in rat spleen.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID36126	Activity against Alpha-1 adrenergic receptor subtypes of human prostate tissue	1997	Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17	N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.
AID229429	Selectivity ratio against alpha-2B (Adrenergic Receptor-2B) receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID692053	Displacement of [3H]prazosin from rat salivary gland adrenergic alpha 1A receptor after 45 mins by liquid scintillation counter	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-adrenergic receptor blocking properties.
AID3675	Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID229435	Selectivity ratio against phenylalkylamine-sensitive [Ca2+] L channels	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID224635	Dose required to inhibit the prostate contractile response by 50% after challenge with selective alpha-1a agonist A61603 and duration of action was 3.5h in an in situ rat prostate model	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.
AID3782	Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID1743295	Antagonist activity at human alpha1B receptor transfected in HEK293 cells co-transfected with Galpha16 assessed as reduction in intracellular calcium release incubated for 40 mins by Fluo-4AM dye based fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH.
AID1323698	Hypotensive activity in normotensive anesthetized Wistar rat assessed as decrease in systolic blood pressure at 2 mg/kg, iv administered as single dose measured 60 mins post dose relative to control	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID229436	Selectivity ratio against serotonin 5-HT1 receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID35309	Binding affinity towards cloned human alpha-1D adrenergic receptor was determined using [125]-HEAT as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID37478	Binding affinity was tested on human Alpha-1B adrenergic receptor	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID239202	Binding constant measured against Alpha-1A adrenergic receptor in human prostate; +++:highly active	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists.
AID36468	In vitro antagonism against Alpha-1A adrenergic receptor using phenylephrine (PE) challenge in dog prostate	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID36389	Compound at 1 uM was tested for the inhibition of radioligand [3H]MK-912 binding to recombinant human alpha-2C adrenergic receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID86591	Compound at 1 uM was tested for the inhibition of radioligand [3H]pyrilamine binding to peripheral histamine H1 receptor in guinea pig brain	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID32968	In vitro binding affinity using [3H]prazosin as radioligand against adrenoceptor alpha 1A	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID229438	Selectivity ratio against serotonin 5-HT1A receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID231524	Ratio of binding affinity towards Alpha1d to Alpha-1A	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1323691	Selectivity ratio of EC50 for human alpha1B adrenergic receptor expressed in CHOK1 cells co-expressing aequorin assessed as inhibition of agonist induced calcium mobilization to EC50 for alpha1A adrenergic receptor (unknown origin) assessed as inhibition	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID321750	Displacement of [125I]HEAT from human recombinant adrenergic alpha1A receptor	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
AID296252	Binding affinity to human cloned adrenergic Alpha-1D receptor	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	(Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID545216	Selectivity ratio of Ki for human alpha1A adrenoceptor to Ki for human Alpha-1D adrenoceptor	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID36915	In vitro antagonism against Alpha-1A adrenergic receptor using phenylephrine (PE) challenge in rat vas deferens	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID35938	Binding affinity towards recombinant human alpha-2A adrenergic receptor was determined using [3H]MK-912 as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID36249	Compound at 1 uM was tested for the inhibition of radioligand [3H]yohimbine binding to rat alpha-2B adrenergic receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID157616	Inhibition of [3H]nitrendipine binding to phenylalkylamine-sensitive [Ca2+] L-type channels in rat cerebral cortex at 1 uM	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID37033	In vitro antagonistic activity towards alpha-1A adrenergic receptor in rat vas deferens	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID545228	Selectivity ratio of EC50 for alpha1D adrenoceptor in Wistar rat thoracic aorta to Ki for Alpha-1B adrenoceptor in Wistar rat spleen	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID59533	Intraurethral pressure (IUP) in Beagle dogs values are expressed as pseudo pA2 values.	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID229437	Selectivity ratio against serotonin 5-HT17 receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID545223	Selectivity ratio of EC50 for alpha1A adrenoceptor in Wistar rat vas deferens to EC50 for Alpha-1B adrenoceptor in Wistar rat spleen	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID64468	Binding affinity towards recombinant human Dopamine receptor D2L was determined using [3H]spiperone as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID86747	Binding affinity towards central histamine H1 receptor was determined in guinea pig brain using [3H]-pyrilamine as radioligand; Not determined	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1320810	Toxicity in conscious rat assessed as reduction in mean blood pressure at 1 mg/kg, po measured after 60 mins
AID86590	Compound at 1 uM was tested for the inhibition of radioligand [3H]pyrilamine binding to central histamine H1 receptor in guinea pig brain	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID29126	Antagonist dissociation constant in rat spleen, number of determinations => 3.	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID197368	Compound was tested for selectivity in a challenge spontaneously hypertensive rat (SHR) model using an ascending in vitro dose paradigm	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID64182	Compound at 1 uM was tested for the inhibition of radioligand [3H]spiperone binding to recombinant human Dopamine receptor D4.7	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID64652	Compound at 1 uM was tested for the inhibition of radioligand [3H]spiperone binding to recombinant human Dopamine receptor D2S	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID36371	Binding affinity towards rat alpha-2B adrenergic receptor was determined using [3H]yohimbine as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID229175	Selectivity ratio against central Histamine H1 receptor; Not determined	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID229428	Selectivity ratio against alpha-1a (Adrenergic Receptor-1a) receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID1320518	Selectivity ratio of IC50 for human full-length N-terminal SNAP-tagged alpha1D adrenoceptor to IC50 for human full-length N-terminal SNAP-tagged alpha1A adrenoceptor	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α
AID62842	Compound was tested for efficacy in a challenge intraurethral pressure (IUP) model using aged anesthetized dogs	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID36753	Binding affinity was tested on human Alpha-1A adrenergic receptor	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID1296472	Displacement of [125I] HEAT from human alpha1D adrenergic receptor expressed in Chlorocebus aethiops COS1 cell membranes incubated for 60 mins by liquid scintillation counting analysis	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related G
AID1470705	Antagonist activity at recombinant human alpha1a adrenergic receptor expressed in human Chem1 cell membrane assessed as reduction in ephinephrine-induced calcium mobilization at 1 uM by fluoforte dye based fluorescence assay relative to ephinephrine	2017	European journal of medicinal chemistry, May-26, Volume: 132	Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression.
AID59363	50% reduction in agonist induced pressor response in anesthetized dog	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID64664	Binding affinity towards recombinant human Dopamine receptor D2S was determined using [3H]spiperone as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID6590	Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID232246	Selectivity ratio (antolog[pA2rat vas deferens/pA2 rat spleen]) of the compound	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID1320517	Selectivity ratio of IC50 for human full-length N-terminal SNAP-tagged alpha1B adrenoceptor to IC50 for human full-length N-terminal SNAP-tagged alpha1A adrenoceptor	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α
AID32975	In vitro binding affinity using [3H]prazosin as radioligand against adrenoceptor alpha 1d expressed in LTK cell	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID1743294	Antagonist activity at human alpha1A receptor transfected in HEK293 cells co-transfected with Galpha16 assessed as reduction in intracellular calcium release incubated for 40 mins by Fluo-4AM dye based fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH.
AID625278	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID35154	In vitro antagonism against Alpha-1B adrenergic receptor using phenylephrine (PE) challenge in rat spleen	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID545215	Selectivity ratio of Ki for human Alpha-1D adrenoceptor to Ki for human alpha1B adrenoceptor	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID1320512	Antagonist activity at human full-length N-terminal SNAP-tagged alpha1A adrenoceptor expressed in HEK293 cells assessed as inhibition of agonist-induced calcium mobilization preincubated for 10 mins followed by agonist addition by fluo-4 AM dye-based assa	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID32974	In vitro binding affinity using [3H]prazosin as radioligand against adrenoceptor alpha 1b expressed in LTK cell	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID1743296	Antagonist activity at human alpha1D receptor transfected in HEK293 cells co-transfected with Galpha16 assessed as reduction in intracellular calcium release incubated for 40 mins by Fluo-4AM dye based fluorescence assay	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH.
AID545226	Selectivity ratio of EC50 for alpha1A adrenoceptor in Wistar rat vas deferens to Ki for Alpha-1B adrenoceptor in Wistar rat spleen	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID36466	In vitro for the displacement of [3H]prazosin binding to bovine Alpha-1A adrenergic receptor	1997	Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17	N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.
AID37205	Binding affinity towards cloned human alpha-1B adrenergic receptor was determined using [125]-HEAT as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID545221	Selectivity ratio of Ki for alpha1A adrenoceptor in Wistar rat vas deferens to Ki for Alpha-1D adrenoceptor in Wistar rat thoracic aorta	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID35613	In vitro antagonism against Alpha-1D adrenergic receptor using phenylephrine (PE) challenge in rat aorta	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID36252	Binding affinity against rat Alpha-2B adrenergic receptor using [3H]rauwolscine as radioligand	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID36478	Binding affinity against human adrenergic receptor subtype Alpha-1A adrenergic receptor using [3H]prazosin as radioligand	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID3685	Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID545225	Selectivity ratio of EC50 for alpha1D adrenoceptor in Wistar rat thoracic aorta to EC50 for Alpha-1B adrenoceptor in Wistar rat spleen	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1323687	Intrinsic activity at alpha1A adrenergic receptor (unknown origin) assessed as inhibition of agonist induced effect preincubated for 30 mins followed by agonist addition measured after 5 hrs in presence of CCF4-AM by cell based beta lactamase reporter gen	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID290866	Binding affinity to human cloned adrenergic alpha-1a receptor	2007	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14	(Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID545212	Displacement of [3H]prazosin from human Alpha-1B adrenoceptor expressed in CHO cells	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID545227	Selectivity ratio of Ki for alpha1A adrenoceptor in Wistar rat vas deferens to EC50 for Alpha-1D adrenoceptor in Wistar rat thoracic aorta	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID1323701	Hypotensive activity in normotensive anesthetized Wistar rat assessed as decrease in systolic blood pressure at 1 mg/kg, iv administered as single dose measured 60 mins post dose relative to control	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID1636472	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 44.8 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID35303	Binding affinity against human adrenergic receptor subtype Alpha-1D adrenergic receptor using [3H]prazosin as radioligand	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID36469	In vitro antagonistic activity against alpha-1A receptor in dog prostate.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID224639	Inhibition of A61603-induced contraction; n=4 and data for each concentration was averaged (SEM<10%) in rat.	2000	Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14	In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.
AID29124	Antagonist dissociation constant in dog prostate, number of determinations => 3.	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID1320516	Antagonist activity at human full-length N-terminal SNAP-tagged alpha1D adrenoceptor expressed in HEK293 cells assessed as inhibition of agonist-induced calcium mobilization preincubated for 10 mins followed by agonist addition by fluo-4 AM dye-based assa	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α
AID56037	Inhibition of [3H]nitrendipine binding to Dihydropyridine-sensitive L-type [Ca2+] channel in rat cerebral cortex at 1 uM	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID545222	Selectivity ratio of Ki for alpha1D adrenoceptor in Wistar rat thoracic aorta to Ki for Alpha-1B adrenoceptor in Wistar rat spleen	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID91718	Displacement of [3H]-idazoxan from imidazoline receptor I-2 of rat cerebral cortex	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID196110	Antagonist dissociation equilibrium constant was tested against rat prosta contraction	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID296251	Binding affinity to human cloned adrenergic alpha-1B receptor	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	(Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID35926	Compound at 1 uM was tested for the inhibition of radioligand [3H]MK-912 binding to recombinant human alpha-2A adrenergic receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID545220	Selectivity ratio of Ki for alpha1A adrenoceptor in Wistar rat vas deferens to Ki for Alpha-1B adrenoceptor in Wistar rat spleen	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID1296473	Selectivity ratio of Ki for human alpha1A adrenergic receptor to Ki for human alpha1D adrenergic receptor	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related G
AID190260	Pseudo ED50 in Spontaneously Hypertensive Rat (SHR) model. Number determinations => 3.	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID290868	Binding affinity to human cloned adrenergic alpha-1d receptor	2007	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14	(Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
AID62832	In vivo antagonist dissociation constant in intaraurethral pressure model in dogs.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID59364	50% reduction in intraurethral pressure (IUP) in response to hypogastric nerve stimulation or agonist (phenylephrine or norepinephrine) administration in anesthetized dog	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID64831	Compound at 1 uM was tested for the inhibition of radioligand [3H]spiperone binding to recombinant human Dopamine receptor D3	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID195356	Antagonist dissociation equilibrium constant was tested against rat aorta contraction	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID692048	Selectivity ratio of Ki for rat liver adrenergic alpha1B receptor to Ki for rat salivary gland adrenergic alpha 1A	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-adrenergic receptor blocking properties.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID65117	Binding affinity towards recombinant human Dopamine receptor D3 was determined using [3H]spiperone as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID36483	Binding affinity towards cloned human alpha-1A adrenergic receptor was determined using [125]-HEAT as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID1323695	Hypotensive activity in normotensive anesthetized Wistar rat assessed as decrease in diastolic blood pressure at 1 mg/kg, iv administered as single dose measured 60 mins post dose relative to control	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID24855	Antagonist dissociation constant in rat vas deferens, number of determinations => 3.	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
AID545213	Displacement of [3H]prazosin from human Alpha-1D adrenoceptor expressed in CHO cells	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID3814	Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID545219	Antagonist activity at Alpha-1D adrenoceptor in Wistar rat thoracic aorta assessed as noradrenaline induced contractions after 30 mins	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID229372	Ratio of intraurethral pressure to that of pressor response in dog.	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID1636356	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID197367	Antagonistic activity in spontaneously hypertensive rat model.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
AID321752	Displacement of [125I]HEAT from human recombinant adrenergic alpha1C receptor	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
AID37200	Binding affinity against human adrenergic receptor subtype Alpha-1B adrenergic receptor using [3H]prazosin as radioligand	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID1296474	Selectivity ratio of Ki for human alpha1B adrenergic receptor to Ki for human alpha1D adrenergic receptor	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related G
AID296250	Binding affinity to human cloned adrenergic alpha-1A receptor	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	(Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).
AID231523	Ratio of binding affinity towards Alpha1b to Alpha-1A	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID37056	Antagonistic activity against alpha 1A/1L receptor was assessed in a rabbit bladder neck functional assay	1997	Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17	N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.
AID224975	Duration of action with repeated challenges of A61603 agonist, n=4, data from each time point was averaged (SEM<10%) in rat.	2000	Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14	In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1320809	Reduction in intraurethral pressure in conscious rat at 1 mg/kg, po measured after 60 mins
AID6581	Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID36124	pA2 for Alpha-1 adrenergic receptor from human prostate.	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Pharmacological options in the treatment of benign prostatic hyperplasia.
AID157617	Inhibition of [3H]nitrendipine binding to phenylalkylamine-sensitive [Ca2+] L-type channels in rat cerebral cortex	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID64322	Compound at 1 uM was tested for the inhibition of radioligand [3H]spiperone binding to recombinant human Dopamine receptor D2L	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID229430	Selectivity ratio against alpha-2a (Adrenergic Receptor-2a) receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1323699	Hypotensive activity in normotensive anesthetized Wistar rat assessed as decrease in diastolic blood pressure at 2 mg/kg, iv administered as single dose measured 60 mins post dose relative to control	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α
AID229426	Selectivity ratio against D2S( dopaminergic) receptor	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.
AID36397	Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID545211	Displacement of [3H]prazosin from human alpha1A adrenoceptor expressed in CHO cells	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.
AID290867	Binding affinity to human cloned adrenergic alpha-1b receptor	2007	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14	(Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
AID321751	Displacement of [125I]HEAT from human recombinant adrenergic Alpha-1B receptor	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
AID35936	Binding affinity against human adrenergic receptor subtype Alpha-2A adrenergic receptor using [3H]rauwolscine as radioligand	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
AID1345971	Human alpha1D-adrenoceptor (Adrenoceptors)	1997	British journal of pharmacology, Jul, Volume: 121, Issue:6	Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
AID1345908	Human alpha1A-adrenoceptor (Adrenoceptors)	1999	British journal of pharmacology, May, Volume: 127, Issue:1	In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.
AID1345971	Human alpha1D-adrenoceptor (Adrenoceptors)	1999	British journal of pharmacology, May, Volume: 127, Issue:1	In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.
AID1346000	Human alpha1B-adrenoceptor (Adrenoceptors)	1995	Molecular pharmacology, Aug, Volume: 48, Issue:2	KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
AID1345908	Human alpha1A-adrenoceptor (Adrenoceptors)	1998	FEBS letters, Jan-30, Volume: 422, Issue:2	Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms.
AID1346000	Human alpha1B-adrenoceptor (Adrenoceptors)	1997	British journal of pharmacology, Jul, Volume: 121, Issue:6	Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
AID1345908	Human alpha1A-adrenoceptor (Adrenoceptors)	1997	British journal of pharmacology, Jul, Volume: 121, Issue:6	Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
AID1345971	Human alpha1D-adrenoceptor (Adrenoceptors)	1995	Molecular pharmacology, Aug, Volume: 48, Issue:2	KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
AID1346000	Human alpha1B-adrenoceptor (Adrenoceptors)	1999	British journal of pharmacology, May, Volume: 127, Issue:1	In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.
AID1345908	Human alpha1A-adrenoceptor (Adrenoceptors)	1999	European journal of pharmacology, Apr-16, Volume: 370, Issue:3	Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies.
AID1345908	Human alpha1A-adrenoceptor (Adrenoceptors)	1995	Molecular pharmacology, Aug, Volume: 48, Issue:2	KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (0.07)	18.7374
1990's	124 (9.24)	18.2507
2000's	451 (33.61)	29.6817
2010's	599 (44.63)	24.3611
2020's	167 (12.44)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	468 (32.05%)	5.53%
Reviews	198 (13.56%)	6.00%
Case Studies	59 (4.04%)	4.05%
Observational	28 (1.92%)	0.25%
Other	707 (48.42%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (195)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia [NCT05834270]		60 participants (Actual)	Interventional	2022-05-01	Completed
Pharmacokinetics, Safety and Tolerability of Single Oral Doses (0.1, 0.2, 0.4 and 0.8 mg) of Tamsulosin Hydrochloride in Children With Voiding Disorders [NCT02266524]	Phase 1	48 participants (Actual)	Interventional	2005-01-31	Completed
PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia [NCT02121613]	Phase 4	833 participants (Actual)	Interventional	2014-04-30	Completed
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions [NCT01149746]	Phase 1	32 participants (Actual)	Interventional	2004-12-31	Completed
"An Open-label, Randomized, Fasted, Single Dose, Crossover Study to Evaluate the Bioequivalence of Chong Kun Dang Pharmaceutical Chong Kun Dang Tamsulosin HCl Tablet and Astellas Phama Korea Inc. Harnal-D in Healthy Volunteers" [NCT03887858]	Phase 1	30 participants (Actual)	Interventional	2019-03-11	Completed
Effect of Tamsulosin on Premature Ejaculation Compared With Paroxetine Hydrochloride [NCT03879746]	Phase 3	160 participants (Anticipated)	Interventional	2019-04-30	Not yet recruiting
Efficacy of Tamsulosin OCAS in the Conjunctive Medical Treatment of Distal Ureteral Stones.A Randomized, Double-blind, Placebo-controlled Study [NCT01167062]	Phase 4	120 participants (Anticipated)	Interventional	2010-06-30	Recruiting
The Impact of Tamsulosin on Duration of Post-Operative Urinary Retention in Women Undergoing Pelvic Reconstructive Surgery- A Double Blind, Randomized, Placebo-Controlled Study [NCT04597372]	Phase 2	154 participants (Anticipated)	Interventional	2021-11-03	Recruiting
Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation [NCT03750656]	Phase 4	6 participants (Actual)	Interventional	2018-11-12	Terminated(stopped due to Not accruing patients quickly enough)
Effect of Tamsulosin and Nifedipine on the Elimination of Fragments After Extracorporeal Shock Waves Lithotripsy in Patients With Kidney Stones - a Prospective, Double-blind and Randomized Study [NCT01215708]	Phase 3	136 participants (Actual)	Interventional	2006-08-31	Active, not recruiting
PlacEbo-controlled, Randomized, Patient-Selected Outcomes N-of-1 triALs (PERSONAL-pilot): Alpha-blockers for Lower Urinary Tract Symptoms [NCT05415748]	Phase 4	31 participants (Actual)	Interventional	2021-09-18	Active, not recruiting
TryptoBPH - Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients With BPH. [NCT05401032]	Phase 2	70 participants (Anticipated)	Interventional	2022-06-30	Not yet recruiting
Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection: a Double-blind Placebo-controlled Clinical Trial [NCT05941806]	Phase 3	220 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia : a Randomized, Double Blinded, Parallel Design, Active Controlled, Multi-center [NCT02827578]	Phase 3	588 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Benign Prostatic Hyperplasia and Ischemic Heart DIsease [NCT03856242]	Phase 4	83 participants (Actual)	Interventional	2015-09-01	Completed
Randomized, Quadruple Blinded, Placebo Controlled, Multi-centered Trial Investigating Prophylactic Tamsulosin in Prevention of Postoperative Urinary Retention in Men After Endoscopic Total Extraperitoneal Inguinal Hernia Repair [NCT04491526]	Phase 4	634 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy: the Impact of One Week of Pre-operative Tamsulosin [NCT05197088]	Phase 3	110 participants (Anticipated)	Interventional	2022-01-09	Not yet recruiting
Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery [NCT02919436]	Phase 4	610 participants (Actual)	Interventional	2016-03-31	Completed
[NCT02034604]	Phase 4	194 participants (Actual)	Interventional	2013-12-31	Completed
"An Open-label, Randomized, Fed, Single Dose, Crossover Study to Evaluate the Bioequivalence of Chong Kun Dang Pharmaceutical Chong Kun Dang Tamsulosin HCl Tablet and Astellas Phama Korea Inc. Harnal-D in Healthy Volunteers" [NCT03887871]	Phase 1	30 participants (Actual)	Interventional	2019-03-11	Completed
[NCT03246880]	Phase 3	455 participants (Actual)	Interventional	2015-09-30	Completed
Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention [NCT02684344]		5 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to Lack of enrollment)
Comparative Efficacy of DuodartTM Versus Watchful Waiting With Step-up Therapy to Tamsulosin in the Management of Treatment naïve Men With Symptomatic BPH [NCT01294592]	Phase 4	742 participants (Actual)	Interventional	2010-12-22	Completed
Impact of Medical Treatment for Benign Prostatic Hyperplasia on Chronic Renal Failure [NCT02033798]		34 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
An Open-label, Randomized, Multiple-dose Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin in Healthy Male Volunteers [NCT02239484]	Phase 1	30 participants (Actual)	Interventional	2014-03-31	Completed
Efectividad de la Tamsulosina Como Tratamiento Adyuvante Previo a Ureterolitotomia Endoscopica [NCT03614052]	Phase 4	14 participants (Actual)	Interventional	2018-06-01	Terminated(stopped due to Problems with the number of participants)
Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty [NCT03808155]	Phase 4	170 participants (Anticipated)	Interventional	2019-08-01	Recruiting
The Effect of Daily Versus Twice Per Day Tamsulosin on Ureteral Stent Symptoms Following Ureteroscopy for Nephrolithiasis [NCT03799120]	Phase 4	80 participants (Anticipated)	Interventional	2019-02-18	Enrolling by invitation
Pharmacokinetic Drug Interaction Between Solifenacin 10mg and Tamsulosin 0.4mg in Healthy Male Volunteers [NCT02180997]	Phase 1	36 participants (Actual)	Interventional	2014-07-31	Completed
[NCT02443844]	Phase 4	40 participants (Anticipated)	Interventional	2015-02-28	Recruiting
A Multicenter, Randomized, Double -Blind, Parallel, Comparative, Phase III Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1 Tablet in BPH Patients With LUTS [NCT02303769]	Phase 3	309 participants (Actual)	Interventional	2014-03-31	Completed
A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With Benign Prostatic Hyperplasia [NCT02390882]	Phase 3	494 participants (Actual)	Interventional	2014-10-31	Completed
Double-Blind, Placebo-Controlled, Active-Referenced, Parallel-Group Comparative Study in Patients With Benign Prostatic Hyperplasia [NCT02038868]	Phase 2	320 participants (Actual)	Interventional	2013-07-22	Completed
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia [NCT03144596]	Phase 4	63 participants (Actual)	Interventional	2015-10-29	Completed
A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects [NCT02058576]	Phase 1	77 participants (Actual)	Interventional	2014-02-11	Completed
The Efficacy and Safety of Medical Expulsive Therapy After Extracorporeal Shock Wave Lithotripsy (ESWL) in Pediatric Urolithiasis [NCT05759767]		120 participants (Anticipated)	Interventional	2021-02-01	Active, not recruiting
Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome：A Prospective, Randomized, Positive Drug-controlled, Multicenter Clinical Study [NCT05890235]	Phase 4	323 participants (Actual)	Interventional	2018-11-16	Completed
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Ur [NCT02757768]	Phase 4	715 participants (Actual)	Interventional	2016-06-13	Completed
An Open Label Randomized Two-way Crossover Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Single Oral Dose Pharmacokinetics of Tamsulosin in Healthy Male Volunteers (CYP2D6 Extensive Metabolizers) [NCT02264184]	Phase 1	24 participants (Actual)	Interventional	2008-09-30	Completed
Tamsulosin as Adjunctive Therapy After Extracorporeal Shock Wave Lithotripsy for Renal Stones [NCT04819828]	Phase 4	60 participants (Actual)	Interventional	2010-01-01	Completed
Ureteral Stent-related Pain and Mirabegron (SPAM) Trial [NCT02095665]	Phase 4	22 participants (Actual)	Interventional	2014-01-01	Completed
Stone Clearance in Patients With Upper Ureteric Stones Using Extracorporeal Shock Wave Lithotripsy Compared With Extracorporeal Shock Wave Lithotripsy Combined With Tamsulosin Therapy [NCT05725122]		82 participants (Actual)	Interventional	2018-02-01	Completed
A Study Evaluating the Therapeutic Efficacy of Tamsulosin and Tadalafil Compared to Placebo in the Treatment and Prevention of Urinary Disorders After Transperineal Prostate Biopsy [NCT05537272]	Phase 4	120 participants (Anticipated)	Interventional	2022-09-01	Enrolling by invitation
A Phase I/II Evaluation of Bromocriptine, Metoprolol and Tamsulosin Combination Therapy in Eyes With Non-Central Diabetic Macular Edema [NCT03384524]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2018-03-31	Withdrawn(stopped due to withdrawn during planning stages)
Clinical Study of Composite Steep-pulse(High-frequency Irreversible Electroporation) Treatment Device Used in Patients With Benign Prostatic Hyperplasia [NCT05531344]	Phase 2/Phase 3	160 participants (Actual)	Interventional	2020-08-20	Completed
A Prospective Randomized Study Examining the Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-Assisted Laparoscopic Radical Prostatectomy [NCT01209988]		220 participants (Anticipated)	Interventional	2010-04-30	Recruiting
A Phase 1, Single-centre, Double-blind, Randomized, Placebo-controlled, Two-cohort, Two-period Crossover Study of the Hemodynamic Interactions Between Avanafil and Two α-Adrenergic Blockers, Doxazosin and Tamsulosin, in Middle-aged Healthy Male Subjects [NCT01100021]	Phase 1	48 participants (Actual)	Interventional	2010-02-28	Completed
A Multicenter, Prospective, Randomized, Controlled Clinical Study of Ningmitai Capsule to Promote the Passage of Residual Fragments After Ureteroscopic Lithotripsy [NCT06105827]	Phase 4	251 participants (Actual)	Interventional	2016-10-02	Completed
Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL [NCT01560091]	Phase 3	0 participants (Actual)	Interventional	2012-03-31	Withdrawn(stopped due to accrual of subjects did not occur as anticipated)
An Open-label, Randomized, Single Dose, Two-Period Crossover Study to Determine the Bioavailability of a Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5m [NCT01254071]	Phase 1	86 participants (Actual)	Interventional	2010-09-10	Completed
Medication Effects on Periurethral Sensation, Urethral Sphincter Activity and Pressure Flow Parameters [NCT01028014]		56 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg and Tamsulosin Hydrochloride OCAS 0.4 mg Monotherapy, in Male [NCT01018511]	Phase 3	1,334 participants (Actual)	Interventional	2010-01-31	Completed
An Open-label, Parallel Group, Randomized, Two-way Crossover, Multiple Dose Study to Compare the Pharmacokinetic Profiles of Solifenacin Succinate and Tamsulosin HCl Following Co-administration of Single Entity Tablets and Administration of Three Differen [NCT02634489]	Phase 1	46 participants (Actual)	Interventional	2009-03-31	Completed
A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi Center Dose Ranging Study of Solifenacin Succinate in Combination With Tamsulosin Hydrochloride Compared With Solifenacin Succinate Monotherapy and Tamsulosin Hydrochloride Monotherapy [NCT00510406]	Phase 2	919 participants (Actual)	Interventional	2007-01-31	Completed
A Parallel Group Study With Three Different α-antagonists and Placebo Once Daily Over Three Weeks to Assess Their Influence on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Voluntee [NCT02266537]	Phase 1	97 participants (Actual)	Interventional	2005-11-30	Completed
A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Tamsulosin HCl in Healthy Male Subjects [NCT02169713]	Phase 1	20 participants (Actual)	Interventional	2014-05-31	Completed
An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg [NCT02180789]	Phase 4	100 participants (Actual)	Interventional	2013-03-31	Completed
Randomized Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Discomfort in the Pediatric Population [NCT02483793]		60 participants (Anticipated)	Interventional	2015-07-31	Not yet recruiting
Prophylactic Alpha-blockers in the Prevention of Post-operative Urinary Retention After Inguinal Hernia Repair: A Randomized Double-Blind Placebo-Controlled Trial [NCT03314259]	Early Phase 1	300 participants (Anticipated)	Interventional	2017-12-01	Not yet recruiting
Prophylactic Administration of Alpha Blockers for Prevention of Post Operative Urinary Retention in Males Undergoing Open Inguinal Hernia Repair Under Spinal Anaesthesia. [NCT03976934]	Phase 1/Phase 2	100 participants (Actual)	Interventional	2020-02-01	Completed
Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial [NCT03314025]	Phase 2	158 participants (Anticipated)	Interventional	2017-10-06	Recruiting
THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS [NCT06124066]	Phase 4	42 participants (Actual)	Interventional	2022-07-01	Completed
A Randomized, Single Dose, Open-label, Cross-over Study on Bioequivalence of Two Formulations of Tamsulosin Hydrochloride Prolonged Release Capsule (Tamsulosin Pellet From Meppel Plant and Nishine Plant) Under Fed and Fasted Conditions in Chinese Healthy [NCT02138773]	Phase 1	80 participants (Actual)	Interventional	2014-04-30	Completed
A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects [NCT02052713]	Phase 1	78 participants (Actual)	Interventional	2014-02-19	Completed
A Randomized, Open-label, Single-dose, Four-sequence, Four -Period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers [NCT02072213]	Phase 1	36 participants (Actual)	Interventional	2013-08-31	Completed
An Open Label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. [NCT04485585]	Phase 1	36 participants (Actual)	Interventional	2020-07-20	Completed
Comparison of Silodosin Versus Tamsulosin on Passage of Acutely Obstructing Ureteral Calculi (History of Last 4 Weeks) in Medical Expulsive Therapy [NCT05977647]	Phase 4	240 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Post-operative Urinary Retention (POUR) Following Thoracic Surgery [NCT03609580]	Phase 1/Phase 2	127 participants (Anticipated)	Interventional	2018-05-07	Recruiting
A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical O [NCT00090103]	Phase 3	4,844 participants (Actual)	Interventional	2003-11-30	Completed
COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI [NCT05790902]	Phase 1	142 participants (Actual)	Interventional	2022-09-01	Completed
Prevention of Acute Voiding Difficulty After Radical Proctectomy for Rectal Cancer With Tamsulosin [NCT00606983]	Phase 3	100 participants (Anticipated)	Interventional	2007-05-31	Completed
An Open-label, Randomized, Parallel Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms [NCT02715024]	Phase 4	52 participants (Actual)	Interventional	2007-09-30	Completed
Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mg [NCT00954889]		220 participants (Actual)	Interventional	2009-08-31	Active, not recruiting
Reduction of Post-Operative Urinary Retention With Tamsulosin Versus Placebo (REPOURT- P) Trial [NCT04159077]	Phase 3	350 participants (Anticipated)	Interventional	2021-07-30	Not yet recruiting
Effect of Preoperative Single-dose Tamsulosin on Postoperative Urinary Retention After Mid-urethral Sling Placement: a Randomized, Double-blinded, Placebo-controlled Trial [NCT05753670]	Phase 3	160 participants (Anticipated)	Interventional	2023-07-01	Recruiting
Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women [NCT05439902]		60 participants (Anticipated)	Interventional	2022-10-05	Recruiting
The Use of Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair: A Randomized Double-Blind Placebo-Controlled Study [NCT04434378]	Phase 4	170 participants (Actual)	Interventional	2017-11-16	Terminated(stopped due to Significant difference not reached on interim analysis)
the Therapeutic Effect Treated With Tamsulosin After ESWL in Urinary Calculus [NCT01010048]	Phase 4	120 participants (Anticipated)	Interventional	2009-10-31	Recruiting
A Two Phase, Double-blinded, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia [NCT02244294]	Phase 2	176 participants (Actual)	Interventional	2001-03-31	Completed
Behavior and Exercise Versus Drug Treatment in Men With Nocturia [NCT00824200]	Phase 4	72 participants (Actual)	Interventional	2008-07-31	Completed
Medical Expulsive Therapy of Single Distal Ureteral Stones. A Randomised, Double-blind and Placebo-controlled Study [NCT00831701]		100 participants (Actual)	Interventional	2006-09-30	Completed
Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) [NCT04107896]	Phase 4	141 participants (Actual)	Interventional	2017-08-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride [NCT00771394]	Phase 4	638 participants (Actual)	Interventional	2008-10-31	Completed
A Phase IIb/III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Dose Ranging Study of Tamsulosin Hydrochloride (Low, Medium and High Dose) as Treatment in Children With Neuropathic Bladder for Three Months [NCT00796614]	Phase 2/Phase 3	231 participants (Actual)	Interventional	2008-01-31	Completed
The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients [NCT00448123]		127 participants (Actual)	Interventional	2007-02-28	Completed
[NCT02862483]	Phase 3	330 participants (Anticipated)	Interventional	2016-03-31	Recruiting
A Phase 3, Randomized, Double Blind, Placebo and Tamsulosin Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil Once a Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplas [NCT00861757]	Phase 3	612 participants (Actual)	Interventional	2009-03-31	Completed
Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms [NCT00913315]		30 participants (Anticipated)	Interventional	2009-08-31	Not yet recruiting
The Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic BPH [NCT01404637]		150 participants (Anticipated)	Interventional	2011-07-31	Not yet recruiting
The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia: A Prospective Randomized Multicenter Trial [NCT00687388]	Phase 4	0 participants (Actual)	Interventional	2008-05-31	Withdrawn(stopped due to in order to prepare a new clinical trial to evaluate with pathological change)
Randomised Controlled Trial on Silodosin Versus Tamsulosin for Medical Expulsive Treatment of Ureteral Stones Size 5-10mm in Chinese [NCT05570084]	Phase 3	80 participants (Anticipated)	Interventional	2022-05-31	Recruiting
A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 After a Single Oral Dose in Healthy Male Subjects [NCT02615782]	Phase 1	16 participants (Actual)	Interventional	2015-12-31	Completed
A Randomized Clinical Trial Comparing Alpha Blacker (Tamsulosin) and Anticholinergic (Solifenacin) in Treatment of Ureteral Stent Related Symptoms [NCT01880619]	Phase 4	131 participants (Actual)	Interventional	2013-01-31	Completed
Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy [NCT00209131]		24 participants (Actual)	Interventional	2005-04-30	Terminated(stopped due to Due to frequent turnover of research coordinators and thus poor study accrual.)
Comorbidity and Comedication During Prescription of ALNA® (Tamsulosin) for Patients With BPH (Benign Prostatic Hyperplasia) [NCT02245503]		7,391 participants (Actual)	Observational	2003-05-31	Completed
An Uncontrolled, Open-label, Titration, Long-term Safety (up to 12 Months) and Efficacy Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder, With a Randomized Pharmacokinetic Sub-study Investigating Low, Medium and High Dose Ranges. [NCT00340704]	Phase 2	143 participants (Actual)	Interventional	2006-04-30	Completed
A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate With 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects With [NCT00507455]	Phase 2	222 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 1, Open-label, One-sequence Study to Assess the Effect of Verapamil on the Steady State Pharmacokinetics of Solifenacin and Tamsulosin Administered as a Combination Tablet EC905 in Healthy Male Subjects. [NCT01943487]	Phase 1	36 participants (Actual)	Interventional	2009-08-31	Completed
Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin [NCT04994431]	Phase 4	60 participants (Anticipated)	Interventional	2021-08-01	Recruiting
An Open-label, Randomized, Two-way Crossover, Multiple Dose Study to Evaluate the Steady State Pharmacokinetics of the Two Final Combination Tablet Formulations (EC905; Tamsulosin HCl/ Solifenacin Succinate; 0.4 mg/6 mg and 0.4 mg/9 mg) in Healthy Male Vo [NCT01953848]	Phase 1	27 participants (Actual)	Interventional	2010-04-30	Completed
An Open-label, Randomized, Three-period Crossover, Single Dose Study to Compare the Pharmacokinetics of the Final EC905 Formulation to Marketed Solifenacin (Vesicare®) and Tamsulosin OCAS (Omnic OCAS®) [NCT01953887]	Phase 1	30 participants (Actual)	Interventional	2010-03-31	Completed
An Open Label, Single Sequence, Three Period, Drug-Drug Interaction Study To Examine The Pharmacokinetics Of Dutasteride And Tamsulosin And Their Interactions In Chinese Male Healthy Volunteers [NCT01957189]	Phase 1	24 participants (Actual)	Interventional	2013-10-25	Completed
Ciprofloxacin or Tamsulosin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Randomized, Double-blind Trial [NCT04552431]	Phase 2	196 participants (Actual)	Interventional	1997-09-30	Completed
Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: A Randomized Controlled Trial [NCT03709992]		200 participants (Anticipated)	Interventional	2020-12-18	Suspended(stopped due to Because of COVID-19 Crisis)
Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospecti [NCT01604811]	Phase 4	206 participants (Actual)	Interventional	2012-06-30	Completed
EFFICACY AND SAFETY OF COMBINATION THERAPY WITH β3-ADRENOCEPTOR AGONIST (MIRABEGRON) AND α-ADRENOCEPTOR ANTAGONIST (TAMSULOSIN) FOR TREATMENT OF OVERACTIVE BLADDER IN MALE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. [NCT02279615]	Phase 4	200 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients [NCT00600405]		81 participants (Actual)	Interventional	2006-08-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Pilot Study to Evaluate the Efficacy and Safety of Tadalafil and Tamsulosin Once-a-Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia [NCT00540124]	Phase 2	151 participants (Actual)	Interventional	2007-10-31	Completed
Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease. [NCT04359979]		50 participants (Anticipated)	Interventional	2020-05-01	Recruiting
Combined Behavioral and Drug Treatment of Overactive Bladder in Men [NCT01175382]	Phase 2/Phase 3	204 participants (Actual)	Interventional	2010-07-31	Completed
An Open-label, Long Term, Multi-center Study to Assess the Safety and Efficacy of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associa [NCT01021332]	Phase 3	1,067 participants (Actual)	Interventional	2010-04-26	Completed
Observational Study in Patients With Functional BPH (Benign Prostatic Hyperplasia) Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin) [NCT02244320]		4,150 participants (Actual)	Observational	2002-09-30	Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia [NCT00970632]	Phase 3	511 participants (Actual)	Interventional	2009-10-31	Completed
[NCT00451061]	Phase 4	120 participants (Anticipated)	Interventional	2007-04-30	Not yet recruiting
An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia [NCT02244255]	Phase 4	1,993 participants (Actual)	Interventional	1998-08-31	Completed
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin [NCT01489696]	Phase 1	48 participants (Actual)	Interventional	2010-08-31	Completed
An Open-label, Randomized, Single Dose, Multi-stage, Cross-over Study to Determine the Relative Bioavailability of Fixed Dose Combination Products Containing a 3-oblong Dutasteride Soft Gel Capsule and Tamsulosin (0.5 mg Dutasteride /0.2 mg Tamsulosin HCl [NCT01495026]	Phase 1	63 participants (Actual)	Interventional	2011-11-06	Completed
Phase II Study Comparing Two Groups of Patients Undergoing ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin [NCT00478998]	Phase 2	0 participants	Interventional		Not yet recruiting
The Use of Tamsulosin in Treatment of (10-15 mm) Lower Ureteric Stones in Adults With Non-emergent Symptoms: A Prospective Randomized Study [NCT03274700]	Early Phase 1	80 participants (Anticipated)	Interventional	2017-10-01	Not yet recruiting
Can Acupoint Low Intensity Shockwave Therapy Improve Bladder Voiding Efficiency: A Pilot Study. [NCT06020963]		100 participants (Anticipated)	Interventional	2023-08-11	Recruiting
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms: a Randomized Controlled Trial [NCT04325880]	Phase 3	240 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Prospective Observational Trial of Combination Therapy of Tadalafil 5mg Plus Tamsulosinmg for Men With Lower Urinary Tract Symptoms and Erectile Dysfunction [NCT04383093]		75 participants (Actual)	Observational	2017-01-01	Completed
A Pivotal, Open-label Trial Assessing the Safety and Efficacy of the 0.5 mg Dutasteride and 0.4 mg Tamsulosin Combination Once Daily for Six Months in Patients With Benign Prostatic Hyperplasia [NCT01673490]	Phase 4	59 participants (Actual)	Interventional	2012-06-29	Terminated(stopped due to The sole investigative site refused to accept the amended protocol and declined to continue the study. There was no safety signal nor any other reason.)
Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery [NCT05657990]	Early Phase 1	46 participants (Anticipated)	Interventional	2023-04-03	Recruiting
A Randomized Trial of Tamsulosin and/or Dutasteride Versus Placebo to Relieve Urinary Symptoms After Brachytherapy for the Treatment of Localized Prostate Cancer [NCT00244309]	Phase 3	348 participants (Anticipated)	Interventional	2005-11-30	Completed
Prostate Medication, Metabolism and Gut Microbiota [NCT06001619]	Phase 4	100 participants (Anticipated)	Interventional	2022-12-01	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare® (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Fre [NCT00333112]	Phase 4	398 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Wit [NCT00147654]	Phase 4	830 participants	Interventional	2004-11-30	Completed
Valutazione Dell'Efficacia Del Trattamento Dell'Ipertrofia Prostatica Benigna Con Serenoa Repens Estratta Con CO2 + PEA (Palmitoilethanolamide) in Monoterapia o in Combinazione Alla Tamsulosina: ProSeRePEA Trial [NCT06181175]		250 participants (Anticipated)	Interventional	2021-10-01	Recruiting
Comparison of Silodosin vs. Tamsulosin on Spontaneous Passage of Acutely Obstructing Ureteral Calculi in Medical Expulsive Therapy [NCT02369744]	Phase 4	1 participants (Actual)	Interventional	2013-03-31	Terminated(stopped due to due to lack of suitable patient population)
Evaluating the Effect of Tamsulosin on Postoperative Urinary Retention in Women Undergoing Same Day Hospital Discharge Following Pelvic Reconstructive Surgery: A Randomized Trial [NCT04682366]	Phase 4	4 participants (Actual)	Interventional	2021-10-19	Terminated(stopped due to Challenges in enrollment led to decission for termination)
Study of Tamsulosin for Urolithiasis in the Emergency Department [NCT00382265]	Phase 4	512 participants (Actual)	Interventional	2008-01-31	Completed
[NCT00489723]		0 participants	Observational	2007-05-31	Recruiting
Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia [NCT02972268]	Phase 3	780 participants (Actual)	Interventional	2016-02-01	Completed
Interest of a Treatment With the alpha1-blocker Tamsulosin in the Elimination of Pelvis Ureteral Stones [NCT00151567]	Phase 3	129 participants (Actual)	Interventional	2002-02-28	Completed
The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure [NCT00223717]	Phase 1	152 participants (Actual)	Interventional	2001-01-31	Completed
A Multi-center Randomized Placebo Controlled Trial Evaluating the Efficacy of JALYN in Improving Symptoms in Men Diagnosed With Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) [NCT01830829]	Phase 3	1 participants (Actual)	Interventional	2013-04-30	Terminated(stopped due to Difficulty in enrolling particpants)
Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fed Conditions [NCT02417844]	Phase 1	34 participants (Actual)	Interventional	2015-04-30	Completed
Effect of Perioperative Selective alpha1-blockers in Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones [NCT04557202]	Phase 3	120 participants (Actual)	Interventional	2017-09-01	Completed
An Open-label, Randomized, Single Dose, Four-Period Crossover Study to Compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) With 10% and 15% of Enteric Coated Pellets With H [NCT01471678]	Phase 1	27 participants (Actual)	Interventional	2011-06-30	Completed
An Open-Label, Randomized, Single Dose Crossover Study to Determine the Bioequivalence of Duodart® 0.5mg/0.4mg (Capsule Formulation of Dutasteride 0.5mg and Tamsulosin Hydrochloride 0.4mg) Compared to Concomitant Dosing of Avodart® 0.5mg and Omnic® 0.4mg [NCT01657851]	Phase 1	35 participants (Actual)	Interventional	2012-08-23	Completed
A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH [NCT01736033]	Phase 4	545 participants (Actual)	Interventional	2012-02-29	Active, not recruiting
Tamsulosin to Facilitate Early Catheter Removal After Urinary Retention in Older Women Hospitalized for an Acute Medical Condition [NCT01747993]	Phase 3	34 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to low inclusion)
A Prospective Study of Sexual Function in Sexually Active Men Treated for BPH [NCT01777269]	Phase 4	489 participants (Actual)	Interventional	2013-02-18	Completed
Comparative Study Between Use of Alpha Blocker Versus Alpha Blocker and Antihistaminic in Management of Acute Renal Colic Prevent Pain Recurrence and Increase Expulsion Rate of Ureteric Stone ≤ 1cm [NCT05150899]		100 participants (Anticipated)	Observational [Patient Registry]	2021-11-30	Not yet recruiting
Open Label, Randomized Comparative Study to Evaluate the Pharmacokinetic Characteristics Between Coadministered Finasteride Tablet and Tamsulosin HCl Tablet and GL2701 Capsule, in Healthy Subjects [NCT01829893]	Phase 1	26 participants (Actual)	Interventional	2012-01-31	Completed
Effect of ALNA® (Tamsulosin) on the Primary Symptoms of BPH (Benign Prostatic Hyperplasia) Syndrome [NCT02244268]		3,629 participants (Actual)	Observational	2000-10-31	Completed
A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Pharmacokinetic Effect of Tamsulosin on Tadalafil in Healthy Male Volunteers [NCT02247518]	Phase 1	16 participants (Actual)	Interventional	2014-09-30	Completed
Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms [NCT01741454]	Phase 4	181 participants (Actual)	Interventional	2012-11-30	Completed
PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF NAFTOPIDIL AND TAMSULOSIN TO TREATMENT THE SYMPTOMS OF LOWER URINARY TRACT IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA [NCT01203371]	Phase 3	0 participants (Actual)	Interventional	2011-01-01	Withdrawn
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy [NCT01435954]		13,551 participants (Actual)	Observational	2010-08-31	Completed
An Eight-week, Double-blind, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Daily Versus Placebo, in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms [NCT02244281]	Phase 2	74 participants (Actual)	Interventional	2001-05-31	Completed
Secotex ®: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH) [NCT02245529]		982 participants (Actual)	Observational	2005-03-31	Completed
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions [NCT01149733]	Phase 1	32 participants (Actual)	Interventional	2004-11-30	Completed
Clinical Trial to Investigate and Compare the Pharmacokinetic Characteristics and Safety/Tolerability After Single Administration of JLP-1207 and Soifenacin/Tamsulosin in Healthy Male Volunteers. [NCT02494349]	Phase 1	54 participants (Actual)	Interventional	2015-08-31	Completed
Comparison of the Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With OAB: A Prospective Randomized Multicenter Study [NCT01533597]	Phase 4	70 participants (Actual)	Interventional	2010-12-31	Completed
"A Prospective Randomized Trial The Effectiveness of Peripheral Magnetic Stimulation in Men With Lower Urinary Tract Symptoms" [NCT04807569]		68 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
A 6-month OTC-simulated, Open Label, Uncontrolled Study of Tamsulosin 0.4 mg in Men [NCT02573311]	Phase 3	1,117 participants (Actual)	Interventional	2015-09-23	Completed
MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, [NCT02244229]	Phase 4	403 participants (Actual)	Interventional	1998-04-30	Completed
Observational Study About the Use of Tamsulosin in Patients With Benign Prostatic Hyperplasia [NCT02245555]		1,060 participants (Actual)	Observational	2006-04-30	Completed
Preoperative Tamsulosin to Prevent Postoperative Urinary Retention in Females After Surgery For Pelvic Floor Disorders [NCT04232683]	Early Phase 1	100 participants (Actual)	Interventional	2019-12-18	Active, not recruiting
Pre-operative Tamsulosin After Minimally Invasive Hysterectomy and Time to Spontaneous Void: A Randomized Controlled Trial [NCT04859660]	Phase 2	161 participants (Actual)	Interventional	2021-04-16	Completed
Pre-operative Tamsulosin for the Prevention of Post-operative Urinary Retention: a Randomized, Double-blind, Placebo-controlled Trial [NCT02486653]	Phase 3	158 participants (Actual)	Interventional	2015-08-31	Completed
The Use of an Uroselective Alpha-1-antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery [NCT01568918]	Phase 3	350 participants (Anticipated)	Interventional	2012-05-31	Recruiting
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment [NCT01726270]	Phase 2	689 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia [NCT00379067]	Phase 4	882 participants (Actual)	Interventional	2005-10-31	Completed
Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fasted Conditions [NCT02417831]	Phase 1	34 participants (Actual)	Interventional	2015-04-30	Completed
Perioperative Administration of Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery [NCT03524339]	Phase 2/Phase 3	132 participants (Actual)	Interventional	2018-08-01	Completed
Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair [NCT02958878]	Phase 4	210 participants (Actual)	Interventional	2017-01-03	Completed
Evaluation of the Efficacy and Safety of Silodosin vs. Tamsulosin and Placebo in the Treatment of the Signs and Symptoms of BPH. Multicentre, Randomised, Double-Blind, Controlled Trial With an Optional Long-Term, Open-Label Extension Phase. [NCT00359905]	Phase 3	1,228 participants (Actual)	Interventional	2006-05-31	Completed
Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for Benign Prostatic Hyperplasia [NCT04987892]	Phase 4	250 participants (Anticipated)	Interventional	2021-12-06	Recruiting
A Phase III, Randomized Clinical Trial to Study the Safety and Efficacy of MK-906 (Finasteride) and Tamsulosin Administered Either Alone or Concomitantly in Patients With Benign Prostatic Hyperplasia (BPH) [NCT01534351]	Phase 3	1 participants (Actual)	Interventional	2013-08-01	Terminated(stopped due to Business Reasons)
Comparative Study Between Tadalafil Versus Tamsulosin as a Medical Expulsive Therapy for Lower Ureteric Stones [NCT04641507]	Phase 4	166 participants (Actual)	Interventional	2020-01-01	Active, not recruiting
Post-operative Urinary Retention: A Prospective Randomized Study Identifying Patients at Risk and Reducing the Incidence Using Tamsulosin Pretreatment [NCT03027115]	Phase 4	140 participants (Anticipated)	Interventional	2017-01-13	Recruiting
Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy and Endoscopic-Guided Percutaneous Nephrolithotomy: A Randomized Double-Blind Placebo Controlled Trial of Tadalafil, Tamsulosin and Combination [NCT03229889]	Phase 4	220 participants (Anticipated)	Interventional	2017-06-07	Enrolling by invitation
Efficacy of Tadalafil and Solifenacin Versus Tamsulosin and Solifenacin Combination Therapy for the Treatment of Benign Prostatic Hyperplasia With Overactive Bladder: A Randomized Controlled Trial [NCT05494567]	Phase 4	60 participants (Anticipated)	Interventional	2021-11-08	Active, not recruiting
The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia (BPH) Complicated With Lower Urinary Tract Symptoms (LUTS) -A Multicenter, Prospective, Randomized, Double-blind, Positive Con [NCT05551221]	Phase 4	312 participants (Anticipated)	Interventional	2022-07-18	Recruiting
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer [NCT04147806]	Phase 2	30 participants (Anticipated)	Interventional	2016-08-01	Active, not recruiting
Efficacy and Safety of a Single Transrectal Ultrasound(TRUS)-Guided Intraprostatic Injection of NX-1207 in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Phase III European Study [NCT02003742]	Phase 3	104 participants (Actual)	Interventional	2013-09-30	Terminated(stopped due to The study was stopped because in two other clinical studies the drug was not superior in comparison with placebo)
Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial [NCT01457573]	Phase 4	10 participants (Actual)	Interventional	2011-10-31	Completed
A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia [NCT02244242]	Phase 4	493 participants (Actual)	Interventional	1998-07-31	Completed
BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Act [NCT02245490]	Phase 4	153 participants (Actual)	Interventional	2003-01-31	Completed
Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia A Randomised Trial [NCT05818670]	Phase 4	160 participants (Actual)	Interventional	2020-11-11	Completed
A Randomized, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride (0.5mg) and Tamsulosin (0.2mg) With Tamsulosin (0.2mg) Monotherapy, Administered Once Daily for 2 Years, on the Improvement of Sy [NCT02058368]	Phase 3	607 participants (Actual)	Interventional	2014-02-10	Completed
An Open-label, Randomized, Single Dose, Two-way Crossover Study to Determine the Bioavailability of One Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) Relative to Coadministration of One Dutasteride [NCT02509104]	Phase 1	56 participants (Actual)	Interventional	2015-07-30	Completed
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients [NCT02518971]	Phase 3	176 participants (Actual)	Interventional	2015-08-31	Terminated(stopped due to interim analysis revealed no significant difference between study groups & increased sample size required to gain significance.)
Effectiveness of OnabotulinumtoxinA (onaBoNT-A) vs Oral Tamsulosin in Men With Benign Prostatic Hyperplasia & Lower Urinary Track Symptoms (#02-10-10-05) [NCT01589263]	Phase 2	63 participants (Actual)	Interventional	2012-06-01	Completed
A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Pharmacokinetic Effect of Tadalafil on Tamsulosin in Healthy Male Volunteers [NCT02247505]	Phase 1	29 participants (Actual)	Interventional	2014-09-30	Completed
An Open Label Randomized Two-way Crossover Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on the Single Oral Dose Pharmacokinetics of Tamsulosin in Healthy Male Volunteers (CYP2D6 Extensive Metabolizers) [NCT02264171]	Phase 1	24 participants (Actual)	Interventional	2008-04-30	Completed
A Single-dose, Randomized, Two-treatment, Two-period, Open-label, Crossover Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride 0.4-mg Capsules in Healthy Male Subjects [NCT02266511]	Phase 1	30 participants (Actual)	Interventional	1999-08-31	Completed
A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Proof of Concept and Dose Ranging Study With an Active Control to Assess the Efficacy and Safety/Tolerability of UK-369,003 Immediate Release (IR) and Modified Release (MR) in th [NCT00457457]	Phase 2	609 participants (Actual)	Interventional	2007-05-31	Completed
A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyp [NCT02656173]	Phase 4	568 participants (Actual)	Interventional	2016-01-25	Completed
Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH [NCT00701779]	Phase 4	63 participants (Actual)	Interventional	2005-09-30	Completed
Medical Expulsive Therapy Post-SWL For Renal Stones. A Randomized Trial [NCT05032287]		235 participants (Actual)	Interventional	2019-09-01	Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Erectile Dysfunc [NCT01937871]	Phase 3	909 participants (Actual)	Interventional	2013-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)
NCT00090103 (31) [back to overview]	Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF)
NCT00090103 (31) [back to overview]	Number of Unscheduled Visits to GP/Urologist (Outpatient) Planned, Not Relating to the Study (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF)
NCT00090103 (31) [back to overview]	Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF)
NCT00090103 (31) [back to overview]	The Number of Participants With Each of the Five Components of BPH Clinical Progression
NCT00090103 (31) [back to overview]	Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit
NCT00090103 (31) [back to overview]	Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48
NCT00090103 (31) [back to overview]	"Number of Yes Responses to the Question: Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned?."
NCT00090103 (31) [back to overview]	"Number of Yes Responses to the Question: Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?"
NCT00090103 (31) [back to overview]	Adjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12, 24, 36, and 48
NCT00090103 (31) [back to overview]	Adjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12, 24, 36, and 48
NCT00090103 (31) [back to overview]	Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48
NCT00090103 (31) [back to overview]	Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48
NCT00090103 (31) [back to overview]	Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48
NCT00090103 (31) [back to overview]	Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.
NCT00090103 (31) [back to overview]	Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4
NCT00090103 (31) [back to overview]	Number of Events of Symptom Deterioration at the Indicated Time Periods
NCT00090103 (31) [back to overview]	Number of Participants With an Event of Post-baseline BPH-related Hematospermia
NCT00090103 (31) [back to overview]	Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria
NCT00090103 (31) [back to overview]	Number of Participants With AUR or BPH-related Surgery
NCT00090103 (31) [back to overview]	Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)
NCT00340704 (28) [back to overview]	AUCτ ,ss ,DW ,Norm
NCT00340704 (28) [back to overview]	Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values,Urinalysis,Occurence of Adverse Events & Cognitive Testing for Group D-527.51 Rollover
NCT00340704 (28) [back to overview]	Vz/F,ss,W,Norm
NCT00340704 (28) [back to overview]	λz,ss
NCT00340704 (28) [back to overview]	Percentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover
NCT00340704 (28) [back to overview]	RA,Cmax
NCT00340704 (28) [back to overview]	t1/2,ss
NCT00340704 (28) [back to overview]	Tmax, 1
NCT00340704 (28) [back to overview]	Early Responders Who Maintained Their LPP Below 40 cm H2O During the Study for Group D-Denovo and Group D-527.51 Rollover
NCT00340704 (28) [back to overview]	Tmax,ss
NCT00340704 (28) [back to overview]	Change From Baseline in LPP for Group D-527.51 Rollover
NCT00340704 (28) [back to overview]	Number of LPP Responders at Each Visit Over Time (Classified by Last Value on Treatment) for Group D-527.51 Rollover.
NCT00340704 (28) [back to overview]	Percent Change From Baseline in LPP for Group D-527.51 Rollover
NCT00340704 (28) [back to overview]	Response Defined as Stabilization or Improvement of Hydronephrosis Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover
NCT00340704 (28) [back to overview]	Vision Testing for Group D-527.51 Rollover
NCT00340704 (28) [back to overview]	Cmax, 1 ,DW ,Norm
NCT00340704 (28) [back to overview]	Vision Testing for Group D-Denovo
NCT00340704 (28) [back to overview]	Response Defined as Stabilization or Improvement of Hydroureter Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover
NCT00340704 (28) [back to overview]	AUCτ,ss
NCT00340704 (28) [back to overview]	CL/F,ss,W,Norm
NCT00340704 (28) [back to overview]	Cmax,1
NCT00340704 (28) [back to overview]	Cmax,ss
NCT00340704 (28) [back to overview]	Cmax,ss, DW, Norm
NCT00340704 (28) [back to overview]	Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values, Urinalysis, Occurence of Adverse Events and Cognitive Testing for Group D-Denovo
NCT00340704 (28) [back to overview]	Cmin,ss
NCT00340704 (28) [back to overview]	Cpre,ss
NCT00340704 (28) [back to overview]	LPP Response at Any Time During the Trial for Group D-Denovo and Group D-527.51 Rollover
NCT00340704 (28) [back to overview]	MRTpo,ss
NCT00382265 (6) [back to overview]	Confirmation of Stone Passage on CT
NCT00382265 (6) [back to overview]	Return to Work (if Employed)
NCT00382265 (6) [back to overview]	Proportion of Patients Passing Their Stone Within 28 Days by Self Report
NCT00382265 (6) [back to overview]	Need for Surgical Intervention
NCT00382265 (6) [back to overview]	Crossover to Open Label Tamsulosin
NCT00382265 (6) [back to overview]	Any Pain Medication
NCT00448123 (3) [back to overview]	Stone Passage
NCT00448123 (3) [back to overview]	High Pain Score by Treatment Group
NCT00448123 (3) [back to overview]	Amount (Mean Number of Tablets Taken) of Pain Medication Taken by Subjects up to Seven (7) Days Post Emergency Department Discharge
NCT00507455 (18) [back to overview]	Change From Baseline in International Prostate Symptoms Score (IPSS)
NCT00507455 (18) [back to overview]	Change From Baseline in IPSS Storage Score
NCT00507455 (18) [back to overview]	Change From Baseline in IPSS Voiding Score
NCT00507455 (18) [back to overview]	Change From Baseline in Number of Incontinence Episodes Per 24 Hours
NCT00507455 (18) [back to overview]	Change From Baseline in Number of Micturitions Per 24 Hours
NCT00507455 (18) [back to overview]	Change From Baseline in Number of Urgency Episodes Per 24 Hours
NCT00507455 (18) [back to overview]	Change From Baseline in Patient Perception of Bladder Condition (PPBC)
NCT00507455 (18) [back to overview]	Change From Baseline in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Symptom Score
NCT00507455 (18) [back to overview]	Change From Baseline in ICIQ-MLUTS Total Symptom Bother Score
NCT00507455 (18) [back to overview]	Change From Baseline in Volume Voided Per Micturition
NCT00507455 (18) [back to overview]	Safety Assessed by Adverse Events (AEs), Electrocardiogram (ECG), Vital Signs, Physical Exam and Laboratory Tests
NCT00507455 (18) [back to overview]	Change From Baseline in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Symptom Score
NCT00507455 (18) [back to overview]	Change From Baseline to End of Treatment in Bladder Contractility Index (BCI)
NCT00507455 (18) [back to overview]	Change From Baseline in Post Void Residual Volume (PVR)
NCT00507455 (18) [back to overview]	Change From Baseline in ICIQ-LUTSqol Overall Symptom Interference of Life Score
NCT00507455 (18) [back to overview]	Change From Baseline to End of Treatment in Percent Bladder Voiding Efficiency (BVE)
NCT00507455 (18) [back to overview]	Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
NCT00507455 (18) [back to overview]	Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax)
NCT00540124 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score
NCT00540124 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Total Urinary Incontinence Episodes Per Week Based on Median as Reported in Patient Voiding Dribble Diary
NCT00540124 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Total, Waking, and Sleeping Voids (Average Number Per Week) Based on Median as Reported in Patient Voiding Dribble Diary
NCT00540124 (13) [back to overview]	Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Irritative Subscore
NCT00540124 (13) [back to overview]	Change From Baseline to 4 Week and 8 Week Endpoints in International Prostate Symptom Score (IPSS) Total Score
NCT00540124 (13) [back to overview]	Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Nocturia Subscore
NCT00540124 (13) [back to overview]	Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Obstructive Subscore
NCT00540124 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BPH-II)
NCT00540124 (13) [back to overview]	Clinician Global Impression of Improvement (CGI-I) Combined Categories - Frequencies
NCT00540124 (13) [back to overview]	Patient Global Impression of Improvement (PGI-I) Combined Categories - Frequencies
NCT00540124 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Voided Urine Volume (Vcomp)
NCT00540124 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Peak Urine Flow Rate (Qmax) and Mean Urine Flow Rate (Qmean)
NCT00540124 (13) [back to overview]	Change From Baseline to 12 Week Endpoint in Voids With Terminal Micturition Dribble and Post Micturition Dribble Per Week Based on Median as Reported by Patient Voiding Dribble Diary
NCT00701779 (9) [back to overview]	Benign Prostate Hyperplasia Impact Index
NCT00701779 (9) [back to overview]	Economic Impact
NCT00701779 (9) [back to overview]	Health Outcome Measures
NCT00701779 (9) [back to overview]	International Prostate Symptom Score
NCT00701779 (9) [back to overview]	Number of Participants With a Reduction of AUR and BPH-related Surgery
NCT00701779 (9) [back to overview]	Peak Flow Rate (QMax)
NCT00701779 (9) [back to overview]	Post-void Residual Volume
NCT00701779 (9) [back to overview]	Prostate Specific Antigen
NCT00701779 (9) [back to overview]	Safety and Tolerability
NCT00796614 (9) [back to overview]	Change From Baseline in Urine Volume at Week 14
NCT00796614 (9) [back to overview]	Change From Baseline in Number of Times Patient Was Wet at Catheterisation
NCT00796614 (9) [back to overview]	Change From Baseline in LPP at Week 14 (End of Treatment)
NCT00796614 (9) [back to overview]	Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electorocardiogram (ECG), Laboratory Values, Urinalysis, Treatment Emergent AE's and Cognitive Testing.
NCT00796614 (9) [back to overview]	Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day.
NCT00796614 (9) [back to overview]	Post Void Residual Volume at Week 14
NCT00796614 (9) [back to overview]	Percentage Change From Baseline in LPP at Week 14 (End of Treatment)
NCT00796614 (9) [back to overview]	Response With Regard to Hydronephrosis Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound Grading at Week 14 (End of Treatment) Compared to Baseline
NCT00796614 (9) [back to overview]	Response With Regard to Hydroureter Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound at Week 14 (End of Treatment) Compared to Baseline
NCT00831701 (5) [back to overview]	Time to Stone Passage
NCT00831701 (5) [back to overview]	Required Analgesics
NCT00831701 (5) [back to overview]	Number of Participants With Stone Expulsion
NCT00831701 (5) [back to overview]	Number of Participants Requiring Active Treatment
NCT00831701 (5) [back to overview]	Maximum Daily Pain Score
NCT00861757 (12) [back to overview]	Change From Baseline in Blood Pressure (Standing) at 12 Weeks
NCT00861757 (12) [back to overview]	Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks
NCT00861757 (12) [back to overview]	Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks
NCT00861757 (12) [back to overview]	Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks
NCT00861757 (12) [back to overview]	Change From Baseline in Blood Pressure (Sitting) at 12 Weeks
NCT00861757 (12) [back to overview]	Change From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])
NCT00861757 (12) [back to overview]	Clinician Global Impression of Improvement (CGI-I) at Week 12
NCT00861757 (12) [back to overview]	Patient Global Impression of Improvement (PGI-I) at Week 12
NCT00861757 (12) [back to overview]	Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks
NCT00861757 (12) [back to overview]	Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks
NCT00861757 (12) [back to overview]	Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks
NCT00861757 (12) [back to overview]	Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 4 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in Total International Prostate Symptom Score (IPSS) at 4 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in Volume of Voided Urine (V-Comp) at 12 Weeks
NCT00970632 (17) [back to overview]	Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 12 Weeks: Overall
NCT00970632 (17) [back to overview]	Clinician Global Impression of Improvement (CGI-I) at 12 Weeks
NCT00970632 (17) [back to overview]	Patient Global Impression of Improvement (PGI-I) at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12 Weeks.
NCT00970632 (17) [back to overview]	Change From Baseline in Mean Urine Flow Rate (Q-Mean) at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at 1 Week
NCT00970632 (17) [back to overview]	Change From Baseline in International Prostate Symptom Score (IPSS) Nocturia Question at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in Peak Urine Flow Rate (Q-Max) at 12 Weeks
NCT00970632 (17) [back to overview]	Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks
NCT01018511 (44) [back to overview]	Maximum Concentration at Steady State (Cmaxss) of Tamsulosin
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Self-care Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Pain/Discomfort Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Mobility Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Anxiety/Depression Score
NCT01018511 (44) [back to overview]	AUCss of Solifenacin
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in HRQoL Subscale: Sleep Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in HRQoL Subscale: Concern Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Health Related QoL (HRQoL) Subscale: Coping Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Visual Analogue Scale (VAS) Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Urgency Episodes (PPIUS Grade 3 or 4) Per 24 Hours
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Average Flow Rate (Qmean)
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Nocturia Episodes Per 24 Hours
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Pads Used Per 24 Hours
NCT01018511 (44) [back to overview]	Tmaxss of Solifenacin
NCT01018511 (44) [back to overview]	Time of Maximum Concentration at Steady State (Tmaxss) of Tamsulosin
NCT01018511 (44) [back to overview]	Patient Global Impression Scale at End of Treatment: Overall Bladder Symptoms
NCT01018511 (44) [back to overview]	Patient Global Impression Scale at End of Treatment: General Health
NCT01018511 (44) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01018511 (44) [back to overview]	Minimum Concentration at Steady State (Cminss) of Tamsulosin
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Symptom Bother Score
NCT01018511 (44) [back to overview]	Cminss of Solifenacin
NCT01018511 (44) [back to overview]	Cmaxss of Solifenacin
NCT01018511 (44) [back to overview]	Clinician Global Impression Scale at End of Treatment: Overall Bladder Symptoms
NCT01018511 (44) [back to overview]	CL/F of Solifenacin
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Individual IPSS Scores
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Usual Activities Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Maximum Volume Voided Per Micturition
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in IPSS Voiding Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in IPSS Storage Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in IPSS QoL Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in HRQoL Subscale: Total Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in HRQoL Subscale: Social Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Voided Volume Per Micturition
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Post Void Residual (PVR) Volume
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Total International Prostate Symptom Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Total Urgency Frequency Score (TUFS, Previously Known as Total Urgency Score [TUS])
NCT01018511 (44) [back to overview]	Percentage of Participants Who Were OAB-q Responders at End of Treatment
NCT01018511 (44) [back to overview]	Apparent Clearance (CL/F) of Tamsulosin
NCT01018511 (44) [back to overview]	Area Under the Curve at Steady State (AUCss) of Tamsulosin
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Social Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in IPSS Quality of Life (QoL) Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in IPSS Storage Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in IPSS Voiding Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Maximum Volume Voided Per Micturition
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Visual Analogue Scale (VAS) Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Individual IPSS Scores
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Usual Activities Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Self-care Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Pain/Discomfort Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Mobility Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Anxiety/Depression Score
NCT01021332 (31) [back to overview]	Number of OAB-q Responders Based on Health-related Quality of Life: Total Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Total Urgency Frequency Score (TUFS) (Previously Known as Total Urgency Score [TUS])
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Total International Prostate Symptom Score (IPSS)
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Voided Volume Per Micturition
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Pads Used Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Urgency Episodes (PPIUS Grade 3 or 4) Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Nocturia Episodes Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Post Void Residual (PVR) Volume
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Average Flow Rate (Qmean)
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Total Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Symptom Bother Score
NCT01021332 (31) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Concern Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Coping Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Sleep Score
NCT01028014 (3) [back to overview]	Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG
NCT01028014 (3) [back to overview]	Difference (Pre - Post) in Maximum Urine Flow Rate (Qmax) (Milliliters Per Second) as Measured by Pressure Flowmetry
NCT01028014 (3) [back to overview]	Difference (Pre - Post) in Urethral Sensation (Milliamps) as Measured by Current Perception Threshold Testing.
NCT01149733 (3) [back to overview]	Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
NCT01149733 (3) [back to overview]	AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01149733 (3) [back to overview]	AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01175382 (18) [back to overview]	Change in Urgency Score From 6 Weeks to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urgency Score From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urinary Incontinence Episodes From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urinary Incontinence From 6 Weeks to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urinary Incontinence From Baseline to 6 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Frequency of Urination After 6-week Intervention (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Frequency of Urination From 6 Weeks to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Frequency of Urination From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in International Prostate Symptom Score (I-PSS) From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in International Prostate Symptom Score (I-PSS) From Baseline to 6 Weeks. (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in International Prostate Symptom Score (IPSS) From 6 to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Nocturia From 6 Weeks to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Nocturia From Baseline to 6 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Nocturia Measured From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Overactive Bladder Questionnaire (OAB-q) From 6 to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Overactive Bladder Questionnaire (OAB-q) From Baseline to 12 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Overactive Bladder Questionnaire (OAB-q) From Baseline to 6 Weeks (Last Observation Carried Forward)
NCT01175382 (18) [back to overview]	Change in Urgency From Baseline to 6 Weeks (Last Observation Carried Forward)
NCT01294592 (11) [back to overview]	Change From Baseline in the BPH Impact Index (BII) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach
NCT01294592 (11) [back to overview]	Exposure to Study Drug
NCT01294592 (11) [back to overview]	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) Starting Post-randomization
NCT01294592 (11) [back to overview]	Number of Participants With Change From Baseline in the Indicated Improvement Categories in the IPSS at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach
NCT01294592 (11) [back to overview]	Number of Participants With the Indicated First-occurring Component of Clinical Progression (CP) of BPH
NCT01294592 (11) [back to overview]	Number of Participants With the Indicated Responses to Question 1 of the Patient Perception of Study Treatment (PPST) Questionnaire at Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach
NCT01294592 (11) [back to overview]	Number of Participants With the Indicated Responses to Question 2 of the Patient Perception of Study Treatment (PPST) Questionnaire at Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach
NCT01294592 (11) [back to overview]	Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the Last Observation Carried Forward (LOCF) Approach
NCT01294592 (11) [back to overview]	Number of Participants Who Had Any BPH-related Surgery, Who Had the Indicated Type of Surgery, Who Had 2 BPH-related Surgeries, and Who Had >=3 BPH-related Surgeries
NCT01294592 (11) [back to overview]	Change From Baseline in the BPH-related Health Status (BHS) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach
NCT01294592 (11) [back to overview]	Number of Events of Clinical Progression (CP) of BPH
NCT01457573 (11) [back to overview]	Change in IPSS-International Prostate Score Scale at Baseline Compared to Post Dose Survey at Month 1, 2, and Month 3/Week12.
NCT01457573 (11) [back to overview]	Change in Maximum Urinary Flow Rate (ml/s) at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in PBC-Patient Perception of Bladder Condition at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in PPUS-Patient Perception of Urinary Urgency Survey Score at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in Post Void Residual (mL) at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in ICIQ-MLUTS - International Consultation on Incontinence Modular Questionnaire for Male LUTS Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change From Baseline in Urinary Growth Factor to Creatinine Ratio (GF/Cr)
NCT01457573 (11) [back to overview]	Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.3/Wk12
NCT01457573 (11) [back to overview]	Change in ICIQ LUTS QoL -International Consultation on Incontinence Modular Questionnaire LUTS Quality of Life for Male LUTS Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in Urinary Growth Factor to Creatinine Ratio (GF/Cr) From Baseline Compared to Month 1/Week4 and Month 2/Week 8.
NCT01457573 (11) [back to overview]	Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.1/Wk4 and Mo.2/Wk8
NCT01533597 (6) [back to overview]	Change in Total Score of OABSS
NCT01533597 (6) [back to overview]	Change of PVR
NCT01533597 (6) [back to overview]	Numeric Change of Urgency Episodes Per 24 Hours
NCT01533597 (6) [back to overview]	Change of Qmax
NCT01533597 (6) [back to overview]	Change in Mean Number of Micturition Episodes Per 24 Hours
NCT01533597 (6) [back to overview]	Change in Score of IPSS
NCT01534351 (2) [back to overview]	Number of Participants Who Discontinued Treatment Due to an Adverse Event
NCT01534351 (2) [back to overview]	Number of Participants Who Experienced an Adverse Event
NCT01589263 (1) [back to overview]	American Urologic Association Symptom Score (AUASS)
NCT01673490 (10) [back to overview]	Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline
NCT01673490 (10) [back to overview]	Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 6
NCT01673490 (10) [back to overview]	Change From Baseline in Maximum Rate of Urinary Flow (Qmax) at the Indicated Time Points
NCT01673490 (10) [back to overview]	Change From Baseline in Total Prostate -Specific Antigen (PSA) at the Indicated Time Points
NCT01673490 (10) [back to overview]	Free to Total PSA Ratio at the Indicated Time Points
NCT01673490 (10) [back to overview]	Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points
NCT01673490 (10) [back to overview]	Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs
NCT01673490 (10) [back to overview]	Number of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs
NCT01673490 (10) [back to overview]	Number Participants With a Negative or Positive Response at the Indicated Time Points
NCT01673490 (10) [back to overview]	Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline
NCT01726270 (6) [back to overview]	Percentage of Participants Who Took no More Than One Capsule Per Day
NCT01726270 (6) [back to overview]	Percentage of Participants Who Have a Correct Self-selection Response Out of the Total Study Population
NCT01726270 (6) [back to overview]	Percentage of Participants Who Are Potentially at Risk of Harm by Incorrectly Selecting to Use the Study Product Out of the Total Study Population
NCT01726270 (6) [back to overview]	Percentage of Participants Who Appropriately Followed the Label Instructions
NCT01726270 (6) [back to overview]	Percentage of Participants < 45 Years of Age Who Spoke to a Doctor During the Actual Use Phase
NCT01726270 (6) [back to overview]	"Percentage of Use-Days for All Participants Who Took no More Than One Capsule Per Day"
NCT01741454 (4) [back to overview]	Ureteral Stent Symptom Questionnaire Score
NCT01741454 (4) [back to overview]	Ureteral Stent Symptom Questionnaire Score 5-7 Days Post-stent Insertion
NCT01741454 (4) [back to overview]	Ureteral Stent Symptom Questionnaire Score Up to 24 Hours After Stent Removal
NCT01741454 (4) [back to overview]	Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion
NCT01777269 (11) [back to overview]	Change From Baseline in Ejaculatory Dysfunction (EjD) at 1, 3, 6, 9 and 12 Months
NCT01777269 (11) [back to overview]	Change From Baseline in Erectile Dysfunction (ED) at 1, 3, 6, 9 and 12 Months
NCT01777269 (11) [back to overview]	Change From Baseline in International Prostate Symptom Score (IPSS) Scores Using the Observed Cases Approach at 2 Weeks, 1, 3, 6, 9, and 12 Months
NCT01777269 (11) [back to overview]	Change From Baseline in Perception of Treatment Benefit/Satisfaction With Treatment (Patient Perception of Study Medication - PPSM Questionnaire Scores) at 2 Weeks, 1, 3, 6, 9, and 12 Months
NCT01777269 (11) [back to overview]	Change From Baseline in Quality of Life (BPH Impact Index -BII Scores) at 2 Weeks, 1, 3, 6, 9, and 12 Months
NCT01777269 (11) [back to overview]	Change From Baseline in Satisfaction Score at 1, 3, 6, 9 and 12 Months
NCT01777269 (11) [back to overview]	Change From Baseline in Total MSHQ Scores From Baseline at 12 Months Among Participants With IPSS Improvement of >=25 Percent
NCT01777269 (11) [back to overview]	Change From Baseline in Total MSHQ Scores From Baseline at 12 Months Among Participants With IPSS Improvement of >=2 Points and >=3 Points
NCT01777269 (11) [back to overview]	Number of Participants Reaching Various Thresholds of Change in Total MSHQ From Baseline at 12 Months
NCT01777269 (11) [back to overview]	Changes From Baseline (BL) in Total Score From the Full Men's Sexual Health Questionnaire (MSHQ) at 12 Months
NCT01777269 (11) [back to overview]	Change From Baseline in Scores From the Full Men's Sexual Health Questionnaire (MSHQ) at 1, 3, 6 and 9 Months
NCT01937871 (22) [back to overview]	Number of Participants With Patient Global Impression of Improvement (PGI-I) at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in IPSS Quality of Life (QoL) Index at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in IIEF Intercourse Satisfaction at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in IIEF Orgasmic Function at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in IIEF Overall Satisfaction (OS) at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in IIEF Sexual Desire at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in IPSS at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in IPSS Storage (Irritative) Subscore at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in IPSS Voiding (Obstructive) Subscore at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at Week 2
NCT01937871 (22) [back to overview]	Change From Baseline in Postvoid Residual Volume (PVR) at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in Uroflowmetry Measures at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in Yes Responses to Question 2 of the Sexual Encounter Profile (SEP) Questionnaire at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in IIEF EF at Week 4 and Week 8
NCT01937871 (22) [back to overview]	Change From Baseline in IIEF Subscores at Week 12
NCT01937871 (22) [back to overview]	Change From Baseline in Total IPSS at Week 4 and Week 8
NCT01937871 (22) [back to overview]	Change From Baseline in Yes Responses to Question 2 of the SEP Questionnaire at Week 4 and Week 8
NCT01937871 (22) [back to overview]	Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 4 and Week 8
NCT01937871 (22) [back to overview]	Number of Participants With Clinician Global Impression of Improvement (CGI-I) at Week 12
NCT02058368 (23) [back to overview]	Number of Participants With Digital Rectal Examination (DRE)
NCT02058368 (23) [back to overview]	Number of Participants With Hospital Admissions
NCT02058368 (23) [back to overview]	Number of Subjects With AUR
NCT02058368 (23) [back to overview]	Percent Change in Prostate Volume From Baseline
NCT02058368 (23) [back to overview]	Number of Participants With IPSS Improvement From Baseline
NCT02058368 (23) [back to overview]	Number of Participants With Non-serious Adverse Events (AE) and Serious AE (SAE)
NCT02058368 (23) [back to overview]	Number of Participants With Qmax Improvement From Baseline by LOCF Approach.
NCT02058368 (23) [back to overview]	Number of Participants With Suicidal Ideation and Suicidal Behavior
NCT02058368 (23) [back to overview]	Number of Participants With Threshold Clinical Chemistry Value.
NCT02058368 (23) [back to overview]	Number of Participants With Threshold Hematology Value.
NCT02058368 (23) [back to overview]	Number of Participants With Vital Signs Exceeding Threshold Values
NCT02058368 (23) [back to overview]	Change From Baseline in Problem Assessment Scale of the Sexual Function Inventory (PAS-SFI)
NCT02058368 (23) [back to overview]	Change From Baseline in Serum Prostate Specific Antigen (PSA)
NCT02058368 (23) [back to overview]	Number of Participants With Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery
NCT02058368 (23) [back to overview]	Number of Participants With BPH-related Surgery
NCT02058368 (23) [back to overview]	Number of Participants With Clinically Significant Qualitative Breast Examination
NCT02058368 (23) [back to overview]	Number of Hospitalization Days
NCT02058368 (23) [back to overview]	Change From Baseline in BPH Impact Index (BII) by LOCF Approach
NCT02058368 (23) [back to overview]	Change From Baseline in International Prostate Symptom Score (IPSS) by Last Observation Carried Forward (LOCF) Approach at 24 Months
NCT02058368 (23) [back to overview]	Change From Baseline in Maximum Urine Flow Rate (Qmax) by LOCF Approach
NCT02058368 (23) [back to overview]	Number of Participants in a Hospital Ward
NCT02058368 (23) [back to overview]	Change From Baseline in the BPH-related Health Status (BHS) by LOCF Approach
NCT02058368 (23) [back to overview]	Change From Baseline in Post Void Residual Volume
NCT02417831 (6) [back to overview]	λz
NCT02417831 (6) [back to overview]	(AUC0-inf)
NCT02417831 (6) [back to overview]	AUC0-tz
NCT02417831 (6) [back to overview]	Cmax
NCT02417831 (6) [back to overview]	t1/2
NCT02417831 (6) [back to overview]	Tmax
NCT02417844 (6) [back to overview]	Terminal Elimination Rate Constant (λz)
NCT02417844 (6) [back to overview]	Maximum Measured Concentration (Cmax)
NCT02417844 (6) [back to overview]	Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
NCT02417844 (6) [back to overview]	Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)
NCT02417844 (6) [back to overview]	Apparent Terminal Elimination Half-life (t1/2)
NCT02417844 (6) [back to overview]	Time to Maximum Plasma Concentration (Tmax)
NCT02486653 (8) [back to overview]	First Post-void Residual Urine Volume
NCT02486653 (8) [back to overview]	Hospital Length of Stay in Days
NCT02486653 (8) [back to overview]	Need for Any Intermittent Catheterization Postoperatively as a Binary Outcome
NCT02486653 (8) [back to overview]	Need for Replacement of Indwelling Urinary Catheter as a Binary Outcome
NCT02486653 (8) [back to overview]	Number of Participants Who Experienced Adverse Events
NCT02486653 (8) [back to overview]	Total Number of Intermittent Catheterizations Required Per Subject
NCT02486653 (8) [back to overview]	Urinary Tract Infection (UTI)
NCT02486653 (8) [back to overview]	Discharge From Hospital With Indwelling Urinary Catheter
NCT02518971 (6) [back to overview]	Incidence of Postoperative Complications
NCT02518971 (6) [back to overview]	Acute Postoperative Pain Medication Dosages
NCT02518971 (6) [back to overview]	Incidence of Discharge to a Skilled Nursing Facility
NCT02518971 (6) [back to overview]	Incidence of Surgical Site Infection
NCT02518971 (6) [back to overview]	Length of Hospital Stay
NCT02518971 (6) [back to overview]	Number of Patients to Develop Postoperative Urinary Retention (POUR)
NCT02573311 (9) [back to overview]	Percentage of Men Who Seek the Advice of a Physician Within the First 12/24 Weeks of the Study Out of the Total Population in Cohort 1
NCT02573311 (9) [back to overview]	"Percentage of Men Who Report a Condition Listed Under the Stop Use and Ask a Doctor if Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 1"
NCT02573311 (9) [back to overview]	"Percentage of Men Who Report a Condition Listed Under the Stop Use and Ask a Doctor if Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 1"
NCT02573311 (9) [back to overview]	"Percentage of Men Who Report a Condition Listed Under the Stop Use and Ask a Doctor if Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 1"
NCT02573311 (9) [back to overview]	"Percentage of Men Who Report Condition Listed Under Stop Use and Ask a Doctor if Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks"
NCT02573311 (9) [back to overview]	"Percentage of Men Who Report at Baseline a Symptom or Condition Under the Ask A Doctor Before Use Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 1"
NCT02573311 (9) [back to overview]	Percentage of Men Who Took Two or More Capsules Per Day Within the First 12/24 Weeks of Using Study Product Out of the Total Population in Cohort 1
NCT02573311 (9) [back to overview]	"Percentage of Men Who Report Condition Listed Under Stop Use and Ask a Doctor if Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks"
NCT02573311 (9) [back to overview]	"Percentage of Men Who Report at Baseline a Symptom or Condition Under the Ask A Doctor Before Use Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition"
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Number of Incontinence Episodes Per 24 Hours
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Maximum Urine Flow Rate (Qmax)
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Number of Nocturia Episodes
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Number of Urgency Episodes Per 24 Hours
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Mean Volume Voided Per Micturition
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Postvoid Residual (PVR) Volume
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Symptom Bother as Assessed by the Overactive Bladder Questionnaire (OAB-q)
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Total Health-Related QoL (HRQoL) Scores as Assessed by the OAB-q
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Total Overactive Bladder Symptom Score (OABSS)
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in IPSS Subscale Scores
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in OABSS Subscale Scores
NCT02656173 (16) [back to overview]	Change From Baseline to Weeks 4, 8, 12 in Mean Number of Micturitions Per 24 Hours
NCT02656173 (16) [back to overview]	Number of Participants With Adverse Events
NCT02656173 (16) [back to overview]	Change From Baseline to EoT in Total International Prostate Symptom Score (IPSS)
NCT02656173 (16) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per 24 Hours
NCT02684344 (1) [back to overview]	Number of Participants With Post-operative Urinary Retention
NCT02757768 (21) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per Day
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Total Urgency and Frequency Score (TUFS)
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, and Week 12 in Mean Number of Micturitions Per Day
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in European Quality of Life in 5 Dimensions and 5 Levels (EQ-5D-5L Questionnaire) Utilities
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Concern Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Coping Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Sleep Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Social Interaction Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in IPSS Subscale Quality of Life (QoL) Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in IPSS Subscale Voiding Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Incontinence Episodes Per Day
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per Day
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in International Prostate Symptom Score (IPSS) Total Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Volume Voided Per Micturition
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Patient Perception of Bladder Condition (PPBC)
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Symptom Bother Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Total Health Related Quality of Life (HRQL) Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Treatment Satisfaction Visual Analog Scale (TS-VAS)
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12, and EoT in IPSS Subscale Storage Score
NCT02757768 (21) [back to overview]	Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Urgency Incontinence Episodes Per Day
NCT02919436 (2) [back to overview]	Number of Patients Who Undergo Postoperative Catheterization for Urinary Retention
NCT02919436 (2) [back to overview]	Length of Stay
NCT03524339 (4) [back to overview]	International Prostate Symptom Score
NCT03524339 (4) [back to overview]	Sent Home With Catheterization
NCT03524339 (4) [back to overview]	Postoperative Urinary Tract Infection
NCT03524339 (4) [back to overview]	Postoperative Urinary Retention

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)

"This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of How satisfied are you with the effect the study medication has on your pain prior to urinating?. Satisfact., satisfaction." (NCT00090103)
Timeframe: Baseline and Months 12, 24, 36, and 48

Intervention	participants (Number)
	Baseline (BL), Any Satisfact., n=908, 932, 889	BL, Neutral/Any Dissatisfact., n=908, 932, 889	Month (M) 12, Any Satisfact., n=1022, 1088, 1019	M12, Neutral/Any Dissatisfact., n=1022, 1088, 1019	M24, Any Satisfact., n=1077, 1151, 1085	M24, Neutral/Any Dissatisfact., n=1077, 1151, 1085	M36, Any Satisfact., n=1115, 1200, 1135	M36, Neutral/Any Dissatisfact., n=1115, 1200, 1135	M48, Any Satisfact., n=1135, 1223, 1161	M48, Neutral/Any Dissatisfact., n=1135, 1223, 1161
Dutasteride 0.5 mg	351	581	672	416	740	411	785	415	792	431
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	375	533	712	310	764	313	799	316	810	325
Tamsulosin 0.4 mg	351	538	681	338	708	377	736	399	739	422

Intervention	visits (Number)
	Month 3, n=1550, 1581, 1564	Month 6, n=1479, 1517, 1514	Month 9, n=1439, 1465, 1477	Month 12, n=1400, 1431, 1434	Month 15, n=1343, 1386, 1380	Month 18, n=1318, 1350, 1328	Month 21, n=1281, 1326, 1287	Month 24, n=1263, 1293, 1244	Month 27, n=1233, 1262, 1206	Month 30, n=1222, 1221, 1165	Month 33, n=1202, 1199, 1128	Month 36, n=1187, 1174, 1095	Month 39, n=1160, 1144, 1055	Month 42, n=1149, 1126, 1035	Month 45, n=1129, 1110, 1009	Month 48, n=1113, 1093, 990
Dutasteride 0.5 mg	3	1	2	2	5	0	0	0	3	1	1	2	3	2	3	2
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	0	2	2	1	2	4	1	2	3	0	0	2	1	1	0	0
Tamsulosin 0.4 mg	3	2	3	7	7	4	3	3	4	1	5	1	2	5	2	1

Intervention	participants (Number)
	Baseline (BL), Any Improvement, n=1585, 1600, 1586	BL, No Change/Any Worsening, n=1585, 1600, 1586	Month (M) 12, Any Improvement, n=1576, 1593, 1581	M12, No Change/Any Worsening, n=1576, 1593, 1581	M24, Any Improvement, n=1576, 1593, 1581	M24, No Change/Any Worsening, n=1576, 1593, 1581	M36, Any Improvement, n=1576, 1593, 1581	M36, No Change/Any Worsening, n=1576, 1593, 1581	M48, Any Improvement, n=1576, 1593, 1581	M48, No Change/Any Worsening, n=1576, 1593, 1581
Dutasteride 0.5 mg	656	944	1171	422	1200	393	1203	390	1212	381
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	696	889	1281	295	1273	303	1268	308	1278	298
Tamsulosin 0.4 mg	706	880	1218	363	1195	386	1152	429	1138	443

Intervention	participants (Number)
	Baseline (BL), Any Satisfact., n=1574, 1600, 1576	BL, Neutral /Any Dissatisfact., n=1574, 1600, 1576	Month (M) 12, Any Satisfact., n=1575, 1593, 1580	M12, Neutral/Any Dissatisfact., n=1575, 1593, 1580	M24, Any Satisfact., n=1575, 1593, 1580	M24, Neutral/Any Dissatisfact., n=1575, 1593, 1580	M36, Any Satisfact., n=1575, 1593, 1580	M36, Neutral/Any Dissatisfact., n=1575, 1593, 1580	M48, Any Satisfact., n=1575, 1593, 1580	M48, Neutral/Any Dissatisfact., n=1575, 1593, 1580
Dutasteride 0.5 mg	565	1035	1073	520	1116	477	1098	495	1123	470
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	611	963	1176	399	1205	370	1210	365	1213	362
Tamsulosin 0.4 mg	584	992	1114	466	1088	492	1074	506	1043	537

Intervention	participants (Number)
	Baseline (BL), Any Satisfact., n=1573, 1598, 1574	BL, Neutral/Any Dissatisfact., n=1573, 1598, 1574	Month (M) 12, Any Satisfact., n=1574, 1592, 1581	M12, Neutral/Any Dissatisfact., n=1574, 1592, 1581	M24, Any Satisfact., n=1574, 1592, 1581	M24, Neutral/Any Dissatisfact., n=1574, 1592, 1581	M36, Any Satisfact., n=1574, 1592, 1581	M36, Neutral/Any Dissatisfact., n=1574, 1592, 1581	M48, Any Satifact., n=1574, 1592, 1581	M48, Neutral/Any Dissatisfact., n=1574, 1592, 1581
Dutasteride 0.5 mg	683	915	1159	433	1188	404	1188	404	1182	410
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	717	856	150	324	1279	295	1270	304	1262	312
Tamsulosin 0.4 mg	699	875	1202	379	1163	418	1119	462	1097	484

Intervention	participants (Number)
	Baseline, Yes, n=1560, 1579, 1562	Baseline, No/Not Sure, n=1560, 1579, 1562	Month 12, Yes, n=1574, 1592, 1581	Month 12, No/Not Sure, n=1574, 1592, 1581	Month 24, Yes, n=1574, 1592, 1581	Month 24, No/Not Sure, n=1574, 1592, 1581	Month 36, Yes, n=1574, 1592, 1581	Month 36, No/Not Sure, n=1574, 1592, 1581	Month 48, Yes, n=1574, 1592, 1581	Month 48, No/Not Sure, n=1574, 1592, 1581
Dutasteride 0.5 mg	557	1022	920	671	955	636	956	636	918	674
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	587	973	972	602	1027	547	1031	543	1003	571
Tamsulosin 0.4 mg	582	980	970	611	952	629	915	666	874	707

Intervention	participants (Number)
	Baseline (BL), Any Satisfact., n=1587, 1600, 1583	BL, Neutral/Any Dissatisfact., n=1587, 1600, 1583	Month (M) 12, Any Satisfact., n=1576, 1593, 1581	M12, Neutral/Any Dissatisfact., n=1576, 1593, 1581	M24, Any Satisfact., n=1576, 1593, 1581	M24, Neutral/Any Dissatisfact., n=1576, 1593, 1581	M36, Any Satisfact., n=1576, 1593, 1581	M36, Neutral/Any Dissatisfact., n=1576, 1593, 1581	M48, Any Satisfact., n=1576, 1593, 1581	M48, Neutral/Any Dissatisfact., n=1576, 1593, 1581
Dutasteride 0.5 mg	652	948	1127	466	1166	427	1167	426	1172	421
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	707	880	1224	352	1261	315	1260	316	1267	309
Tamsulosin 0.4 mg	686	897	1178	403	1150	431	1120	461	1088	493

Intervention	participants (Number)
	Baseline (BL), Any Satisfact., n=1583,1601,1582	BL, Neutral/Any Dissatisfact., n=1583,1601,1582	Month (M) 12, Any Satisfact., n=1576, 1593, 1581	M12, Neutral/Any Dissatisfact., n=1576, 1593, 1581	M24, Any Satisfact., n=1576, 1593, 1581	M24, Neutral/Any Dissatisfact., n=1576, 1593, 1581	M36, Any Satisfact., n=1576, 1593, 1581	M36, Neutral/Any Dissatisfact., n=1576, 1593, 1581	M48, Any Satisfact., n=1576, 1593, 1581	M48, Neutral/Any Dissatisfact., n=1576, 1593, 1581
Dutasteride 0.5 mg	586	1015	1037	556	1072	521	1075	518	1089	504
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	632	951	1154	422	1203	373	1201	375	1208	368
Tamsulosin 0.4 mg	613	969	1097	484	1051	530	1039	542	1022	559

Intervention	participants (Number)
	Baseline (BL), Any Improvement, n=869, 901, 849	BL, No Change/Any Worsening, n=869, 901, 849	Month (M) 12, Any Improvement, n=769, 817, 771	M12, No Change/Any Worsening, n=769, 817, 771	M24, Any Improvement, n=720, 780, 771	M24, No Change/Any Worsening, n=720, 780, 771	M36, Any Improvement, n=714, 753, 748	M36, No Change/Any Worsening, n=714, 753, 748	M48, Any Improvement, n=709, 756, 751	M48, No Change/Any Worsening, n=709, 756, 751
Dutasteride 0.5 mg	331	570	526	291	526	254	514	239	510	246
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	337	532	556	213	537	183	540	174	531	178
Tamsulosin 0.4 mg	332	517	527	244	535	236	496	252	489	262

Intervention	visits (Number)
	Month 3, n=1550, 1581, 1564	Month 6, n=1479, 1516, 1514	Month 9, n=1439, 1465, 1477	Month 12, n=1400, 1431, 1434	Month 15, n=1343, 1386, 1381	Month 18, n=1318, 1350, 1328	Month 21, n=1281, 1326, 1287	Month 24, n=1263, 1293, 1244	Month 27, n=1233, 1262, 1206	Month 30, n=1222, 1221, 1166	Month 33, n=1202, 1199, 1128	Month 36, n=1187, 1174, 1095	Month 39, n=1160, 1144, 1055	Month 42, n=1149, 1126, 1035	Month 45, n=1129, 1110, 1009	Month 48, n=1113, 1093, 990
Dutasteride 0.5 mg	27	29	27	28	28	21	27	23	12	16	13	12	10	9	7	4
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	27	23	12	30	19	23	20	29	13	10	6	8	12	15	5	7
Tamsulosin 0.4 mg	30	33	26	29	32	34	26	26	16	10	20	18	18	15	8	8

Intervention	participants (Number)
	Baseline (BL), Any Improvement, n=852, 889, 822	BL, No Change/Any Worsening, n=852, 889, 822	Month (M) 12, Any Improvement, n=760, 781, 755	M12, No Change/Any Worsening, n=760, 781, 755	M24, Any Improvement, n=706, 760, 747	M24, No Change/Any Worsening, n=706, 760, 747	M36, Any Improvement, n=704, 741, 733	M36, No Change/Any Worsening, n=704, 741, 733	M48, No Change/Any Worsening, n=702, 739, 740	M48, Any Improvement, n=702, 739, 740
Dutasteride 0.5 mg	314	575	500	281	508	252	504	237	252	487
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	321	531	550	210	532	174	529	175	175	527
Tamsulosin 0.4 mg	319	503	529	226	519	228	491	242	257	483

Intervention	participants (Number)
	Baseline (BL), Any Satisfact., n=890, 925, 851	BL, Neutral/Any Dissatisfact., n=890, 925, 851	Month (M) 12, Any Satisfact., n=1022, 1088, 1011	M12, Neutral/Any Dissatisfact., n=1022, 1088, 1011	M24, Any Satisfact., n=1077, 1155, 1079	M24, Neutral/Any Dissatisfact., n=1077, 1155, 1079	M36, Any Satisfact., n=1121, 1206, 1131	M36, Neutral/Any Dissatisfact., n=1121, 1206, 1131	M48, Any Satsifact., n=1146,1224,1160	M48, Neutral/Any Dissatisfact., n=1146, 1224, 1160
Dutasteride 0.5 mg	348	577	655	433	730	425	784	422	785	439
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	354	536	712	310	763	314	807	314	827	319
Tamsulosin 0.4 mg	333	518	678	333	708	371	724	407	729	431

Intervention	participants (Number)
	Baseline (BL), Any Improvement, n=1574, 1599, 1575	BL, No Change/Any Worsening, n=1574, 1599, 1575	Month (M) 12, Any Improvement, n=1575, 1593, 1580	M12, No Change/Any Worsening, n=1575, 1593, 1580	M24, Any Improvement, n=1575, 1593, 1580	M24, No Change/Any Worsening, n=1575, 1593, 1580	M36, Any Improvement, n=1575, 1593, 1580	M36, No Change/Any Worsening, n=1575, 1593, 1580	M48, Any Improvement, n=1575, 1593, 1580	M48, No Change/Any Worsening, n=1575, 1593, 1580
Dutasteride 0.5 mg	481	1118	1027	566	1053	540	1593	529	1063	530
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	509	1065	1124	451	1146	429	1575	412	1148	427
Tamsulosin 0.4 mg	494	1081	1084	496	1049	531	1580	553	1008	572

Intervention	participants (Number)
	Symptom deterioration	BPH-related AUR	BPH-related incontinence	Recurrent BPH-related UTI	BPH-related renal insufficiency
Dutasteride 0.5 mg	203	31	49	5	2
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	132	22	46	2	1
Tamsulosin 0.4 mg	221	64	56	3	5

Intervention	visits (Number)
	Month 3, n=1550, 1581, 1565	Month 6, n=1479, 1517, 1514	Month 9, n=1439, 1465, 1477	Month 12, n=1400, 1431, 1434	Month 15, n=1343, 1386, 1380	Month 18, n=1318, 1350, 1328	Month 21, n=1281, 1326, 1287	Month 24, n=1263, 1293, 1244	Month 27, n=1233, 1262, 1206	Month 30, n=1222, 1221, 1166	Month 33, n=1202, 1199, 1128	Month 36, n=1187, 1174, 1095	Month 39, n=1160, 1144, 1055	Month 42, n=1149, 1126, 1035	Month 45, n=1129, 1110, 1009	Month 48, n=1113, 1093, 990
Dutasteride 0.5 mg	6	4	3	3	6	4	3	2	6	2	4	1	2	2	2	2
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	8	2	4	3	3	3	3	2	1	3	3	2	2	3	1	1
Tamsulosin 0.4 mg	7	3	8	9	6	10	9	7	7	8	5	5	5	8	4	2

Intervention	points on a scale (Least Squares Mean)
	Month 12	Month 24	Month 36	Month 48
Dutasteride 0.5 mg	-4.2	-4.9	-5.2	-5.3
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	-5.6	-6.2	-6.3	-6.3
Tamsulosin 0.4 mg	-4.5	-4.3	-4.0	-3.8

Intervention	yes responses (Number)
	Month 3, n=1550, 1581, 1564	Month 6, n=1479, 1516, 1513	Month 9, n=1439, 1465, 1477	Month 12, n=1400, 1431, 1434	Month 15, n=1343, 1386, 1380	Month 18, n=1318, 1350, 1328	Month 21, n=1281, 1326, 1287	Month 24, n=1263, 1293, 1244	Month 27, n=1233, 1262, 1206	Month 30, n=1222, 1221, 1166	Month 33, n=1202, 1199, 1128	Month 36, n=1187, 1174, 1095	Month 39, n=1160, 1144, 1055	Month 42, n=1149, 1126, 1035	Month 45, n=1129, 1110, 1009	Month 48, n=1113, 1093, 990
Dutasteride 0.5 mg	32	26	14	13	15	13	15	9	11	9	10	4	9	8	8	9
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	31	21	18	8	9	17	10	5	9	7	9	5	7	6	7	2
Tamsulosin 0.4 mg	29	26	18	9	12	19	17	8	8	9	11	5	6	8	5	5

Intervention	yes responses (Number)
	Month 3, n=1550, 1581, 1564	Month 6, n=1479, 1516, 1513	Month 9, n=1438, 1465, 1477	Month 12, n=1400, 1431, 1434	Month 15, n=1343, 1386, 1380	Month 18, n=1318, 1350, 1328	Month 21, n=1281, 1326, 1287	Month 24, n=1263, 1293, 1244	Month 27, n=1233, 1262, 1206	Month 30, n=1222, 1221, 1166	Month 33, n=1202, 1199, 1128	Month 36, n=1187, 1174, 1095	Month 39, n=1160, 1144, 1055	Month 42, n=1149, 1126, 1034	Month 45, n=1129, 1110, 1009	Month 48, n=1113, 1093, 990
Dutasteride 0.5 mg	34	23	10	10	9	12	9	7	9	9	7	5	8	8	8	3
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	16	20	12	5	9	13	10	4	9	7	5	3	7	9	6	1
Tamsulosin 0.4 mg	28	16	17	6	9	10	8	3	5	4	8	2	5	2	5	1

Intervention	percent change (Least Squares Mean)
	Month 12, n= 150, 159, 160	Month 24, n= 153, 164, 160	Month 36, n= 155, 164, 162	Month 48, n= 155, 164, 163
Dutasteride 0.5 mg	-15.6	-22.8	-26.7	-26.5
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	-17.2	-23.4	-20.9	-17.9
Tamsulosin 0.4 mg	5.6	8.7	14.7	18.2

Intervention	milliliters (mL)/second (sec) (Least Squares Mean)
	Month 12, n=1477, 1482, 1510	Month 24, n= 1492, 1501, 1519	Month 36, n= 1495, 1504, 1521	Month 48, n= 1495, 1505, 1523
Dutasteride 0.5 mg	1.5	1.9	1.9	2.0
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	2.0	2.4	2.6	2.4
Tamsulosin 0.4 mg	0.9	0.9	0.6	0.7

Intervention	percent change (Least Squares Mean)
	Month 12, n=1411, 1442, 1451	Month 24, n= 1427, 1451, 1465	Month 36, n= 1430, 1455, 1468	Month 48, n= 1430, 1455, 1468
Dutasteride 0.5 mg	-25.2	-28.0	-28.8	-28.0
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	-24.1	-26.9	-27.6	-27.3
Tamsulosin 0.4 mg	-1.5	0.0	1.6	4.6

tamsulosin

Cross-References

Synonyms (86)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (1)

Protein Targets (23)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (193)

Molecular Functions (25)

Ceullar Components (36)

Bioassays (185)

Research

Studies (1,342)

Market Indicators

Research Demand Index: 132.78

Study Types

Clinical Trials (195)

Trial Overview

Trial Outcomes

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)

Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF)

Number of Unscheduled Visits to GP/Urologist (Outpatient) Planned, Not Relating to the Study (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF)

Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF)

The Number of Participants With Each of the Five Components of BPH Clinical Progression

Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit

Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48

"Number of Yes Responses to the Question: Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned?."

"Number of Yes Responses to the Question: Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?"

Adjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12, 24, 36, and 48

Adjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12, 24, 36, and 48

Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48

Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48

Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48

Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.

Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4

Number of Events of Symptom Deterioration at the Indicated Time Periods

Number of Participants With an Event of Post-baseline BPH-related Hematospermia

Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria

Number of Participants With AUR or BPH-related Surgery

Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)

AUCτ ,ss ,DW ,Norm

Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electrocardiogram (ECG), Laboratory Values,Urinalysis,Occurence of Adverse Events & Cognitive Testing for Group D-527.51 Rollover

Vz/F,ss,W,Norm

λz,ss

Percentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover

RA,Cmax

t1/2,ss

Tmax, 1

Early Responders Who Maintained Their LPP Below 40 cm H2O During the Study for Group D-Denovo and Group D-527.51 Rollover

Tmax,ss

Change From Baseline in LPP for Group D-527.51 Rollover

Number of LPP Responders at Each Visit Over Time (Classified by Last Value on Treatment) for Group D-527.51 Rollover.

Percent Change From Baseline in LPP for Group D-527.51 Rollover

Response Defined as Stabilization or Improvement of Hydronephrosis Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover

Vision Testing for Group D-527.51 Rollover

Cmax, 1 ,DW ,Norm

Vision Testing for Group D-Denovo

Response Defined as Stabilization or Improvement of Hydroureter Measured by Renal Ultrasound Compared to Baseline for Group D-Denovo and Group D-527.51 Rollover

Intervention	events (Number)
	Year 1, n=1610, 1623, 1611	Year 2, n=1457, 1484, 1464	Year 3, n=1347, 1365, 1307	Year 4, n=1274, 1277, 1176
Dutasteride 0.5 mg	27	22	16	19
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	29	14	15	9
Tamsulosin 0.4 mg	40	62	44	45

Intervention	events (Number)
	Year 1, n=1610, 1623, 1611	Year 2, n= 1264, 1240, 1262	Year 3, n=1135, 1082, 1048	Year 4, n= 1047, 959, 880
Dutasteride 0.5 mg	184	54	29	22
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	126	31	30	16
Tamsulosin 0.4 mg	171	78	67	31

Intervention	events (Number)
	Year 1, n=1610, 1623, 1611	Year 2, n=1286, 1278, 1296	Year 3, n=1158, 1132, 1088	Year 4, n=1083, 1001, 926
Dutasteride 0.5 mg	138	38	23	13
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	91	23	14	11
Tamsulosin 0.4 mg	119	49	42	19

Intervention	participants (Number)
	Overall Crude Rate	Non-BPH-related Crude Rate	BPH-related Crude Rate
Dutasteride 0.5 mg	19	3	17
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	18	2	17
Tamsulosin 0.4 mg	20	9	11

Intervention	participants (Number)
	AUR	BPH-related surgery
Dutasteride 0.5 mg	44	40
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg	35	32
Tamsulosin 0.4 mg	109	82

Intervention	ngh/mL/mgkg (Geometric Mean)
Tamsulosin - Low Dose Level (Steady State - PK Study)	26100
Tamsulosin - Medium Dose Level (Steady State - PK Study)	25200
Tamsulosin - High Dose Level (Steady State - PK Study)	27700

Intervention	Participants (Number)
Tamsulosin - Low Dose Level (Group D-527.51 Rollover)	1
Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)	0
Tamsulosin - High Dose Level (Group D-527.51 Rollover)	0

Intervention	1/hours (Geometric Mean)
Tamsulosin - Low Dose Level (Steady State - PK Study)	0.0589
Tamsulosin - Medium Dose Level (Steady State - PK Study)	0.0671
Tamsulosin - High Dose Level (Steady State - PK Study)	0.0496

Intervention	percentage of responders (Number)
Tamsulosin - Low Dose Level (Group D-Denovo)	73.1
Tamsulosin - Medium Dose Level (Group D-Denovo)	35.7
Tamsulosin - High Dose Level (Group D-Denovo)	26.7
Tamsulosin - Low Dose Level (Group D-527.51 Rollover)	67.9
Tamsulosin - Medium Dose Level (Group D-527.51 Rollover)	58.3
Tamsulosin - High Dose Level (Group D-527.51 Rollover)	20.7

Intervention	hours (Geometric Mean)
Tamsulosin - Low Dose Level (Steady State - PK Study)	11.80
Tamsulosin - Medium Dose Level (Steady State - PK Study)	10.30
Tamsulosin - High Dose Level (Steady State - PK Study)	14.00